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Abstract  
Hypertension (HTN) is a major risk factor for cardiovascular diseases including 
stroke, coronary heart disease (CHD), chronic renal failure, peripheral vascular 
disease, myocardial infarction, congestive heart failure and premature death. The 
prevalence of HTN in Scotland is very high and although a high proportion of the 
patients receive antihypertensive medications, blood pressure (BP) control is very 
low. Recommendations for starting a specific antihypertensive class have been 
debated between various guidelines over the years. Some guidelines and HTN 
studies have preferred to start with a combination of an antihypertensive class 
instead of using a single therapy, and they have found greater BP reductions with 
combination therapies than with monotherapy. However, it has been shown in 
several clinical trials that 20% to 35% of hypertensive patients could not achieve 
the target BP, even though they received more than three antihypertensive 
medications. Several factors were found to affect BP control. Adherence and 
persistence were considered as the factors contributing the most to uncontrolled 
hypertension. Other factors such as age, sex, body mass index (BMI), alcohol 
intake, baseline systolic BP (SBP), and the communication between physicians and 
patients have been shown to be associated with uncontrolled BP and resistant 
hypertension.  
Persistence, adherence and compliance are interchangeable terms and have been 
used in the literature to describe a patient’s behaviour with their antihypertensive 
drugs and prescriptions. The methods used to determine persistence and 
adherence, as well as the inclusion and exclusion criteria, vary between 
persistence and adherence studies. The prevalence of persistence and adherence 
have varied between these studies, and were determined to be high in some 
studies and low in others. The initiation of a specific antihypertensive class has 
frequently been associated with an increase or decrease in adherence and 
persistence. The tolerability and efficacy of the initial antihypertensive class have 
been the most common methods of explaining this association. There are also 
many factors that suggest a relationship with adherence and persistence. Some 
factors in previous studies, such as age, were frequently associated with 
adherence and persistence. On the other hand, relationships with certain factors 
have varied between the studies. The associations of age, sex, alcohol use, 
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smoking, baseline systolic blood pressure (SBP) and diastolic BP (DBP), the 
presence of comorbidities, an increase in the number of pills and the relationship 
between patients and physicians with adherence and persistence have been the 
most commonly investigated factors.  
Most studies have defined persistence in terms of a patient still taking medication 
after a period of time. A medication possession ratio (MPR) ≥ 80 has been used to 
define compliance. Either of these terminologies, or both, have been used to 
estimate adherence. In this study, I used the same definition for persistence to 
identify patients who have continued with their initial treatment, and used 
persistence and MPR to define patients who adhered to their initial treatment. 
The aim of this study was to estimate the prevalence of persistence and adherence 
in Scotland. Also, factors that could have had an effect on persistence and 
adherence were studied. The number of antihypertensive drugs taken by patients 
during the study and factors that led to an increase in patients being on a 
combination therapy were also evaluated. The prevalence of resistance and BP 
control were determined by taking the BP after the last drug had been taken by 
persistent patients during five follow-up studies. The relationship of factors such 
as age, sex, BMI, alcohol use, smoking, estimated glomerular filtration rate 
(eGFR), and albumin levels with BP reductions for each antihypertensive class 
were determined.  
Information Services Division (ISD) data, which includes all antihypertensive drugs, 
were collected from pharmacies in Scotland and linked to the Glasgow Blood 
Pressure Clinic (GBPC) database. This database also includes demographic 
characteristics, BP readings and clinical results for all patients attending the 
GBPC. The case notes for patients who attended the GBPC were reviewed and all 
new antihypertensive drugs that were prescribed between visits, BP before and 
after taking drugs, and any changes in the hypertensive drugs were recorded. A 
total of 4,232 hypertensive patients were included in the first study. The first 
study showed that angiotensin converting enzyme inhibitor (ACEI) and beta-
blockers (BB) were the most prescribed antihypertensive classes between 2004 
and 2013. Calcium channel blockers (CCB), thiazide diuretics and angiotensin 
receptor blockers (ARB) followed ACEI and BB as the most prescribed drugs during 
the same period. The prescription trend of the antihypertensive class has changed 
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over the years with an increase in prescriptions for ACEI and ARB and a decrease 
in prescriptions for BB and diuretics. I observed a difference in antihypertensive 
class prescriptions by age, sex, SBP and BMI.  For example, CCB, thiazide diuretics 
and alpha-blockers were more likely to be prescribed to older patients, while 
ACEI, ARB or BB were more commonly prescribed for younger patients.  
In a second study, 4,232 and 3,149 hypertensive patients were included to 
investigate the prevalence of persistence in the Scottish population in 1- and 5-
year studies, respectively. The prevalence of persistence in the 1-year study was 
72.9%, while it was only 62.8% in the 5-year study. Those patients taking ARB and 
ACEI showed high rates of persistence and those taking diuretics and alpha 
blockers had low rates of persistence. The association of persistence with clinical 
characteristics was also investigated. Younger patients were more likely to totally 
stop their treatment before restarting their treatment with other antihypertensive 
drugs. Furthermore, patients who had high SBP tended to be non-persistent.  
In a third study, 3,085 and 1,979 patients who persisted with their treatment were 
included. In the first part of the study, MPR was calculated, and patients with an 
MPR ≥ 80 were considered as adherent. Adherence rates were 29.9% and 23.4% in 
the 1- and 5-year studies, respectively. Patients who initiated the study with ACEI 
were more likely to adhere to their treatments. However, patients who initiated 
the study with thiazide diuretics were less likely to adhere to their treatments. 
Sex, age and BMI were different between the adherence and non-adherence 
groups. Age was an independent factor affecting adherence rates during both the 
1- and 5-year studies with older patients being more likely to be adherent. In the 
second part of the study, pharmacy databases were checked with patients' case 
notes to compare antihypertensive drugs that were collected from the pharmacy 
with the antihypertensive prescription given during the patient’s clinical visit. 
While 78.6% of the antihypertensive drugs were collected between clinical visits, 
21.4% were not collected. Patients who had more days to see the doctor in the 
subsequent visit were more likely to not collect their prescriptions.   
In a fourth study, 3,085 and 1,979 persistent patients were included to calculate 
the number of antihypertensive classes that were added to the initial drug during 
the 1-year and 5-year studies, respectively. Patients who continued with 
treatment as a monotherapy and who needed a combination therapy were 
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investigated during the 1- and 5-year studies. In all, 55.8% used antihypertensive 
drugs as a monotherapy and 44.2% used them as a combination therapy during the 
1-year study. While 28.2% of patients continued with treatment without the 
required additional therapy, 71.8% of the patients needed additional therapy. In 
all, 20.8% and 46.5% of patients required three different antihypertensive classes 
or more during the 1-year and 5-year studies, respectively. Patients who started 
with ACEI, ARB and BB were more likely to continue as monotherapy and less likely 
to need two more antihypertensive drugs compared with those who started with 
alpha-blockers, non-thiazide diuretics and CCB. Older ages, high BMI levels, high 
SBP and high alcohol intake were independent factors that led to an increase in 
the probability of patients taking combination therapies.  
In the first part of the final study, BPs were recorded after the last drug had been 
taken during the 5 year study. There were 815 persistent patients who were 
assigned for this purpose. Of these, 39% had taken one, two or three 
antihypertensive classes and had controlled BP (controlled hypertension [HTN]), 
29% of them took one or two antihypertensive classes and had uncontrolled BP 
(uncontrolled HTN), and 32% of the patients took three antihypertensive classes 
or more and had uncontrolled BP (resistant HTN). The initiation of an 
antihypertensive drug and the factors affecting BP pressure were compared 
between the resistant and controlled HTN groups. Patients who initiated the study 
with ACEI were less likely to be resistant compared with those who started with 
alpha blockers and non-thiazide diuretics. Older patients, and high BMI tended to 
result in resistant HTN. In the second part of study, BP responses for patients who 
initiated the study with ACEI, ARB, BB, CCB and thiazide diuretics were compared. 
After adjusting for risk factors, patients who initiated the study with ACEI and ARB 
were more respondent than those who took CCB and thiazide diuretics. In the last 
part of this study, the association between BP reductions and factors affecting BP 
were tested for each antihypertensive drug. Older patients responded better to 
alpha blockers. Younger patients responded better to ACEI and ARB. An increase 
in BMI led to a decreased reduction in patients on ACEI and diuretics (thiazide and 
non-thiazide). An increase in albumin levels and a decrease in eGFR led to 
decreases in BP reductions in patients on thiazide diuretics. An increase in eGFR 
decreased the BP response with ACEI.  
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In conclusion, although a high percentage of hypertensive patients in Scotland 
persisted with their initial drug prescription, low adherence rates were found with 
these patients. Approximately half of these patients required three different 
antihypertensive classes during the 5 years, and 32% of them had resistant HTN. 
Although this study was observational in nature, the large sample size in this study 
represented a real HTN population, and the large pharmacy data represented a 
real antihypertensive population, which were collected through the support of 
prescription data from the GBPC database. My findings suggest that ACEI, ARB and 
BB are less likely to require additional therapy. However, ACEI and ARB were 
better tolerated than BB in that they were more likely to be persistent than BB.  
In addition, users of ACEI, and ARB have good BP response and low resistant HTN. 
Linkage patients who participated in these studies with their morbidity and 
mortality will provide valuable information concerning the effect of adherence on 
morbidity and mortality and the potential benefits of using ACEI or ARB over other 
drugs. 
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Chapter 1 Introduction 
1.1 Historical perspectives of hypertension 
1.1.1 Historical perspectives in the Measurement of Blood 
Pressure  
The history of hypertension research starts with the development of suitable 
methods for measuring blood pressure (BP). The first published account of blood 
pressure measurement was by the clergyman Stephen Hales in 1733, with 
illustrated experiments on animal including the measurement of direct arterial 
pressure in the horse (1,2). In 1856, using a surgical method the surgeon Faivre 
measured the first truly accurate blood pressure in humans (3).   
Until 1854 there was no method for measuring arterial pressure other than by 
surgery. The first external, non-invasive device used to measure blood pressure 
was invented by Vierordt in 1855. He showed that BP could be determined by 
measuring the counter pressure necessary to cause obliteration of the radial pulse 
(4,5). This device was cumbersome and relatively insensitive and was further 
improved upon by individuals, such as Etienne Jules Marey, and R.E. Dudgeon (6). 
The first sphygmomanometer was invented by Samuel K. von Basch in 1881(3). It 
was von Basch who decided to obtain a direct measure of the blood pressure by a 
column of fluid rather than obtain blood pressure measurements from an arterial 
puncture. His device consisted of an inflatable rubber bag which was filled with 
water and tightly connected to the neck of a manometer bulb. The manometer 
bulb was filled with mercury used to determine the pressure required to obliterate 
the arterial pulse (5).  
The introduction of Von Basch's sphygmomanometer into clinical medicine was 
accepted by some physicians as a valuable aid to diagnosis. However, many 
practitioners of the time were sceptical of new technology, and the British Medical 
Journal held the view that by using the sphygmomanometer 'we pauperize our 
senses and weaken clinical acuity'. Despite the accusation of weakening clinical 
acuity, this did not stop some from attempting to produce a more useful device 
(6)  
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In 1896 Riva-Rocci reported the method which led to a prototype of the modern 
mercury sphygmomanometer. His technique involved a rubber bag surrounded by 
a cuff that was wrapped round the whole circumference arm and inflated with 
air. This inflatable cuff was connected to a glass mercury manometer to measure 
the systolic blood pressure. However, Riva-Rocci’s sphygmomanometer used a 
narrow cuff, only 5 cm wide, which resulted in slightly inaccurate readings. In 
1900, von Recklinghausen corrected this error by replacing the narrow armband 
with one about 13 cm wide (4,6). 
 In 1905 Nikolai Korotkoff reported that tapping sounds could be heard as the cuff 
was deflated by placing a stethoscope over the brachial artery at the cubital fossa, 
caused by blood flowing back into the artery. This auscultatory technique to 
measure blood pressure became widespread in the first half of the 20th century. 
This technique was used for more than half a century with practically no changes 
made (7). 
Toward the end of the 20th century, the mercury manometer was replaced with 
electronic devices and aneroid devices because of mercury-related health 
concerns.  However, using mercury to ensure accuracy for these devices have been 
recommended by standardized protocols and mercury is still used for calibrating 
these devices (8,9). More recently, the emergence of automated BP measurement 
such as home or ambulatory blood pressure monitoring devices has been increased 
recognition of the prognostic and clinical value of BP measured in different 
settings. The introduction these devices allow blood pressure to be measured 
repeatedly during the day and night(10–13). 
1.1.2 Historical perspectives in the pathogenesis of primary 
hypertension 
Improvements in BP measurement techniques facilitated the discovery of the 
association between mortality and hypertension in the early 20th century. In 1918, 
BP was measured by insurance companies in the United States. The Actuarial 
Society of the United States (US) first reported on BP in 1925, and a subsequent 
report in 1939, showed a positive relationship between age and BP elevations as 
well as mortality (14,15). Relatively small increases in BP were associated with 
sharp increases in mortality, and the relationships of gradual increases in BP to 
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both age and weight were reported by the Build and Blood Pressure Studies in 
1959(16). Though these data were obtained from those participants who were 
either issued or applied for life insurance policies, the basic conclusions of the 
Actuarial Society of the US reports have been corroborated and extended to the 
general population in studies such as the large Multiple Risk Factor Intervention 
Trial (MRFIT) and the Framingham Heart Study (FHS). Multiple risk factors were 
screened in more than 350,000 individuals and a graded and continuous influence 
of BP on end stage renal disease (ESRD) and coronary heart disease (CHD) were 
documented by the MRFIT cohort (1993)(17). The BP increases associated with 
incremental increases in mortality, even within the non-hypertensive range, were 
observed by investigators in the FHS in 2001(18). In 2002, consistent with a 
positive relationship between BP increases and mortality, a meta-analysis from 61 
prospective studies on more than one million adults reported that mortality 
increased progressively throughout the BP range, and there was no evidence of an 
abnormal BP threshold(19). 
1.1.3 Drug development and clinical trials 
Despite evidence for relationships between increased BP and mortality and 
Cardiovascular disease (CV) events, there have been doubters in the medical 
profession and in the lay press about the imperative need to reduce BP. 
“Hypertension may be an important compensatory mechanism which should not 
be tampered with, even were it certain that we could control it.” was written by 
cardiologist Dr. Paul Dudley White in 1931(20). Also, Dr. John Hay in the British 
Medical Journal in 1931 stated “The greatest danger to a man with high BP lies in 
its discovery, because then some fool is certain to try and reduce it.” (21) Nitrites, 
thiocyanates, dehydrogenated alkaloids of ergot, pyrogens and Veratrum viride 
and its extracts were the earliest pharmacological treatments. Diuretics, 
Rauwolfia alkaloids, ganglion blockers and sympathetic antagonists were the most 
frequently used drugs in the late 1960s(22)  
Early clinical trials provided the evidence that antihypertensive agents reduced 
the incidence of cardiovascular (CV) events; these trials were the landmark 
Veterans Administration Cooperative Studies published in 1967 and 1970. In these 
studies, active drug treatments were compared to placebos for their ability to 
reduce the incidence of CV events in patients with diastolic blood pressures (DBPs) 
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of 115 to 129 mmHg in 1967, and DBPs of 90 to 114 mmHg in 1970 (23,24). Lowering 
DBP with antihypertensive drugs in mildly hypertensive patients also reduced the 
incidence of CV events as evaluated by several placebo-controlled trials including 
the US Public Health Service Cooperative Study in 1977, the Hypertension 
Detection and Follow-Up Program (HDFP) in 1979 and the Oslo Study in 1980 (25–
27). Additionally, antihypertensive treatments have demonstrated their ability to 
reduce the incidence of stroke and major CV events in older patients with isolated 
systolic hypertension (ISH) (e.g., Systolic Hypertension in the Elderly Program 
[SHEP] in 1991, and Systolic Hypertension in Europe [Syst-Eur] in 1997) (28,29). 
Lower BP targets for hypertension control have been evaluated in many trials 
(e.g., Hypertension Optimal Treatment (HOT) study in 1998) (30). The HOT study 
showed that the lowest rate of CV events for patients who were allocated to three 
DPB targets, ≤90, ≤85, ≤80 mm Hg, appeared to lower the DBP level to less than 
85 mm Hg (30). Antihypertensive drugs have also been evaluated to determine 
effective drug-induced decreases in BP and the incidence of CV events and 
mortality (e.g., Losartan Intervention For Endpoint [LIFE] Reduction in 
Hypertension Study, and the Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial [ALLHAT] in 2002)(31,32). LIFE suggested that CV 
morbidity and mortality have been prevented with losartan more than with 
atenolol for similar BP reduction in hypertensive patients who had left ventricular 
hypertrophy (LVH) (33). There was no difference in the primary outcome of 
combined fatal coronary heart disease or non-fatal myocardial infarction in 
patients who enrolled to receive one of these (antihypertensive class 
chlorthalidone, amlodipine, or Lisinopril) in the ALLHAT study (32). Recently, the 
Systolic Blood Pressure Intervention Trial (SPRINT) study noted that the lower the 
systolic blood pressure (SBP) (a level less than 120 mm Hg), the better the CV 
mortality and morbidity outcomes, some of which were even lower than normal 
SBP control levels (140 mm Hg in patients with a high risk of CV events but non-
diabetic) (34). 
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1.2 Hypertension definition, blood pressure target, and 
measurements 
1.2.1 Development of hypertension definition 
Hypertension has been known to be extremely difficult to define and the BP 
threshold at which an individual is considered hypertensive or not has been 
considered arbitrary for a long time. The definition has changed many times over 
the years. During the mid-twentieth century, the great divide in hypertension was 
debated by Pickering versus Platt, who were considered the two giants in this 
field. Platt's viewpoint was that hypertension is a discrete disorder, whereas 
Pickering’s position was that hypertension is the upper end of a normal 
distribution, and this vision ultimately triumphed (35).  
The threshold BP level, that is used to define hypertension, is the BP level to 
which BP should be reduced to the point at which the level is more beneficial than 
harm (36). For most of the 20th century, the consensus was to use DBP as the basis 
for diagnosis and treatment of hypertension (37), because of the general belief 
DBP contributed more to CV risk than SBP. 
The guidelines were revised in 2000 with SBP considered to be a stronger predictor 
of CV disease than DBP. SBP was recommended to be reviewed, evaluated and 
treated for hypertension by the Clinical Advisory Statement (38). The threshold 
used to define hypertension has been downgraded over the last 20 years; for 
example, it was 160/90 mmHg and later became 140/90 mmHg (39). Figures 1-1 
and 1-2 illustrate how the definition of hypertension has changed since 1976. 
Hypertension has been defined by the most recent guidelines as BP exceeding 
140/90 mmHg, which is a systolic pressure over 140 mmHg and/or a diastolic 
pressure over 90 mmHg (40–43). 
Hypertension is classified as either primary hypertension or secondary 
hypertension. Primary hypertension, which affects the majority of the 
hypertensive population (approximately 90%), refers to sustained high BP for 
which there is no obvious, underlying medical cause. The remaining 10% are cases 
of secondary hypertension in which the BP elevation is caused by other specific 
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conditions that can be determined. Causative factors for secondary hypertension 
include Conn's adenoma, renovascular disease and phaeochromocytoma (43).  
With the increasing use of ambulatory BP measurements, subtypes of hypertension 
such as white coat hypertension (WCH) and masked hypertension are increasingly 
recognised and detected. Isolated systolic hypertension (ISH) is another 
hypertension subtype and refers to systolic blood pressure exceeding 140mmHg, 
while diastolic pressure remains normal or low (less than 90 mmHg). O’Rourke et 
al. suggested that there is no benefit to using anti-hypertensive drugs in young, 
healthy males with ISH. According to this study, young individuals usually have 
normal, central BPs, whereas in the elderly (aged >60 years), ISH occurs due to 
aortic stiffening .(44)  
White coat hypertension is a phenomenon used to describe individuals who have 
hypertension in the doctor’s office, but are normotensive otherwise. Masked 
hypertension is term used to describe patients who are diagnosed as normotensive 
in clinic, but with elevated ABPM and/or HBPM measurements (45).  
 
 
Figure 1-1: Evolution of blood pressure classification in systolic blood pressure (SBP) per 
the Joint National Committee (JNC) guidelines between 1976 and 2003. 
ISH = Isolated Systolic Hypertension, SBP is not included in JNC I and JNC II. Picture is 
adapted from (46). 
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Figure 1-2: Evolution of blood pressure classification in diastolic blood pressure (DBP) per 
the Joint National Committee (JNC) guidelines between 1976 and 2003. 
Picture is adapted from (46). 
 
1.2.1.1 White coat hypertension (WCH) 
WCH has been observed in as many as 20 to 25% of the population (47). Females, 
non-smokers and older individuals exhibited higher susceptibility for WCH. The 
method used to measure BP also affects WCH prevalence; WCH levels were low 
when BP was repeatedly measured or measured by a nurse or other healthcare 
giver (48,49). The prevalence of WCH varied with the level of office BP - 55% of 
WCH is found in individuals with grade 1 hypertension and 10% in those with grade 
3 hypertension (50). The risk of CV disease was shown to be similar to the true 
normotensive subjects in several studies (45,50,51). However, while long-term CV 
event rates were high in WCH and masked hypertension more than normotensive 
individuals, they were lower in WCH and masked hypertension more than sustained 
hypertension in some studies (52). 
In addition, office measurements found BP to be higher with WCH than with ABPM, 
and other factors that did not appear in true normotensive subjects appeared with 
WCH individuals, such as increased LVH frequency (53), long-term elevated 
development of blood glucose abnormalities and increased incidence of 
progressive sustained hypertension and diabetes (54,55).  
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1.2.1.2 Masked hypertension 
The prevalence of masked hypertension has been estimated to be 10%–17% in the 
population(50). Factors associated with the increased prevalence of masked 
hypertension include young age, male gender, alcohol consumption, smoking, 
physical activity, anxiety, exercise-induced hypertension, job stress, diabetes, 
obesity, family history of hypertension, CKD and high normal range of office BP 
(56). Asymptomatic organ damage and increased incidence of diabetes and 
sustained hypertension have been shown to correlate frequently with masked 
hypertension (53–56). The similarity of CV event incidence with masked 
hypertension and sustained hypertension have been shown in several meta-
analyses of prospective studies. The incidence of CV events in masked 
hypertension and sustained hypertension was higher than in true normotensive 
people by approximately two times (45,50,56). Increased risk of nephropathy was 
associated with masked hypertension in diabetic patients. This was evident 
particularly among patients who had nocturnal BP elevation (57,58). 
1.2.2 Blood pressure targets  
Most guidelines recommend the initiation of antihypertensive treatment in all 
patients with a BP level ≥140/90 mmHg to lower the pressure to be below this 
threshold. This definition of hypertension is rather arbitrary as BP is directly 
related to CV events, even at levels below that defined as hypertensive. Several 
clinical trials have shown the benefit of reducing BP targets to levels less than 
140/90 in CV events for patients with low to moderate CV risk (34,59–61). CV 
outcomes among patients who were observed for 10 years in a Felodipine Event 
Reduction (FEVER) study were reduced to approximately 11 and 17% when SBP 
values were reduced to 137 mmHg in place of 142 mmHg for patients with low to 
moderate CV risk (62). The 2007 European Society of Hypertension and the 
European Society of Cardiology (ESH/ESC) guideline recommend the 
administration of antihypertensive agents in patients with diabetes or in those 
with a history of cardiovascular or renal diseases and have a high-normal BP range 
(130–139/85–89 mmHg), aiming at achieving blood pressure values <130/ 80 mmHg 
(63). However, the ESH/ESC guidelines published after 2007 (ESH/ESC 2009, 2014) 
reappraised this recommendation and suggested a new target (140/90 mmHg) to 
initiate antihypertensive drugs with these conditions (diabetes or history of 
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cardiovascular or renal diseases) based on a recent study showing that CV risks 
that were diminished by reducing SBP at a target less than 130 mmHg were not 
different than CV reductions achieved by reducing SBP to less than 140 mmHg 
(64). These recent guidelines (2009, 2013) recommended the reduction of SBP 
targets to levels <150 instead of <140 for patients with SPB >160 mmHg and aged 
>80 years (41,65). 
The recent ESH/ESC (2013) guideline categorize BP levels as shown in Table 1-1. 
While, the recent National Institute of Health and Clinical Excellence (NICE) 
guidelines recommend using clinical BP as well as ambulatory BP monitoring 
(ABPM) or home BP monitoring (HBPM) (if ABPM is declined or not tolerated) to 
confirm the hypertension diagnosis. It divided hypertension into three stages 
(stage one, stage two and severe hypertension). Stage one hypertension includes 
patients with a BP ≥ 140/90 mmHg, confirmed by AMPB or HBP when the BP is ≥ 
135/85 mmHg. Stage two hypertension is defined as BP ≥ 160/100 mmHg, while 
the average BP for AMBP or HBPM is ≥ 150/95 mmHg. Severe hypertension is 
defined as a clinical BP ≥ 180/110 mmHg (43).  
 
Table 1-1: Hypertension definition according to recent ESH/ECH guidelines 
Category  Systolic   Diastolic 
Optimal  <120  and <80 
Norma 120–129  and/or 80–84 
High normal  130–139 and/or 85–89 
Grade 1 hypertension  140–159 and/or 90–99 
Grade 2 hypertension  160–179 and/or 100–109 
Grade 3 hypertension  ≥180 and/or ≥110 
Isolated systolic hypertension  ≥140 and <90 
Table is reproduced from (41). 
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1.2.2.1 The ‘lower the better’ vs. the J-shaped curve 
The hypothesis that ‘the lower the better’ was described in a large meta-analysis 
that observed for approximately 14 years one million subjects with no 
Cardiovascular disease (CVD). This study noted that the lower the BP, the better 
the CV and mortality outcomes, some of which were even lower than normal BP 
control levels (140/90). The lowest levels achieved were 115/75 mmHg SBP 
(SBP/DBP) (19). In a meta-analysis of 32 randomized controlled trials (RCT) of 
201,566 individuals, comparable benefits were observed between SBP reductions 
to 126 mmHg and SBP level 131 mmHg, and between SBP reduction to 140 mmHg 
and SBP level 145 mmHg (66). 
Upon examining the now-known benefits of reducing BP, it can be observed that 
the association between BP reduction and its benefits seems to obey a J-shaped 
pattern. This relationship appears in more aggressive BP reduction that can lead 
to CV risk. The concept of the J-curve relationship has been supported by several 
studies. For example, the reduction of BP values to less than 120/85 was 
associated with an increase in CVD, CV mortality and congestive heart failure 
(CHF)-related hospitalisation (67–69). Some studies assume that the relationship 
between more intensive BP reduction and serious CV risk is applicable to coronary 
events but not to stroke (67,69–71). Okin et al. concluded that BP at the 130 target 
or less has no CV event-associated benefits, unlike SBP at a target between 131 
and 141 mmHg. This study also found that the reduction of BP to levels less than 
130 was related to an increase in risk of death (72). However, many studies have 
suggested that no J-shaped relationship exists. In such studies, no serious 
complications have been observed as a result of intensive BP reduction (30,73,74). 
Recently, the SPRINT study showed that the lowest rates of morbidity and 
mortality due to CV events have been found in patients with a high risk of CV 
events but non-diabetic when targeting their SBP of less than 120 mm Hg, as 
compared with an SBP of less than 140 mm Hg. Despite the benefit of the intensive  
reduction of SBP to less than 120 mmHg, the rate of some adverse events in the 
intensive treatment subjects were higher than standard treatment group (SBP 
<140 mm Hg)(34). 
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1.2.2.2 Hypertension in the elderly 
A large randomised trial study involving 3,845 individuals aged 80 and above with 
SBP 160 mmHg or more to investigate the effect of antihypertensive drugs on 
elderly hypertensive patients (75) found that CV events and mortality declined 
when BP levels reduced, even though the SBP did not achieve levels less than 140 
mmHg. The benefits of lowering BP were examined by comparing more and less 
intensive BP reductions in recent Japanese trials; no benefits were found in 
reducing SBP to the 136 or 137mmHg level rather than 142 or145 mmHg (76,77). 
However, the FEVER study showed that reducing BP to less than 140 mmHg in turn 
reduced CV events. CV events were reduced to a greater degree in patients with 
SBP of less than 140 than among those with SBP of 145 mmHg (62). 
1.2.2.3 Diabetes mellitus  
A number of large trials have demonstrated the effect of lowering BP on reducing 
CV events in diabetic patients (30,62,78–80). Some of these results are applicable 
exclusively with diabetic patients (81,82). The benefit of reducing DBP to levels 
between 80 and 85 has been reported in two trials. However, none of the trials 
found any benefit of reducing BP to less than 130 mmHg (30,79). The effect of 
intensive SBP reduction to just below 130 mmHg in normotensive people with 
diabetes was shown to be significant for a secondary endpoint (it reduced overt 
and incipient diabetic nephropathy development, slowed the progression of 
diabetic retinopathy and reduced the stroke incidence). However, the study was 
small and the primary endpoint (change in creatinine clearance) was non-
significant (83). In an Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
study, no differences in the incidence of major CV events were found between 
diabetic patients in whom the average SBP was lowered to 119 mmHg and those 
for whom the SBP average was lowered to 133 mmHg (84). 
1.2.2.4 Previous cardiovascular events  
The benefit of intensive reduction of BP to less than 130/80 mmHg in patients 
with previous CV events has been tested in several studies. The effect of reducing 
BP to less than 130/80 mmHg in individuals treated with ACEI and with previous 
CV events was examined by the Efficacy of Perindopril in Reduction of 
Cardiovascular Events among Patients with Stable Coronary Artery Disease: a 
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Randomised, Double-blind, Placebo-controlled, Multicentre Trial Study (EUROPA). 
CV events were reduced significantly in this study (85). The effects of blood-
pressure-lowering on the risk of stroke for hypertensive and non-hypertensive 
subjects with a previous history of stroke or transient ischaemic attacks were 
tested by the Perindopril Protection Against Recurrent Stroke Study (PROGRESS); 
the risks of stroke were reduced in both hypertension and non-hypertension groups 
(86). 
The effects of CCB and ACEI drugs on CV events for patients who had previous 
coronary artery disease (CAD) and normal BP were shown in Nissen et al.’s study. 
BP levels of less than 130/80 mmHg were achieved and CV events were reduced 
in patients with amlodipine (CCB) but not with enalapril (ACEI) (87). Only minor 
CV events were affected by the reduction of BP to less than 130/80 mmHg among 
patients with previous CV events (major CV events non-significant) in three studies 
(88–90). The results in these trials were inconsistent, while a much larger study 
found no significant differences in CV events between normal SBP (140 mmHg) and 
more aggressive SBP reductions (136 mm Hg) in patients with previous CV events 
(91). Finally, two studies showed that BP reductions in patients with previous CV 
events lead to decreased stroke and CV events. However, SBP levels in these 
studies never reached the SBP target of less than 130 mmHg (85,86).  
1.2.2.5 Renal disease 
The objective of treating hypertensive patients with chronic kidney disease (CKD) 
is to prevent CV events and renal deterioration or failure. Several studies have 
reported varied prevention outcomes; some improved CV events and renal failure 
through aggressive BP reduction in hypertensive patients who had CKD or both CKD 
and diabetes.   
The benefit of reducing BP to lower than 130/80 mmHg to prevent renal function 
deterioration leading to End Stage Renal Disease (ESRD) in patients with CKD has 
been tested in three trials. No significant differences in the decline of glomerular 
filtration rate (GFR), ESRD or mortality were noted in these studies between 
patients with conventional BP targets and those for whom BP was intensively 
lowered to 130/80 mmHg (93–95). In contrast, the incidence of ESRD was reduced 
in two observational studies of patients on intensive BP control (96,97). The 
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follow-up for these patients was long and the decline in the incidence of events 
was clearer in patients with proteinuria.  
The effect of reducing BP in patients with diabetic nephropathy on limiting the 
progression to ESRD has been reported by two large trials. However, patients in 
both studies did not achieve SBP targets of less than 130 mmHg (mean SBP was 
140 and 143) (98,99). A reduction in GFR and ESRD was reported in a recent 
cooperative study involving paediatric patients with intensive BP targets below 
the 50th percentile. Although the intensive BP reduction reached goal in this 
study, it is difficult to compare these values with adult values (100).  
The results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
study should also be considered. The effect of more intensive BP targets on CV 
events in reducing normal SBP targets (140 mmHg) to levels less than 120 mmHg 
in patients with type 2 diabetes who were at high risk of CV events was 
investigated in this study. According to the results, CV events were not reduced, 
and the intensive treatment group exhibited double the incidence of estimated 
glomerular filtration rates (eGFRs) below 30ml/min/1.73 m2 (84).  Although, 
SPRINT study showed that, fatal and nonfatal CV events were reduced significantly 
with intensive treatment group who their SBPs were reduced less than 120 mm 
Hg, more than that in standard treatment group who their SBPs were reduced less 
than 140, the incidence of acute kidney injury or acute renal failure was higher in 
intensive group. It has been noted that value of eGFR was decease 30% less than 
60 ml/min/1.73 m2 in intensive group higher than standard group (34). 
Finally, two meta-analyses conducted recently observed no benefits from using 
more intensive treatment (<130/80) on renal, clinical or CV events in patients with 
CKD (101,102). The benefit to using intensive BP targets applied only to patients 
with proteinuria. However, the evidence of this benefit was of low quality, and 
these meta-analyses recommend further study to prove this benefit (102). 
  
31 
 
1.2.3 Blood pressure measurement 
The British Hypertension Society (BHS) recommends that adults should measure 
routinely blood pressure at least 5 yearly and annual re-measurement for those 
who with high blood pressure readings at any time previously or with high-normal 
blood pressure (systolic blood pressure 130–139 mmHg and/or diastolic blood 
pressure 85–89 mmHg (103). Table 1-2 shows the BHS protocol which should be 
used to measure blood pressure. 
 
Table 1-2: BHS protocol of blood pressure measurement using standard mercury 
sphygmomanometer or semiautomated device 
• Use a properly maintained, calibrated, and validated device  
• Measure sitting blood pressure routinely: standing blood pressure should be recorded 
at least at the initial estimation in elderly or diabetic patients  
• Remove tight clothing, support arm at heart level, ensure arm relaxed and avoid 
talking during the measurement procedure 
• Use cuff of appropriate size  
• Lower mercury column slowly (2 mm per second)  
• Read blood pressure to the nearest 2 mm Hg  
• Measure diastolic blood pressure as disappearance of sounds (phase V)  
• Take the mean of at least two readings, more recordings are needed if marked 
differences between initial measurements are found  
Table is reproduced from (103). 
 
Blood pressure can be measured in the clinic, or by using home or ambulatory 
blood pressure devices. There are potential advantages of home BP monitoring 
than clinic readings. These advantages include: the ability to record multiple 
reading throughout the waking duration taken over many days, which may 
decrease white coat effect. Home measurements values are usually lower than 
clinic levels (104). 
ABPM has potential advantages of home BP monitoring and clinic readings. It 
provides more information, for instance, ABPM profile reports mean daytime and 
night-time values, and blood pressure variability. There is evidence that ABPM 
values are a better predictor of CVD risk (105,106) and target organ damage(TOD) 
(107,108) and is a better method of assessing treatment effects on BP.  ABPM 
provides multiple measurements taken over a 24–26-h duration (the first and last 
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hours of reading are sometimes ignored, though the value of doing this is unclear). 
It can estimate more than 70 BP values during a single 24-h period which may 
minimise the white coat effect. Similar to home readings, ABPM values tend 
usually to be lower than clinic levels (109). Consequently, ABPM and home BP 
thresholds should probably be adjusted downwards (eg by 10/5mmHg)  for 
diagnosis of and treatment target for  hypertension (110).  
The emergence of automated BP monitoring into the clinic has revealed that there 
can be marked discrepancies between clinic BP measurement and home or 
ambulatory BP averages, which are known as either white coat hypertension or 
masked hypertension. The identification of these variations in the blood measure 
has prompted consideration about whether the traditional method which is used 
to measure blood pressure in the clinic is still the most accurate at predicting the 
risk of future cardiovascular disease. The recent NICE guideline recommends out-
of-office such as ABPM or home BP for the diagnosis of HTN. NICE guideline 
recommends of using ABPM for patient’s diagnosis as a first choice and home BP 
as second choice if a patient is unable to tolerate ABPM. The recommendation was 
based on the results from numerous studies and health economic evaluation. The 
results showed that ABPM is superior to clinic BP in many features. These studies 
conclude that: 1. ABPM is the best method to measure blood pressure in predicting 
the development of cardiovascular events. 2. APBM is a best measurement for 
diagnosing HT followed by home BP. 3. ABPM is the most cost-effective method to 
establish the diagnosis of hypertension by avoiding misdiagnosis and individuals 
being put on unnecessary treatment (43). 
1.3 Cardiovascular disease and hypertension  
1.3.1 Epidemiology 
Worldwide, approximately 16.7 million individuals die annually because of 
cardiovascular (CV) disease (42) and it is considered the leading cause of the death 
globally (111). CV mortality in developing countries was higher than in developed 
countries for middle-aged patients (112). Nearly half of all deaths in Europe are 
attributable to CV disease (113). In Scotland, almost 38% of deaths are due to this 
condition (114). Furthermore, CV disease costs approximately £29.1 billion a year 
in the United Kingdom (115).  
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1.3.2 Risk factors 
Several factors are known to be associated with developing CV disease.  The classic 
factors include hypertension, obesity, diabetes, hyperlipidaemia, and cigarette 
smoking. These factors are modifiable and have been widely used in risk 
evaluations of CV disease. Whilst these factors are important in predicting CV 
disease, they do not completely explain or predict future CV disease (116). 
Microalbuminuria, c-reactive protein, eGFR and homocysteine levels are novel risk 
factors that have been assessed in the risk stratification of developing CV disease 
(117,118). 
1.3.3 Cardiovascular risk and hypertension 
Hypertension is one of the major risk factors for stroke, coronary heart disease 
(CHD), chronic renal failure, peripheral vascular disease, myocardial infarction, 
congestive heart failure and premature death. CV risks associated with 
hypertension vary with age, sex and population.  
1.3.3.1 Hypertension and its relationship with coronary heart disease and 
stroke  
The associations between blood pressure increases and ischemic heart disease and 
stroke have been confirmed by a meta-analysis including 61 observational studies 
for one million individuals. They observed a log-linear relationship even at low BP 
values at just above 115/75 mmHg. Each 20 mmHg increase in SBP and 10 mmHg 
increase in diastolic blood pressure (DBP) resulted in a two-fold increase in death 
in this study (19). A continuous association between BP and stroke has also been 
reported by the Framingham Heart Study (FHS) (119). The importance of 
hypertension was clearly demonstrated by these studies as a modifiable risk factor 
for stroke. These studies also emphasized the importance of decreasing BP with 
the aim of reducing the incidence of stroke.  
The importance of high BP as a modifiable risk factor has also been shown for 
Coronary heart disease (CHD). Evidence that CHD risk increases linearly with 
increases in BP has been suggested by several epidemiological studies. For 
example, the strong association between high BP and CHD has been shown in 
361,662 subjects who participated in the Multiple Risk Factor Intervention Trial 
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(120). The prevalence of hypertension in CHD patients was 32% in Khot et al study 
(121). After total cholesterol, hypertension is considered the second most 
important factor that needs to be reduced to decrease CHD-associated mortality 
in the United States (122).  
It has been shown that antihypertensive drugs are able to reduce the risk of CHD 
and stroke. Law et al. analysed 147 randomized clinical trials to investigate the 
effects of antihypertensive drugs on CV disease protection. With a reduction of 10 
mmHg SBP and 5 mmHg DBP reduction, the risk of CHD and stroke were reduced 
by 20% and 32%, respectively (123).    
1.3.3.2 Hypertension and its relationship with risk of left ventricular 
hypertrophy (LVH) and heart failure  
Prolonged high BP results in an increased workload on the heart, which can result 
in left ventricular hypertrophy (LVH) (124). Depending on the method of 
assessment, the prevalence of LVH in hypertensive patients range from 36% to 41% 
as estimated in a systematic review of 30 studies (125).  
The association between high BP and heart failure has been reported by several 
studies. Between 1997 and 2007, a meta-analysis involving 193,424 patients from 
23 hypertension trials showed that the risk of heart failure was elevated in 
hypertensive patients. The heart failure rate was 8.5 events per 1,000 subjects 
per year (126). Dunlay et al study suggested that hypertension The most powerful 
risk factor for heart failure in the general population (127).In a cohort study, a 
liner-correlation between SBP and heart failure was found in patients not receiving 
antihypertensive drugs (128). 
1.3.3.3 Hypertension and its relationship with kidney function 
There is a close relationship between hypertension and kidney disease (129). The 
regulation of BP by water and sodium excretion is a fundamentally important 
physiological function of the kidneys. Hypertension is a recognised predisposing 
factor for kidney dysfunction (130). Among individuals with chronic kidney disease 
(CKD), the prevalence of hypertension is nearly 80% (131). African Americans show 
a particularly strong relationship between essential hypertension and end-stage 
renal disease (ESRD)  (132). However, it is not clear if this finding can be extended 
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to other ethnic groups. However, the progression to ESRD in uncomplicated 
hypertensive patients who attended the tertiary/secondary services in the 
Glasgow Blood Pressure Clinic was rare (133). 
1.3.3.4 Evidence for cardiovascular protection using antihypertensive 
agents    
The CV protection provided by antihypertensive drugs has been clearly 
demonstrated in several trials of BP lowering (66,134). This protection of CV risk 
was shown in people of different ages and different risk profiles. Based on the BP 
reduction magnitude achieved by the antihypertensive class, the risk of CV disease 
reduces regardless of which drug was used (123). 
Hypertensive patients whose BP is >20/10 mmHg above treatment target appear 
to need a combination of antihypertensive drugs to reduce the CV risk that a single 
agent is unable to provide (135,136). The Aliskiren and the calcium channel 
blocker amlodipine combination as an initial treatment strategy for hypertension 
control (ACCELERATE) trial suggested that initiating combination therapy had a 
greater benefit than monotherapy. In this trial, a group of patients received either 
aliskiren or amlodipine while another group were assigned to a combination of 
these drugs at baseline. The results indicated  combination therapy had greater 
efficacy in reducing BP than a single agent (137). The superiority of combination 
therapy has also been confirmed by an Egan et al study (138). During the first year, 
the BP levels with monotherapy did not reach the reductions in BP achieved by 
those who started with the combination therapy. A limitation of this study was 
that it was retrospective and lacked randomisation (137). 
CV risk reduction was noted to be greater for certain combinations of drugs 
compared with other combinations. For instance, greater reductions of primary 
endpoints (myocardial infarction, stroke, CHD, angina, CV mortality and 
resuscitation after sudden cardiac arrest) were observed for a combination of 
angiotensin-converting-enzyme inhibitor (ACEI) and calcium channel blocker 
(CCB). This combination proved to be better than the combination of ACEI and 
diuretics in the Avoiding Cardiovascular Complications in People Living with 
Systolic Hypertension (ACCOMPLISH) trial. The BP reduction was slightly greater 
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in the ACEI plus CCB combination than the ACEI and diuretic combination where 
the difference was only 1/1 mmHg (139). 
A meta-analysis designed to investigate the effect of BP reductions on the risk of 
stroke and myocardial infarction in diabetic patients analysed 73,913 patients 
from 31 trials, and showed the greater protection from stroke with greater BP 
reductions; however, no such correlation was observed with myocardial 
infarction. The risk of stroke was significantly reduced with rigorous BP control 
compared with less-tight control. No significant differences in myocardial 
infarction between less-tight and tighter BP controls were shown in this study. 
However, some evidence has shown that extreme BP reductions lead to increased 
myocardial infarctions and other CV diseases (140).  
The CV protection was equivalent between diabetic and non-diabetic patients who 
received antihypertensive drugs in a meta-analysis of 157,709 patients from 27 
trials. No significant difference was observed in this study between 
antihypertensive classes in lowering CV disease risks (141). 
A strong relationship was found between CV risk reduction and BP control in 
patients with high CV risk (135). Evidence from a landmark study involving 9,297 
high-risk individuals (with CV disease risk factor plus vascular disease or diabetes 
mellitus) who were followed for 5 years  demonstrated a significant reduction in 
CV complications with ACEI compared to placebo (142). Although, any dissimilar 
effects of antihypertensive classes in high-risk individuals have been investigated 
in many studies, it is difficult to interpret the results of these studies because the 
sample sizes were insufficient and the number of events was low (143,144). 
For very elderly, antihypertensive treatment has also been shown to reduce CV 
risks (145). One cohort study evaluated 3,845 individuals aged 80 years or older 
who were assigned to receive diuretics with or without ACEI and followed-up for 
a median of 1.8 years. The rate of stroke in this study was significantly reduced 
when BP was reduced to less than the target, which was 150/80 mmHg (75). Also, 
reductions in total CV risk and mortality in the elderly population with short term 
BP treatments have been reported by a sub-analysis study (145).  
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1.4 Hypertension management 
1.4.1 Non pharmacological treatment 
1.4.1.1 Lifestyle changes 
The effectiveness of lifestyle modifications in reducing blood pressure has been 
demonstrated in several studies. Clinical studies show that lifestyle changes and 
antihypertensive monotherapy drugs may have an equivalent effect on BP 
reduction. However, the low BP levels observed in monotherapy may be the result 
of low-levels of drug adherence (146). A suitable lifestyle can protect against 
hypertension or delay it in normotensive people. Other advantages of lifestyle 
modifications include the reduction of doses or amount of medical therapy, 
prevention of the initiation of drug therapy in grade 1 hypertension and the 
reduction of BP in patients already on antihypertensive drugs (147). Lifestyle 
changes have also been shown to reduce CV risk (148). Such lifestyle change 
includes salt restriction, weight reduction (while maintaining adequate BMI), 
moderate alcohol consumption, smoking cessation, regular exercise and diet 
adjustment. 
1.4.1.2 Salt restriction 
High salt consumption leads to an increase in extracellular fluid volume (149) and 
an increase in peripheral vascular resistance (150). A causal association has been 
shown between salt consumption and BP elevation. Excessive salt intake may also 
result in resistant hypertension(150). Salt intake reductions have been shown in 
several studies to lead to BP reductions. Greater BP reductions with salt restriction 
is seen  in people who are black, older, with diabetes or metabolic syndrome 
(151,152). A meta-analysis of 167 studies investigated the effects of a decreased 
salt intake of 120 mmol less than the usual intake (150 mmol) on BP levels in 
normotensive and hypertensive Caucasian, Black and Asian patients. The 
reductions of SBP/DBP were -1.27/-0.05 mmHg in normotensive Caucasian 
patients, -4.02/-2.01 mmHg in Blacks, and -1.27/-1.68 mmHg in Asians. The 
reductions of SBP/DBP were higher in hypertensive patients -5.48/-2.75 mmHg, -
6.44/-2.40 mmHg, and -10.21/-2.60 mmHg in Caucasians, Blacks, and Asians, 
respectively (151). A meta-analysis of 34 trials reported that after adjusting for 
age and ethnic groups, SBP reductions for a population with a salt-intake reduction 
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from 9–12 g/day to 6 g/day was -10.8 mmHg in hypertensive and -4.3 mmHg in 
normotensive subjects (152). Salt intake reduction has also been associated with 
increases of CV protection, as suggested by the Trials of Hypertension Prevention 
(TOHP) (153). However, this causal relationship between dietary salt reduction  
and decreased CV risk is not clear (41,154,155). 
Currently the consensus public health recommendation is 5 to 6 g/day of salt 
intake. Better results have been shown with further reductions of salt intake (to 
3 g/day); this should be considered for the population as the long-term salt intake 
target (152,156). O'Donnell et al. conclude that no evidence exists showing that 
very low sodium intake or reductions of intake to a moderate level can cause harm 
(157). A recent study included 133,118 participants from 49 countries showed that 
high sodium intake (> 6 g/day) leads to an increase in risk of CV events and death 
in hypertensive patients but not in normotensive individuals, however very low 
sodium intake (< 3 g/day) was associated with an increased risk in individuals with 
and without hypertension. Morning fasting urine samples have been collected in 
this study to estimate 24-h urinary excretion of sodium and potassium by using the 
Kawasaki formula as an alternative for daily sodium and potassium intake. 
Although this method has been validated against 24-h urine collections in the 
previous studies, there is about a 10% overestimation of 24-h sodium excretion, 
demonstrating that the true level of sodium intake at which risk of CV events and 
death changes might appear at a slightly lower of sodium intake range (158). 
previous studies of healthy individuals Quality-adjusted life years have been 
observed to increase with reduced salt at the manufacturing level in processed 
cheeses and meats, margarine, bread and cereals. However, 80% of 
commercial/manufacturing use of salt in products is hidden. A combined effort 
among the public, governments and the food industry is necessary to reduce salt 
intake in the overall population (159).  
1.4.1.3 Weight reduction  
Excess body weight is closely associated with high BP (160). Evidence from many 
studies shows that weight loss is followed by a fall in BP. An average 5.1 kg weight 
reduction results in a decrease of 4.4/3.6 mmHg (SBP/DBP) from meta-analysis 
(161). The probability of total mortality increases with higher body mass index 
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(BMI). A meta-analysis of 57 prospective studies involving 894,576 subjects 
concluded that every 5 kg/m2 of BMI above the 22.5-25 kg/m2 range leads to  a 
30% increase in total mortality with mortality at a minimum for this range (162). 
A meta-analysis of 97 studies showed that total mortality was the lowest in 
overweight subjects in the BMI range of 25 to <30, and higher mortality was 
observed in all levels of obesity (163).  Exercise and diet should be combined to 
achieve greater weight loss and CV protection. A systematic review of 43 RCT 
studies involving 3,476 individuals found greater weight loss and better CVD risk 
improvement when exercise and diet were combined compared to diet alone. 
Furthermore, CVD risk factors improved with exercise even when no weight 
reduction occurred (164). A systematic review of 5,168 participants across 9 
studies showed that combining dietary and physical activity in weight control 
strategies resulted in improvements in weight and lowered diabetes incidence 
among subjects with prediabetes (165). Other methods used to decrease weight, 
such as anti-obesity drugs (orlistat) or bariatric surgery, also appear to reduce CV 
risk (166).  
1.4.1.4 Moderation of alcohol consumption 
The linear relationship between regular alcohol consumption and high BP and 
hypertension prevalence has been shown in several epidemiological studies (167). 
Additionally, some studies have linked alcohol intake to increased risk of stroke 
(168). Moderate alcohol consumption has also been attributed to low risk of 
myocardial infarction (MI). The improvement in BP control was seen in treated 
hypertensive patients who reduced their alcohol consumption from heavy or 
moderate to low (167). The Prevention And Treatment of Hypertension Study 
(PATHS) showed that a 50% reduction in alcohol consumption among moderate to 
heavy consumers for six months reduced BP by 1.2/0.7mmHg in the intervention 
group compared to the control group (169). Total alcohol intake in male 
hypertensive patients should not exceed 14 standard drinks per week, and in 
women should not exceed nine standard drinks per week (a standard drink = 14 g 
of alcohol) (43). 
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1.4.1.5 Smoking cessation  
Heart rate and BP measurements were high in young healthy females after 
exposure to passive smoking (170). After smoking one cigarette, an acute increase 
in heart rate and BP for more than 15 minutes was observed in healthy people 
(171). The daily BP levels in untreated hypertensive and normotensive smokers 
were higher than those in non-smokers, as noted by studies using ABPM (172,173). 
However, no chronic effect of smoking on BP levels was observed with office BP 
measurement (174). Smoking is associated with an increase in mortality and CV 
risk (175). Thus, smoking cessation leads to increased CV protection, including 
myocardial infarction, stroke and peripheral vascular disease (175–177). A 
motivated patient and smoking cessation medication are two important tools that 
aid patients to discontinue smoking. A minor impact on smoking rates have been 
effected by simple advice (178). A meta-analysis of 36 trials noted the relatively 
successful cessation rates of 1.69 (1.53–1.85) among participant smokers who took 
bupropion compared to the control group at long-term follow-up (179). No 
additional effect was found by adding bupropion to nicotine replacement therapy 
(180). A modest benefit has been shown with use of varenicline (the partial 
nicotine-receptor agonist), producing better results than bupropion and nicotine 
replacement therapy in terms smoking cessation (179). However, a warning 
against using varenicline has recently been issued by the Food and Drug 
Administration (FDA). A side effects of varenicline have been reported with 
individuals who drank alcohol such as increased drunkenness, or unusual or 
aggressive behaviour. In addition, occurring seizure after using varenicline in some 
subjects who had had no history of seizures(181). 
1.4.1.6 Regular physical exercise 
The benefit of regular aerobic physical activity in preventing hypertension and in 
reducing BP, CV risk and mortality has been observed by several of epidemiological 
studies. A meta-analysis of 72 clinical trials involving 3,936 inactive normotensive 
and hypertensive participants showed that regardless of hypertension, 
participants achieved a reduction of 6.9/4.9mmHg in SBP and DBP, respectively, 
and 3.0/2.4 (SBP/DSBP) mmHg of overall resting BP with aerobic endurance 
training (182). Moderate and vigorous exercise lower mortality risk by 27% and 
32%, respectively, as shown in a large cohort study of 1,265,347 subjects (183). A 
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systematic review showed that inactive hypertensive patients exhibited a two-
fold increased mortality risk compared with those who participated in regular 
physical activity (184). Moderate exercise of at least 30 minutes of aerobic 
exercise (walking, running/jogging, swimming or cycling) for five to seven days 
per week was recommended for hypertensive patients (185). The reduction of BP 
and CV risk were also achieved with use of the aerobic interval training method 
(186). The impact of other forms of physical activity, such as isometric and 
dynamic resistance exercises, on BP values have been tested. Reductions in BP 
and other metabolic risk traits were noted with use of dynamic resistance exercise 
(i.e. force enlargement related with movement). Cornelissen et al. suggested that 
isometric exercises (muscular force enlargement without movement) may be more 
effective in reducing BP than dynamic resistance, but few isometric studies are 
available (187,188). 
1.4.1.7 Other dietary changes 
There is strong evidence for CHD prevention with a diet based on vegetables, nuts, 
Mediterranean which is type of diet, monounsaturated fatty acids and high-quality 
dietary patterns in a systematic review involving 146 prospective cohort (189). BP 
levels were lowered by the consumption of fruits, vegetables, low-fat dairy 
products and reduced saturated fat in the Dietary Approaches to Stop 
Hypertension (DASH) diet (190). The Mediterranean diet has attracted interest 
from a number of studies and meta-analyses in recent years due to its ability to 
protect against CV risk (191,192). Soy milk appears to reduce BP reduction more 
than skimmed cows’ milk (193). Diet adjustment has even greater effect on 
hypertension when accompanied with other lifestyle changes. For example, BP 
reduction was 16.1/9.9 mmHg when the DASH diet, weight reduction and exercise 
were combined rather than using the DASH diet alone (11.2/7.5 mm Hg) (194). 
Drinking 2 to 3 cups of coffee daily has been shown to increase SBP and DBP by 3 
to 14 mmHg and 4 to 13 mmHg, respectively, in normotensive people (195). The 
effect of chronic coffee consumption on BP increase or the risk of hypertension 
was investigated by a recent systematic review of 15 studies. No recommendation 
was made in this study for or against coffee consumption associated to BP 
elevation or hypertension risk because of the deficient quality of the 15 studies 
(196). 
42 
 
1.4.2 Pharmacological therapy 
Several classes of safe and effective drugs are currently available for treating 
hypertension. These include thiazide/thiazide-like diuretics, beta-blockers (BB), 
calcium channel blockers (CCB), angiotensin II receptor blockers (ARB), 
angiotensin converting-enzyme inhibitor (ACEI), alpha-blockers, and older drugs 
whose actions interferes at different sites of activation of the sympathetic nervous 
system (103). In a randomized cross-over study that compared the 
antihypertensive effect of atenolol, lisinopril, and nifedipine, all drugs were found 
to have similar effects on reducing BP. On average, monotherapy will lower BP by 
no more than approximately 7–8%. But large inter-individual variation in response 
to single agents has been reported (197) clearly reflecting the heterogeneity in 
the pathogenesis of BP increases in hypertension and the multiplicity of 
pathophysiological mechanisms responsible for BP elevation (198).  
For three decades, the conventional antihypertensive drugs (BB, and diuretics) 
have been widely recommended as first-line in most hypertension guidelines. 
Recently, the effects of BBs, and diuretics which led to them being used as a first-
line drug, have been questioned. They have been downgraded in the recent NICE 
guidelines that suggested using them as an alternative therapy for patients who 
do not tolerate ACEIs, and CCBs and not as a first line drug (199–201).  
Diuretics, BBs, CCBs, ACEIs and ARBs were recommended initial therapy by the 
most recent guidelines (43). While ESH and ESC Guidelines stated that all these 
classes were suitable to start antihypertensive treatment (41), NICE guidelines 
recommend starting with ACEI or ARB for patients aged below 55 years and CCB 
with individuals aged over 55 years and for people of African or Caribbean origin 
(43). Recent JNC guideline recommend starting with any one of these classes in 
nonblack population and diuretic or CCB in black population. They also 
recommend starting with ACEI or ARB with hypertensive patients who have CKD 
(40). Some of studies preferred to use one of these antihypertensive class in 
preference to other in some specific conditions. Table 1-3 showed the initial drug 
therapy recommendation from different recent guidelines. 
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Table 1-3: Comparisons between different recent guidelines for initial drug therapy 
Guideline Population Goal BP, mm Hg 
Initial Drug Treatment 
Options 
2014 Hypertension 
guideline 
General ≥60 y  <150/90 Nonblack: thiazide-
type diuretic, ACEI, 
ARB, or CCB; black: 
thiazide-type diuretic 
or CCB 
General <60 y 
<140/90 
 
Diabetes 
<140/90 
 
CKD <140/90 ACEI or ARB 
ESH/ESC 2013 
General nonelderly <140/90 
Diuretic, β-blocker, 
CCB, ACEI, or ARB 
General elderly <80 y <150/90 
General ≥80 y <150/90 
Diabetes <140/85 ACEI or ARB 
CKD no proteinuria <140/90 
ACEI or ARB 
CKD + proteinuria <130/90 
CHEP 2013 
General <80 y <140/90 Thiazide, β-blocker 
(age <60y), ACEI 
(nonblack), or ARB 
General <80 y <150/90 
Diabetes <130/80 
ACEI or ARB with 
additional CVD risk 
ACEI, ARB, thiazide, 
or DHPCCB without 
additional CVD risk 
CKD <140/90 ACEI or ARB 
ADA 2013 Diabetes <140/80 ACEI or ARB 
KDIGO 2012 
CKD no proteinuria ≤140/90 
ACEI or ARB 
CKD + proteinuria ≤130/80 
NICE 2011 
General <80 y <140/90  <55 y: ACEI or ARB 
General ≥80 y <150/90 ≥55 y or black: CCB 
ISHIB 2010 
Black, lower risk <135/85 
Diuretic or CCB Target organ damage or 
CVD risk 
<130/80 
ADA, American Diabetes Association; CHEP, Canadian Hypertension Education Program; ESC, 
European Society of Cardiology; ESH, European Society of Hypertension; ISHIB, International 
Society for Hypertension in Blacks; JNC, Joint National Committee; KDIGO, Kidney Disease: 
Improving Global Outcome; NICE, National Institute for Health and Clinical Excellence. Table is 
reproduced from (40) 
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1.4.3 Antihypertensive classes and hypertension treatment 
1.4.3.1 Beta blockers 
Beta blockers are able to lower BP and reduce CV outcomes and have been 
recommended as a first-choice antihypertensive drug in some hypertension 
guidelines (200). A meta-analysis of nine randomized controlled trials reported a 
significant association between heart rate reductions, which were achieved by 
beta blockers, and increased the risk of CV events and mortality for hypertensive 
individuals(202). Although, some study showed that the beneficial effect of using 
beta blockers in reducing heart rate which was associated of reducing the risk of 
CV events and deaths in these studies (203,204).  
a greater effect of using beta blockers more than other agents was found in 
patients who had recent coronary events, but a slight attenuation in stroke 
reduction (17% reduction with beta blockers compared with 29% with other drugs). 
the effect of using beta blockers that was similar to using other antihypertensive 
agents in preventing heart failure and coronary events was reported in a recent 
study of 147 randomized trials (123). Moreover, The incidence of CV outcomes was 
similar when using beta blockers or ACEIs in diabetic patients who were followed 
up for 20 years in the United Kingdom Prospective Diabetes Study (UKPDS), but 
the reduction of all-cause mortality was greater with beta blockers (205). Also. 
Retrospective observational data found that the incidence of CV outcomes was 
not higher with beta blockers than with other antihypertensive drugs in a large 
number of patients (206).  
On the other hand, beta blockers may be worse than some drug classes but not 
all. For example, The effect of BB on reducing the risk of stroke was less than that 
of renin-angiotensin system (RAS) blockers and calcium antagonists , and less 
effectiveness than calcium antagonists for reducing CV events and total mortality 
(207). Moreover, beta blockers have been shown to be less effective in delaying 
organ damage when compared with ACEIs, RAS blockers and calcium antagonists. 
This decreased organ damage has been reported in left ventricular mass (208), 
carotid intima-media thickness (IMT) thickening (209), aortic stiffness (210) and 
artery remodelling (211–213). Also, a significant association between body weight 
gain and beta blockers was noted by Sharma et al (214).  
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1.4.3.2 Diuretics 
Diuretics were recommended as the only first-choice antihypertensive drug to 
start hypertension treatments by the Joint National Committee (JNC) and WHO in 
1977(215) and 1978(216), respectively; and continued in 2003 for both (217,218). 
A recent JNC (2014) report still recommended diuretics as the initial therapy for 
hypertensive patients, but it also indicated that ACEI, angiotensin-receptor 
blocker (ARB) and CCB were all suitable for the initial treatment (40). 
Diuretics have been recommended as a first-step treatment based on several 
studies suggesting they can reduce various CV events compared with placebos. 
Diuretics have a similar effectiveness on BP control compared with other classes. 
Diuretics were also as effective in reducing CV outcomes as CCBs and ACEIs. 
Finally, another useful aspect is that diuretics are inexpensive (219). 
Recently, the choice of diuretics as a first therapy has been debated in many 
studies and guidelines (219,220). For example, diuretics have been moved from 
the first choice to the second choice in the recent NICE guidelines (43). The 
findings from ACCOMPLISH were the main reasons for the NICE guidelines decision. 
ACCOMPLISH found that the ability of calcium antagonists with ACEIs has a 
diminished ability to reduce CV events compared to diuretics with the same ACEI. 
However, the superiority of a calcium antagonist above a diuretic was not proven 
by other randomized studies (201). Diuretics with beta blockers have been shown 
to have a low tolerance and persistence when they were compared with other 
classes (221,222).  
Some have asked, Is chlorthalidone really better than conventional diuretics? The 
NICE committee preferred to use chlorthalidone or indapamide instead of using 
conventional diuretics such as hydrochlorothiazide (43). This was based on the 
statement, “There is limited evidence confirming benefit of initial therapy on 
clinical outcomes with low doses of hydrochlorothiazide”. However, this 
statement was not supported by a number of studies (201,223). Also, the results 
of meta-analyses, which showed an inferiority of hydrochlorothiazide in lowering 
ambulatory BP compared with chlorthalidone and other classes, were criticised as 
they were based on a limited number of trials with no head-to-head comparisons 
(224,225). 
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1.4.3.3 CCBs 
The effectiveness of CCB in lowering blood pressure and reducing CV morbidity 
and mortality events has been confirmed by several recent large clinical trials. 
Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-
BPLA) showed that more major cardiovascular events were prevented with a 
combination of amlodipine with perindopril than with a combination of atenolol 
with thiazide (226). The superiority of a calcium antagonist above a diuretic in 
reducing CV events for hypertension disease has been proven by the ACCOMPLISH 
study. This study found that the ability of CCB combined with ACEI to reduce CV 
events was higher than that of diuretics with the same ACEI in hypertension 
patients who were at high risk for CV events (139). Although no differences were 
found between the outcomes of ARB and CCB in reducing CV morbidity and 
mortality in hypertensive patients, the Valsartan Antihypertensive Long-term Use 
Evaluation (VALUE) study found that blood pressure was reduced more with CCB 
treatment than with ARB (227). The ALLHAT study showed that black hypertensive 
patients had better cardiovascular outcomes when using CCB rather than ACEI 
(32). Because of greater effectiveness in reducing blood pressure and CV events, 
CCBs have been recommended by most recent hypertension guidelines, as shown 
in Tables 1-3. 
The authors who had raised the suspicion that calcium antagonists cause a relative 
excess of coronary events, have cleared the class from this suspicion. Calcium 
antagonists may be more effective in preventing strokes, which has been 
suggested by recent meta-analyses (123,141,228). The reason they led to 
preventing strokes was not clear, and it was uncertain if it was because a slightly 
better BP control is achieved by this class or because of a specific protective effect 
on brain circulation (65). 
Calcium antagonists appeared to be less effective than other classes in preventing 
new-onset heart failure as reported by large meta-analyses. A recent meta-
analysis showed that incipient heart failure was reduced by about 20% by calcium 
antagonists compared with a placebo, but calcium antagonists were inferior in 
reducing heart failure when compared with other antihypertensive agents (19% 
with calcium antagonists versus 24% with other antihypertensive agents) (123). 
The trial design may be a reason that led the authors to conclude that calcium 
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antagonists have a lower effectiveness in preventing new-onset heart failure than 
others. The design of the trials was that patients who were randomized to take 
calcium antagonists needed to withdraw drugs essential in heart failure 
treatment, such as diuretics, beta-blockers and ACEIs (229). Alternatively, no 
inferior results were found with calcium antagonists in preventing heart failure 
when compared with diuretics, beta-blockers or ACEIs in the trials designed to 
allow the simultaneous use of these classes (87,89,226). A greater effectiveness 
of calcium antagonists compared with beta-blockers in delaying the development 
of carotid atherosclerosis and in lowering LV hypertrophy were observed by 
several controlled studies (209,230). 
1.4.3.4 ACEI and ARB (Renin angiotensin system (RAS) blocker) 
Renin angiotensin system blockers (ACEI, ARB) have been widely recommended in 
the recent hypertension guidelines table (1-3). Both antihypertensive classes have 
been shown to be effective in lowering CV events and reducing blood pressure in 
hypertensive patients (231). The effects of ACEI on reducing blood pressure and 
CV events have been found in three large population trials to be similar to or lower 
than those of diuretics, BB, or CCB. The ALLHAT study suggested that diuretics of 
the antihypertensive class have  a greater effect on preventing major CV risk than 
that of ACEI, BB and CCB (32). The rates of fatal and non-fatal myocardial 
infarction for 10985 hypertensive patients who were assigned to ACEI, or diuretics 
or BB in the captopril prevention project (CAPPP) study were the same for all 
antihypertensive classes. However, the rate of fatal and non-fatal stroke for 
patients who were assigned to ACEI in this study was more than that of those who 
were assigned to diuretics or BB (232). Hansson et al.’s study showed that the 
blood pressure reduction and the rate of CV mortality for patients who received 
ACEI, CCB, BB, or diuretics were similar (233). However, the superiority of RAS for 
both ACEI and ARB in preventing CV risk in hypertension patients was found in two 
large population trials (ASCOT-BPLA and LIFE studies). The ASCOT-BPLA study 
showed that the effect of ACEI in combination with CCB on reducing the risk of CV 
events in hypertensive patients was higher than that of diuretics in combination 
with BB (226). The LIFE study suggested that ARB is more effective than BB at 
reducing BP and cardiovascular morbidity and motility risk (31).  
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The effects of ACEI and ARB on reducing blood pressure and preventing CV events 
were different in several studies. George et al.’s study showed that ACEI is more 
effective at reducing blood pressure measured by ambulatory blood pressure 
monitoring (ABPM) than ARB antihypertensive class (234). A meta- analysis of 20 
trials including 158998 patients showed that reductions in CV events and the 
overall death-rate were higher with ACEI than with ARB antihypertensive class 
(235). 
ACEIs appear somewhat inferior in preventing strokes according to some meta-
analyses that compared ACEIs with other antihypertensive classes (123,228,236). 
However, there is a lower effectiveness of angiotensin receptor antagonists in 
preventing myocardial infarction (237,238). CV outcomes were directly compared 
in patients who were treated with the ramipril (ACEI) or with the telmisartan 
(angiotensin receptor blocker) by the large Ongoing Telmisartan Alone and in 
Combination With Ramipril Global Endpoint Trial (ONTARGET) study (239). 
ONTARGET found no significant differences between telmisartan and ramipril in 
the incidence of major cardiac outcomes. Also, the incidence of strokes was 
similar in both therapies. The similar effect in preventing myocardial infarction 
for both classes has also been confirmed by other meta-analyses (240,241). The 
hypotheses of peroxisome proliferator-activated receptor (PPAR) of telmisartan 
may be able to prevent the onset of diabetes more than other drugs has been 
tested (242). ONTARGET found no significant difference in the incidence of new 
diabetes between telmisartan and ramipril (239). Fewer new diabetes incidences 
were found with telmisartan but these results were not significant in the 
Telmisartan randomized assessment study in ACE-I intolerant subjects with 
cardiovascular disease (TRANSCEND) and Prevention Regimen for Effectively 
Avoiding Second Strokes (PROFESS) studies (91,243). The hypothesis that using 
angiotensin receptor blockers may lead to an increased cancer incidence has been 
raised recently (244), however, it was been not supported by a larger meta-
analysis (245). 
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1.4.4 Antihypertensive classes and specific conditions 
Some of studies showed that some antihypertensive classes have inferior on other 
in reducing BP with some patient’s characteristics or have ability to prevent CVD 
more than other. 
1.4.4.1 Age and sex 
Recent NICE guidelines recommend patients younger than 55 years initiate 
treatment with an ACEI, an angiotensin receptor blocker or a beta blocker, or to 
initiate treatment with a CCB or diuretic for patients older than 55 years (43). 
Dividing patients into groups at age 55 years has been questioned by many non-
British experts who question the evidence used to support this recommendation. 
First, the evidence to support this recommendation was taken from two BP studies 
that compared drugs for patients younger than 55 years (246,247). However, these 
studies have been criticized by stating that they were small. Second, evidence 
was drawn from a BP study that compared drugs for patients older or younger than 
60 years of age (248). This study was large but there were no significant 
differences between younger and older than age 60 years. Third, the 
recommendation relied on data from the ASCOT-BPLA trial, which compared CCB 
with ACEI versus beta blockers with diuretics for patients with a mean age of 63 
years (226). Although the results were significant between drugs, the study 
included data not related to the NICE line recommendation. 
Moreover, the NICE guidelines ignored the results from a very large meta-analysis 
published by the BP Lowering Treatment Trialists’ Collaboration. In this meta-
analysis, the benefits of various antihypertensive classes in reducing BP and 
reducing the outcome ability were compared in patients older or younger than 65 
years of age. This study found no differences in the effectiveness of different 
classes in the younger or older patients (249). The advantageous effects of 
different drugs with elderly patients have been shown in different 
antihypertensive classes by a number of randomised control trials (RCTs) 
performed with diuretic (75,250–252) beta-blockers (28,253), calcium antagonists 
(29,233,254), ACEIs (233), and angiotensin receptor blockers (255). Recent 
European Society of Hypertension (ESH) and European Society of Cardiology (ESC) 
Guidelines recommended using any one of these antihypertensive classes for 
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elderly patients, or calcium antagonists and diuretics for elderly patients who 
have Isolated systolic hypertension (ISH) (41).  
ACEIs, calcium antagonists, angiotensin receptor blockers or diuretics/beta-
blockers have been compared by 31 RCTs to determine which is more effective in 
reducing BP in one sex over the other. However, no differences in BP reductions 
were found between these classes  (256).   
1.4.4.2 Diabetes mellitus 
A meta-analysis showed that all antihypertensive classes can be used in diabetes 
mellitus patients (141). RAS blockers exhibited a greater effect at reducing 
albuminuria compared to a placebo and other antihypertensive drugs as shown in 
several RCTs in patients with diabetic nephropathy, non-diabetic nephropathy or 
CVD (257–259). Also, RAS blockers have been shown to be effective in protection 
against incident microalbuminuria. For these reasons, RAS blockers have been 
recommended for use with diabetes mellitus, especially in patients who have 
proteinuria or microalbuminuria, and in hypertensive patients with nephropathy 
(41).  
1.4.4.3 Metabolic syndrome 
RAS blockers and calcium antagonists are preferred for metabolic syndrome 
because these treatments have been shown to improve insulin sensitivity, or at 
least not worsen it. However, beta blockers (except for the vasodilating effects) 
have been shown to worsen insulin sensitivity (260–262). Because hypokalaemia 
worsens insulin sensitivity (263), potassium-sparing agents should be used in 
association with diuretics in metabolic syndrome to prevent hypokalaemia, which 
may result from diuretic side effects (262).    
1.4.4.4 Cerebrovascular disease (Stroke prevention) 
A slightly greater effectiveness of calcium antagonists in preventing stroke were 
suggested by meta-analyses and meta-regression analyses. As stroke prevention is 
the most consistent benefit of antihypertensive therapy, and has been observed 
in almost all large RCTs using different drug regimens, all regimens are considered 
acceptable for stroke prevention provided that BP is effectively reduced (264). 
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Meta-analyses and meta-regression analyses suggest that calcium antagonists may 
have a slightly greater effectiveness on stroke prevention (123,228,236) However, 
the incidence of stroke has also been reduced by using diuretics or a combination 
of diuretics and ACEIs (86,92). Meta-analyses and single trials found that ARBs 
have a greater effectiveness on cerebrovascular protection than other 
antihypertensive agents (240,265). All of these medicines are acceptable for 
stroke protection, on the condition that BP is effectively decreased. 
1.4.4.5 Heart disease 
I. Coronary heart disease  
A greater protective effect of beta-blockers has been reported after recent 
myocardial infarctions in patients with a clinical history of CHD (123). Highly 
beneﬁcial effects of an ACEI have been shown with acute myocardial infarctions 
(266,267). All antihypertensive drugs have similar effects in cases of other CHDs 
(123).  
II. Heart failure 
ACEIs, diuretics and beta blockers prevent heart failure better than calcium 
antagonists (236). In ALLHAT, diuretics showed a greater effectiveness in 
preventing heart failure than an ACEI, but this may have resulted from a study 
design that depended on the initial diuretic withdrawal, which could lead to a 
small excess of early heart failure incidences (32). Hospitalizations for heart 
failure were not reduced in patients taking ARBs below the levels of placebo 
patients according to the PROFESS and TRANSCEND trials (91,243). In patients with 
heart failure or sever left ventricular dysfunction (LVD), it is preferable to use 
BBs, ACEIs, ARBs and/or mineralocorticoid receptor antagonists to reduce 
hospitalization and mortality (268). 
III. Left ventricular hypertrophy 
Randomized comparative studies found greater effects of ARBs, ACEIs and calcium 
antagonists in LVH reduction than with beta-blockers, but they have similar BP 
reductions (230). 
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IV. Atherosclerosis 
Atherosclerosis progression has been delayed with calcium antagonists and ACEIs 
to a greater extent than with diuretics and beta-blockers (209,269). 
V. Peripheral artery disease (PAD) 
The advantages of ACEIs was shown in more than 4,000 patients with peripheral 
artery disease (PAD) who had enrolled in the Heart Outcomes Prevention 
Evaluation (HOPE) study (142). The Appropriate Blood pressure Control in Diabetes 
(ABCD) showed that a major benefit benefits of calcium antagonists or ACEIs for 
PAD patients who had intensive BP reductions (<130/80 mm Hg) (270). 
VI. Increased arterial stiffness 
Pulse wave velocity (PWV), which measures arterial stiffness, was reduced by 
ACEIs and ARBs in a meta-analysis and meta-regression analysis (271,272). 
However, the superiority of ACEIs and ARBs to other antihypertensive drugs in 
reducing arterial stiffness is not clear due to the lack of properly powered and 
high-quality RCTs. 
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1.4.5 Initial drug recommendations in the NICE guidelines  
Step one provides treatment guidelines for 80-year-old individuals with stage one 
hypertension (as defined in NICE guideline) if they exhibit one or more of the 
following factors: target organ damage, established CVD, renal disease, diabetes, 
and 10-year cardiovascular risk equivalent to 20% damage or more. In addition, it 
provides guidelines for stage two hypertensive people of any age. For patients 
aged below 55 years, an ACEI or a low-cost ARB is prescribed and they should not 
be combined. A low-cost ARB is prescribed in place of an ACEI, if the ACEI is not 
tolerated by the patient. For individuals aged over 55 years and for people of 
African or Caribbean origin irrespective of age, a CCB is prescribed and substituted 
with a thiazide-like diuretic if the CCB is not tolerated. A thiazide-like diuretic 
such as chlorthalidone or indapamide is replaced by a conventional thiazide 
diuretic such as bendroflumethiazide or hydrochlorothiazide if treatment with a 
thiazide is being started, or changed. However, it is preferred to continue with a 
thiazide for people with a stable and controlled BP. Although a beta-blocker is not 
recommended in step one, it may be considered for younger patients who are 
started on an ACEI or an ARB and if it is not suitable due to contraindication or 
intolerance, and for women who could potentially become pregnant.  
In step one, a combination of either an ACEI or ARB with a CCB is prescribed for 
people with uncontrolled BP. A CCB is substituted with a thiazide-like diuretic if 
the CCB is not suitable. An ARB is preferred to an ACE in the case of individuals of 
African or Caribbean origin. A CCB in preferred to a thiazide-like diuretic in the 
case of people using a beta-blocker to decrease the risk of developing diabetes.  
In step three, a thiazide-like diuretic is added to a combination of CCB and either 
an ACEI or ARB if the BP is not yet under control. In step four (if the BP is not yet 
under control), a spironolactone low-dose (25 mg once daily) is prescribed as the 
fourth medication if the blood potassium level is ≤4.5 mmol/l or a higher-dose 
thiazide-like diuretic is prescribed if the blood potassium level is >4.5 mmol/l, in 
addition to the drugs in step three. Blood levels of sodium and potassium and renal 
function should be monitored within one month and repeated as needed for 
further therapy with a diuretic. An alpha- or beta-blocker is considered in place 
of the additional diuretic in case of contraindication or ineffectiveness (43). Figure 
1-3 illustrate NICE recommendation.   
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Figure 1-3: NICE protocol for treating hypertension (43) 
 
1.4.6 Monotherapy versus Combination Therapy 
Despite the availability of a plethora of antihypertensive drugs as safe and 
effective treatment, poor BP control remains common worldwide (273,274). The 
ability of a single drug to achieve target blood pressure levels (, 140/90 mmHg) 
are rare (247,275).  
Combination therapy of two or more drugs has greater efficacy to reduce blood 
pressure than single agent. A recent meta-analysis on 11,000 participants from 42 
studies has concluded that a greater BP reduction was achieved by combining two 
drugs from two different classes of antihypertensive drugs than doubling the dose 
of a single agent (276). The Assessment of Lescol in Renal Transplantation (ALERT) 
study showed that the low-dose combined antihypertensive drugs (angiotensin-
converting enzyme inhibitor and calcium channel blocker) improved measures of 
cardiovascular structure and function compared with high-dose individual agent 
with either component (277). Moreover, in addition to ability of combination 
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therapy to reduce BP better than monotherapy, combination therapy results in 
attaining BP target more promptly. Several clinical trials have shown the 
importance of achieving these blood pressure goals quickly. Numerous randomized 
trials have observed that combination therapies are required for patients 
especially at high cardiovascular risk to achieve their treatment goals (227,277).  
Combination therapy of different classes 1) have various and complementary 
mechanisms of action, 2) the complementary mechanisms of action that in 
combination minimize their individual side effects so, combination have a 
favourable tolerance profile 3) the combination therapy can reduce blood pressure 
greater than that of either component of the combination. Furthermore, 
combination therapy allow blood pressure goal to be achieved earlier than 
monotherapy which is necessary in some cases such as patients with high risk 
cardiovascular disease. Although the advantages of using combination therapy as 
mentioned before, using combination therapy leading to low patients compliance 
and increasing healthcare costs (63). 
1.5 Mortality and morbidity attributable to high blood 
pressure 
Hypertension is one of the major risk factors for stroke, CHD, chronic renal failure, 
peripheral vascular disease, myocardial infarction, congestive heart failure and 
premature death (43). Hypertension is also considered one of the most 
preventable causes of premature death worldwide. Figure 1-4 shows that 
hypertension is the leading cause of the death worldwide (278). Annually, 
approximately 7.6 million individuals worldwide die an early death because of high 
BP. Four million of these premature deaths are women. Non-optimal BP is 
responsible for 54% of all strokes and 47% of all ischaemic heart disease (IHD). The 
population attributable fraction (PAF) of high BP was 12.8% of the total mortality 
worldwide. Of these, 11.4% were men and 14.3% were women (279). 
The PAF of high BP was significant in all regions of the world ranging from 4.6% to 
14.46% in the African region and in the Western Pacific, respectively. However, 
the PAF is decreasing in industrialised countries for both men and women (280). 
Approximately 2.5 million people died because of hypertension in European 
regions at the top of the chart in the World Health Organization (WHO) regions, 
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this was followed by 1.8 million deaths in the Western Pacific, and 1.4 million 
deaths in the South-East Asian region. Furthermore, 4.9 million deaths associated 
with high BP were contributed by the low-income and lower-middle-income 
countries (281). 
The high BP-associated PAF for total disability adjusted life years lost (DALYs) 
worldwide was 3.7%. DALYs was 3.9% in men and 3.6% in women. The highest 
DALYs lost associated with high BP was in the European region and the second 
highest was in the South-East Asian region. Seventy percent of total DALYs was 
caused by high BP in income and lower-middle-income countries. Associations 
between CV mortality and morbidity with high BP have been established in many 
studies (281). 
 
Figure 1-4: Risk factors leading to mortality based on country income level, estimated by 
WHO publication (2004). 
Low income: USD 825 or less; middle income: USD 826-10,065; high income: USD 10,066 or 
more as per gross national income per capita (281). 
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1.6 Global burden of hypertension  
1.6.1 Hypertension prevalence in the worldwide 
Kearney and colleagues estimated that 972 million (26.4%) of the global adult 
population had hypertension in 2000. The number of people with hypertension in 
economically developed and developing countries were 333 and 639 million, 
respectively. The population of individuals with hypertension is estimated to be 
1.56 billion (29.2%) in 2025: 413 million in developed countries and 1.15 billion in 
developing regions. Although the prevalence of hypertension in developing 
countries was higher than that in developed countries according to the report by 
Kearney and colleagues, which included years 1980–2002 (282), studies published 
from 2001 through 2007 showed no significant difference in the prevalence of 
hypertension between those countries. However, the prevalence of hypertension 
in men of developing countries was lower than that in developed countries by 6.5% 
(283). 
The World Health Organization published a study on the prevalence of 
hypertension in 189 different countries in 2009. The age-standardised prevalence 
of hypertension in men aged ≥25 years was found to be the lowest (17%) and 
highest (50%) in United States of America and Niger, respectively. Hypertension 
prevalence in women of the same age group was found to be the lowest (13.1%) 
and highest (42.4%) in Republic of Korea and Sao Tome and Principe, respectively 
(284). The prevalence of hypertension among adult men and women (aged 18 and 
above) in WHO-member countries is summarised in Figures 1-5. 
A study by Kearney and colleagues published in 2004 showed that the lowest 
hypertension prevalence rates in both men and women were in rural India: 3.4% 
and 6.8%, respectively, and the highest rates in both men and women were in 
Poland: 68.9 and 72.5%, respectively (285). Progress in economic development, 
increased globalisation, demographic changes in populations, reduction in 
physical activity, and increase in food availability are considered the major factors 
contributing to this rapid increase in hypertension (286). 
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Figure 1-5 Worldwide age standardised prevalence of hypertension as estimated in 2014. 
(A) women who aged 18 and over. (B) men who aged 18 and over. Data source for both 
diagrams: Global status report on non-communicable diseases (287). 
 
1.6.2 Hypertension prevalence in Scotland 
The trends in hypertension prevalence in Scotland have been obtained from the 
Scottish Health Survey (SHS), a nationally representative sample of adults in 
Scotland. The first survey was conducted in 1995 and the latest in 2010–2011. The 
protocol for blood pressure measurement as well as the age range of participants, 
which was 16–74 years, has remained unchanged throughout the years. However, 
participants ≥75 years were included in the 2003 survey and subsequent surveys.  
The definition of hypertension and measurement of blood pressure have changed 
since 2003. A new automated equipment, Omron HEM 907, was used to measure 
blood pressure during the 2003 to 2010/2011 surveys; the Dinamap 8100 was used 
in the 1995 and 1998 surveys. The regression equation, which was derived from 
the calibration study, has been used to convert Dinamap readings to Omron 
readings for the analysis of trends in blood pressure level over time. Accordingly, 
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hypertension was classified into four levels and each level has been defined in 
table 1-4 shown below. 
 
Table 1-4: Classification of hypertension in adult according to Scottish Health Survey (SHS) 
Normotensive  
SBP<140 mmHg and DBP<90 mmHg, not currently taking 
any drug specifically prescribed to treat high blood pressure 
Hypertensive 
controlled 
SBP<140 mmHg and DBP<90 mmHg, currently taking a 
drug specifically prescribed to treat high blood pressure 
Hypertensive 
uncontrolled 
SBP 140 mmHg or DBP 90 mmHg, currently taking a drug 
specifically prescribed to treat high blood pressure   
Hypertensive 
untreated 
SBP 140 mmHg or DBP 90 mmHg, not currently taking a 
drug specifically prescribed to treat high blood pressure 
Table is reproduced from (288). 
 
Information regarding prescribed medications was first used to define blood 
pressure categories in the SHS survey of 1998. Therefore, the trends in 
hypertension prevalence exclude the 1995 survey. Hypertension prevalence 
among men aged 16–74 years with a BP level of ≥140/90 mmHg or those on 
antihypertensive medications increased significantly from 22.3% in 1998 to 29.5% 
in 2003.In recent years, the prevalence has remained high at 32.1% and 29.9% in 
2008/2009 and 2010/2011, respectively. However, in women of the same age 
group and characteristics as those of men, the extent of increase in hypertension 
prevalence was lesser at 21.2% in 1998 and 26.7% in 2003. The proportion of 
women with hypertension in the 2008/2009 and 2010/2011 surveys were similarly 
high at 31.9% and 29.9%, respectively. One of the explanations for the increase in 
hypertension prevalence in men and women is related to the change in the 
measurement device used in the 1998 and 2003 surveys, as this might have 
contributed partly to the upward trend in hypertension prevalence. 
 From 2003 onwards, adults aged ≥16 years were included, and were found to have 
the same pattern of hypertension prevalence as that of the 16–74-year-old 
participants. According to the SHS of 2010/2011, the number of adults with 
hypertension who are aged ≥16 years comprise one-third of the adult population 
in Scotland. This number has remained relatively constant since 2003 (288). 
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1.7 Hypertension control rates 
Despite the availability of a plethora of safe and effective antihypertensive drugs, 
poor BP control remains an issue worldwide. A systematic review of studies 
published from 1980 through 2003 showed that the overall worldwide prevalence 
of hypertension was 26% with poorly controlled hypertension almost everywhere 
(from 5 to 58%). This review estimated that the awareness and treatment of 
hypertension varied from 25% to 75% and from 11% to 66%, respectively (285). 
Despite protocol-defined treatments being applied in a number of clinical trials, 
20% to 35% of patients could not achieve target BP, even though they received 
more than 3 antihypertensive Figure 1-6 shows the percentage of participants who 
achieved target BP levels in these trials (289). 
 
 
Figure 1-6: Percentage of patients achieving the JNC-7 BP goals across the number of 
studies. Adapted from Sarafidis et al study.  
ACCOMPLISH: Avoiding Cardiovascular Events Through Combination Therapy in Patients 
Living With Systolic Hypertension: INVEST: International Verapamil-Trandolapril Study; 
CONVINCE: Controlled Onset Verapamil Investigation of Cardiovascular End Points; 
ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; and 
LIFE: Losartan Intervention For Endpoint Reduction in Hypertension Study (289). 
 
Hypertension control level varies from country to country, depending on the 
strategies used to treat hypertension in that country. Surveys of five European 
countries, Canada, and the United States (U.S.) conducted in the 1990 revealed 
that the control and treatment of hypertension in U.S and Canada were higher 
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than that in Europe. Based on a threshold level of 140/90 mmHg, the hypertension 
control rate was one-third of patients in U.S and Canada, compared with 5% to 
10% in the European regions, and according to a BP threshold of 160/95 mmHg, 
the control rate was 49% to 66% in the North America compared with 23% to 38% 
in Europe. This variation of hypertension control in these countries reflected the 
differences in the treatment guidelines and diagnosis of hypertension among these 
countries (290). 
In 2009–2011, the hypertension control rate in the U.S. was 40.3% for men and 
56.3% for women. An improvement in the awareness, management, and control of 
hypertension was observed from 1999 to 2010. However, these indices did not 
improve from 2007 to 2010. The improvement in hypertension control have been 
explained by the increased efforts of several national initiatives, such as strong 
campaigning of programs, guidelines, and policies to simplify the detection, 
awareness, treatment, and control of hypertension in the US (291).  
Among the nations of the United Kingdom (U.K.), hypertension control rate is 
higher in England than in Scotland. The control rate in Scotland was 53% compared 
with 60% in England in 2011(288,292). An improvement of hypertension control 
rate has been observed in England over time; however, the control rate has 
remained constant in Scotland since 2003. The improvement in England can be 
attributed to an increase in patients taking more than two antihypertensive drugs 
in recent years (293). 
1.8 Resistant HTN 
Resistant HTN is a phrase used to describe hypertensive patients whose blood 
pressure remains over treatment goal despite the concomitant use of a three drug 
regimen of different antihypertensive classes one of which is a diuretic. This 
definition of Resistant HTN is somewhat arbitrary with regard to the number of 
medications required(294).  
In an analysis of National Health and Nutrition Examination Survey (NHANES) 
participants, only 53% of treated participants were at goal blood pressure (295). 
A cross-sectional analysis of Framingham Heart Study showed that only 48% of 
treated participants achieved a reduction in blood pressure of under 140/90 mm 
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Hg. Fewer than 40% of elderly participants aged over 75 years had their blood 
pressure controlled (296).  
The proportion of poorly controlled BP in diabetes mellitus or chronic kidney 
disease (CKD) is higher than other high risk populations, and these are the groups 
for whom guidelines recommend the application of the lower goal BP. NHANES 
showed 37% of participants with chronic kidney disease achieved a reduction in BP 
of <130/80 mm Hg (297) and only 25% of diabetes participants achieved a 
reduction in BP of <130/85 mm (295).  
Uncontrolled hypertension may be secondary to poor drug adherence and/or an 
insufficient drug regimen. It also includes those with true treatment resistance. 
There is evidence that uncontrolled hypertension can be explained by true 
treatment resistance. For instance, according to a study surveying 10,017 
hypertension patients, an estimated 30% of those treated took one 
antihypertensive drug, 40% took two antihypertensive drugs and 30% took three or 
more antihypertensive drugs(298).  
In the ALLHAT study, a large number of participants (>33 000) from different 
ethnic backgrounds (47% female, 35% African American, 19% Hispanic and 36% of 
people with diabetes), after approximately five years of follow-up, 34% of 
participants remained poorly BP control and were on an average of two 
antihypertensive drugs. Approximately 50% of participants needed three or more 
antihypertensive drugs to achieve target BP. However, this percentage might 
overestimate or underestimate the degree of treatment resistance due to the 
inclusion criteria and the restrictions posed by the study treatment protocols (32). 
1.9 Factors influencing BP control 
Age, gender, and ethnicity are factors influencing BP control (295,296,299–301). 
Other factors contributing to uncontrolled hypertension include the following: 
non-compliance to prescribed therapy, which is considered one of the most 
common reasons for uncontrolled hypertension; inappropriate measurement 
method; white-coat effect; lifestyle (BMI, alcohol intake, dietary salt, etc.); drug-
related causes (e.g. non-steroidal anti-inflammatory agents (NSAIDs)); secondary 
hypertension (294,302,303). Others causes are shown in table 1-5 (289). The 
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Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) reported that the two most 
important causes of uncontrolled hypertension and resistance are baseline SBP 
and choice of subsequent antihypertensive drug (303). 
 
Table 1-5: Causes of uncontrolled Hypertension 
 Improper blood pressure measurement 
 Heavily calcified or arteriosclerotic arteries that are difficult to compress (in elderly persons) 
 White-coat effect 
 Poor patient adherence 
 Side effects of medication 
 Complicated dosing schedules 
 Poor relations between doctor and patient 
 Inadequate patient education 
 Memory or psychiatric problems 
 Costs of medication 
 Related to antihypertensive medication 
 Inadequate doses 
 Inappropriate combinations 
 Physician inertia (failure to change or increase dose regimens when not at goal) 
Table is reproduced from (289) 
 
1.9.1 Individual factors  
Age, gender, and ethnicity are factors influencing BP control. Many studies 
observed that older patients have lower levels of hypertension control compared 
with middle-aged patients (295,296,299,301). In addition, an improvement in 
hypertension control rate over time was found to be lower in aged hypertensive 
patients. Surveys conducted between 1988 and 2000 revealed that the 
hypertension control rates increased by 12.7% in patients aged 40–59 years 
compared with 4.9% in patients aged ≥60 years (295).  
Sex differences in hypertension control, awareness, and treatment rates have 
been reported. BP control rate was higher in women with 35.5% compared with 
27.5% in men according to the NHANES 1999–2002 study (299). Men and women 
were reported to have similar rates of hypertension control in the Atherosclerosis 
Risk in Communities (ARIC) study, despite women being more likely to be aware 
of and treated for hypertension (300). The Health Survey England (HSE) 2006 
survey also reported the BP control rate to be same in men and women (293). 
ALLHAT indicated that men were more likely to have BP in control compared to 
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women (304). In the Scotland survey of 2010/2011, the overall hypertension 
control rate was similar in men and women. Hypertension control rates were the 
highest for men aged 75 years among different ages, while it was the lowest for 
women of this age (288).  
Several studies have reported that hypertension control levels are lower in 
African-Americans than in Caucasians (300,304,305). In contrast, according to the 
NHANES data of 1992–2002, non-Hispanics and African-Americans had a similar 
rate of hypertension control (299). Low rates of hypertension control, awareness, 
and treatment were more common in Mexican-Americans than in other ethnic 
groups. Only 17% of Mexican-Americans had their hypertension controlled; 
however, this result may not be accurate because of a large sampling error (299). 
1.9.2 Existing comorbidities 
The association between poor BP control and high BMI has been confirmed by 
several studies. Lloyd et al. reported that high BMI contributed to poor rates of 
SBP control in 1,189 hypertensive patients treated with antihypertensive drugs, 
only 49.0% of whom achieved their SBP targets (296). In Sandoval et al.’s study, 
only 59.7% of 1,194 hypertensive patients reached their BP goals, and high BMI 
was one of factors influencing poor BP control (306). Chmiel et al. found that BMI 
was an independent factor strongly related to high BP in uncontrolled 
hypertension patients (307). The probability of having BP controlled decreased by 
30% in hypertensive patients with BMIs over 30 kg/m2 according to Diabetes 
Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of 
Treatment (DETECT), a study that surveyed 55,518 individuals (308). The 
relationship between uncontrolled BP and BMI was also found at just above 25 
kg/m2 in Abaci et al.’s study (309).  
Associations between CVD, diabetes mellitus (DM) and CKD and uncontrolled BP 
have been found in several studies. Diabetes is the most independent comorbidity 
frequently associated with uncontrolled BP. Older hypertensive patients receiving 
more than one antihypertensive agent were the primary focus of these studies. 
Patients in these studies exhibited high baseline BP and long-established 
hypertension (296,310–316). The relationship between longstanding hypertension 
and poor BP control in hypertensive patients was also demonstrated in Kim et al.’s 
65 
 
study (314). However, some studies reported that hypertensive patients with CVD 
and DM had optimal controlled BP (317,318), or that CVD had good BP control and 
DM had no ill effects or poor control on BP (306,308,319). Some found that the BP 
control for hypertensive patients with DM and CVD was better than for those with 
DM alone (320). Petersen et al. suggested that the quality of care provided to 
hypertensive individuals with comorbidity influenced BP control, and that the care 
of these patients was better than that given to patients without comorbidities 
(321). 
Multi-antihypertensive drugs can be independent predictors of poor BP control, as 
shown in some survey studies (322,323). Dennison et al. found that hypertensive 
patients who received few antihypertensive drugs had BP below 140/90 (324). 
However, no association was found in Hedblad et al.’s study between BP reduction 
and the number of antihypertensive drugs (325). 
1.9.3 Social and economic conditions  
Interest in the influence of socioeconomic conditions on health has been growing. 
A complex consideration, these conditions include intersecting factors such as 
occupation, income, place of residence and education (326). Between 1990 and 
2000, 3.5 million deaths in Europe were determined by Mackenbach et al. to be 
due to selected causes including hypertension (327). Differences in healthy habits 
and access to healthcare over socioeconomic status may lead to inequalities in 
the rate of deaths. Kagamimori et al. suggested that health in Japan is less 
effected by socioeconomic status than in Western countries due to Japan’s smaller 
socioeconomic inequalities (328). Even though the National Health and Nutrition 
Examination Survey (NHANES)’s data reported that the prevalence of uncontrolled 
BP declined between 1999 and 2010, the rate of lower income individuals with 
uncontrolled hypertension was higher than that among other income groups (329). 
Hypertensive patients with the lowest income poverty income ratio (PIR) <1 (PIR, 
used to measure family income based on family size) were found to be less likely 
to have good BP control according to NHANES 1999 to 2004 (312). Low 
socioeconomic status has been shown to relate to increases of other CVD as well, 
such as stroke.  
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The association between education level and BP control has been evaluated in a 
number of studies (306,330–332). According to patient information (5,260 
hypertensive patients from 184 general practices) in Paulsen et al.’s study, BP 
control is higher among those with high-level education (>10-year education) than 
among those with low-level education (<10-year education) (319). The same 
results were found in Sandoval et al.’s study, which reported that poor BP control 
was associated with lower levels of education (306).  Between 1986 and 1994, the 
National Health Interview Survey was conducted to estimate the specific causes 
of mortality. Wong et al. showed that life years lost were higher by 3.5 times 
among individuals with low-level education compared to those with high-level 
education. Hypertension contributed 3.5% to the disparity in death according to 
education (333).  
Other social factors, such as whether patients lived alone, have been found to 
hinder the achievement of BP targets. One study recruited 222 subjects from 
outpatient clinics (316). BP control among single patients was compared to that 
of those with partners; poor BP was much more prevalent among the single 
individuals (319). Patients who lived in inner regional areas exhibited better BP 
control than those who lived in major cities, as shown in a longitudinal study of 
6,010 individuals (334). 
1.9.4 Physician-related factors 
Positive physician performance is essential to achieving optimal BP control (335). 
Clinical inertia, which refers to the lack of therapy initiation and/or 
intensification in patients with high BP readings, physician communication skills 
and the physician’s acknowledgment have been associated with BP control 
(336,337). Clinical inertia has been reported as a barrier to achieving BP targets 
in primary care settings. Antihypertensive drugs are not intensified by physicians 
in 20 to 45% of clinical visits from hypertensive individuals with high BP (336,338–
340). Even when SBP levels among 169 patients were observed to be above BP 
targets (>140 mmHg), physicians did not intensify the treatments (335). This lack 
of therapy intensification occurs in 16 to 30% of consultations by physicians who 
observe above-target BP in their patients (336). Viera et al. revealed that 53% of 
the BP targets among 3,742 hypertensive patients continually treated in primary 
care were poor. Only 46% of them were given intensified treatment by physicians, 
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despite their above-target BP levels (341). A positive association between 
treatment intensification and good BP control has been reported by Hicks et al. 
(342). Some physicians prefer to keep patients with the same antihypertensive 
treatments, even when their BP are high, before intensifying their therapy to give 
the drugs adequate chance to reach their full effect (337). 
Clinical guidelines have been produced to assist physicians in making correct 
decisions about suitable hypertension treatment, to reduce variation in clinical 
practices and to measure the quality of care(343,344). The purpose of such 
guidelines is to enhance the outcomes of hypertensive patients by a change in 
physician practices based on evidence (345,346). Many studies have shown the 
adherence of physicians to hypertension guidelines to be low (347–351). This could 
be due in part to differences between drug establishment recommendations and 
BP goals and the criteria used by physicians when commencing treatment 
(136,339,352–357). However,  some studies have found that physicians are more 
likely to use clinical guidelines for hypertension management (358–360). In 
response, physicians have argued that universal prescriptions and ‘one size fits 
all’ prescription attitudes present in the clinical guidelines can restrict medical 
autonomy and may not apply to all scales of hypertensive subjects 
(353,354,361,362). It should be noted that most methodologies used to measure 
physician adherence to clinical guidelines are limited, and thus underestimate 
results (363). The measurement of physician adherence to the former guidelines 
is difficult to estimate because of a lack of a universal standard (364–366).  
Communication between physicians and patients is necessary to improve BP 
control. Instructions given by physicians to patients during clinical visits have been 
observed to affect patient adherence to antihypertensive drugs (367,368). In 
Qureshi et al.’s study, general practitioners attended a programme about 
hypertension. This programme provided standard hypertension treatment based 
on recent guidelines and information about the best communication skills to 
improve BP targets. BP levels were lower in patients who received care from 
trained general practitioners compared to those who received usual care(369). 
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1.9.5 Health system factors  
Health service performance and access to healthcare have been associated with 
hypertension management and BP control. Access to services includes service use 
and healthcare supply (370). Hypertensive patients with insurance were more 
likely to have BP controlled than those without insurance, according to an NHANES 
survey conducted between 1999 and 2002 (371). In addition, BP control was better 
in health-insured patients who attended physician frequently according to a 
NHANES III survey carried out between 1998 and 2004 (312,372). Similar 
connections between health insurance and good BP control have been found in 
other studies as well (373,374).  
The impact of access to healthcare on BP control has been observed in many 
studies. Improving access to healthcare leads to enhanced BP control (375,376). 
Hyman et al., however, found no association between health insurance and 
frequent healthcare visits and good BP control in an NHANES survey (1992 to 1994) 
(377). 
1.10 Adherence 
1.10.1 Definition and its issues 
Adherence is “The extent to which a person’s behaviour—taking medication, 
following a diet, and/or executing lifestyle changes—corresponds with agreed 
recommendations from a health care provider” as defined by the WHO (378). 
Non-adherence is a serious issue that leads to a decrease in the effectiveness of 
drug treatments, substantial worsening of diseases, higher healthcare costs, 
increasing mortality rates and a failure to achieve and maintain BP control with 
hypertensive patients. Poor medication adherence causes 33–69% of all 
medication-related hospitalizations, and costs approximately $100 billion a year 
in the United States (379–382). Sokol et al. observed that overall healthcare costs 
and hospitalization rates were significantly higher for diabetes mellitus, 
hypertension and hypercholesterolemia patients who were non-adherent to their 
medications (383). The Express Scripts Drug Trend Report estimated non-
adherence cost more than $317.4 billion in 2011 (384). In England, the treatment 
costs for hypertensive patients associated with non-adherence were estimated to 
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be more than £390 million per year (385). Non-adherence can lead to significant 
increases in mortality that have been shown in patients who have discontinued 
their relevant medication therapy (i.e., aspirin, β-blockers, and statins) after 
myocardial infarction (MI) (386). 
Non-adherence to prescribed therapy is considered one of the most important and 
common reasons for uncontrolled hypertension, and is recognised as an important 
barrier to the successful treatment of hypertension and many chronic diseases 
(294,387). More than two thirds of hypertensive patients did not achieve BP 
control, and these were associated with poor adherence (388). BP has been found 
to be 30% different between those with high and low adherence in hypertensive 
patients (389).  Moreover, increased adherence to antihypertensive drugs shows a 
decline in BP among patients who enrolled in pharmacy care programmes (390). 
For these reasons, adherence plays a big part in research. Measures of adherence 
methods and the factors related to adherence rates have been evaluated by many 
studies to determine suitable methods of identifying accurate results and finding 
the factors that decrease adherence rates and the suitable solutions for this 
problem. 
1.10.2 Methods used to measure adherence rates 
Several adherence methods have been developed in clinical research that aim to 
achieve valid and reliable methods to estimate adherence in antihypertensive 
medication and other medications related to chronic diseases. Information 
collected from patients, prescription refill data and devices are used to measure 
adherence. Methods of adherence measurement are divided into two types, direct 
and indirect methods. Some of the methods used to monitor adherence are 
described below.  
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1.10.2.1 Indirect methods 
I. Self-reporting:  
Patient diaries, patient interviews and questionnaires are three commonly used 
methods for self-reporting (391). Because of the feasibility, practicality and 
simplicity of these methods (391–393), these were recommended as being the 
most suitable methods for observing adherence in clinical practice by the National 
Collaborating Centre for Primary Care and the Royal College of General 
Practitioners (London, UK) and NICE (394,395). However, these are also 
considered to be less valid estimates and less reliable methods (396–399). 
Limitations of self-reporting include the patient hiding non-adherence leading to 
overestimating adherence, there may also be recall bias and patients may be 
influenced by the quality of questions and the interviewers’ skills (391,400). 
Combining self-reports with prescription fill data or other objective information 
may be necessary to allow for more accurate adherence measurements (400). 
II. Electronic adherence monitoring devices: 
The Medication Events Monitoring System (MEMS) cap is a special prescription 
bottle cap that is an example of an electronic monitoring device for drug 
adherence. Every time the MEMS cap is opened, the date and time are recorded 
by a computer chip built into the MEMS cap (392,401,402). MEMS caps are 
considered the gold standard for adherence due to the successful empirical 
performance results reported in numerous studies (402–405). Disadvantages of this 
method include the fact that it is expensive, cumbersome and could adversely 
affect medication adherence measurements. An example of adversely affecting 
medication adherence measurements is the data recorded when the patient 
simply opens and shuts the cap (unintentionally, or otherwise) (391,394,406). 
 
III. Pharmacy Refill Rates: 
The appearance of centralized computing and the increased availability of drug 
insurance claims data led to an increase in the use of pharmacy refill data to 
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measure medication adherence (391). The most appropriate methods used for 
calculating adherence from pharmacy refill data are the proportion of days 
covered (PDC) and the medication possession ratio (MPR) (407–409). Some 
assumptions should be available in this kind of method to ensure good results, 
such as all the prescription fill data should be completed. Furthermore, all of the 
necessary variables and records should be available (391), and all prescription fill 
data should be obtained from one source (e.g., a nationalized healthcare system). 
For example, the data obtained from different sources (e.g., another pharmacy, 
another healthcare insurer, etc.) may not indicate if all of the medications were 
consumed (392). Pharmacy refill rates are becoming more widely used because 
they are objective, good for large populations and long treatment times, average 
adherence and gaps in medication can be calculated, and the frequency of 
medications obtained by the patient are captured. However, they have some 
drawbacks as variations in prescribed use do not record all of the instructions 
(e.g., pill splitting), the consumption of medication is assumed, and the data may 
not complete if the patients receive medication from other sources (410). 
IV. Pill Counts: 
The dosage units not taken by patients are counted at the time of the 
appointment. The proportion of adherence is calculated by dividing the number 
of dosage units actually taken by the expected number of dosage units that should 
have been taken, and multiplied by 100 (401,411,412).  
Despite the fact that this method is one of the most commonly used in clinical 
trials (413) due to it being relatively simple, objective and economical (392), some 
limitations still exist. One limitation is called an over-adherence estimate that 
occurs when the patient wants to appear more adherent by discarding some of the 
dosage before the scheduled check. Another disadvantage involves the dispensing 
date shown on the label, which may not reflect the actual date when the patient 
began to consume the medication. Also, pill counts do not provide certain 
information about adherence such as behavioural information (396,402,410,412). 
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1.10.2.2 Direct methods 
I. Direct patient observation: 
This technique is considered the ideal method to measure adherence since one 
can directly observe patients while they are taking their medications. These 
methods involve many limitations including the difficulty of use in an outpatient 
setting or in large studies, and the medications can be hidden in the mouth and 
discarded later (391,392,401) 
II. Drug levels in biological fluids/biological assays and biomarkers: 
Adherence can be monitored by detecting the existence of the drug or its 
metabolite in a biological fluid, or by adding a non-toxic marker to the target 
medication and then measure the endogenous biomarker of the drug or its 
associated metabolites (391). For example, an endogenous biomarker of an ACEI 
drug was measured for patients who had hypertension and diabetes mellitus. The 
creatinine ratio for patients who received ACEI drugs was six-times higher than in 
patients who received a placebo (414). These methods are considered objective 
techniques and direct measures of medication adherence. However, criticisms for 
these methods noted by researchers include that these methods are difficult to 
apply on a routine basis, and there is an inability to measure adherence for more 
than one drug, or to detect short-term changes in adherence (391,392,401). Also, 
a patients’ actual medication-taking behaviour is not measured in these methods. 
For example, they can find the required level of the drug or associated metabolite 
in the biological fluids, but the medication may not have been taken as directed 
(391). 
1.10.3 Comparison between different adherence methods 
The level of agreement between different adherence methods measurements 
were compared in several recent reports. Wide variations in adherence were 
reported between these methods. The level of agreement between three 
validated self-report tools and a refill rates method was found to be moderate by 
Cook and colleagues (415). The medication adherence in self-report and non-self-
report methods was evaluated by Garber and colleagues. In this study, the 
comparison of adherence by the three methods of self-report (interview, diary 
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and questionnaire) and several non-self-reports such as pill counting, plasma drug 
concentrations and MEMS was performed (416). The self-reports were compared 
with the non-self-reports in the 86 comparisons, and 17% of these comparisons 
reported high adherence with self-report and electronic methods, while 58% 
reported high adherence with self-report and other non-self-report measures.  
Hamilton et al found a significant correlation between electronic method (MEMS) 
and self-report measures (417). The BP goals were achieved by 50% of adherent 
patients in the African American Study of Kidney Disease and Hypertension (AASK), 
which determined their adherence by electronic and pill counts (418). 
The validity of refill rates and pill counts was assessed by Choo et al. Adherence 
was measured in 286 hypertensive patients using an electronic method as the 
validation standard. They found that the electronic method was highly correlated 
with the quantity of dose adherence for both the pharmacy refill rate and pill 
count (419). 
In a study with 107 hypertensive individuals, Hamilton found significant 
correlations between pill counts and MEMS with partial-to-complete adherence 
(417). 
Regarding the biologic fluid drug assays, adherence was assessed with MEMS and 
the method by Braam et al. In their study, they gave capsules of potassium 
bromide to 24 healthy participants and found a linear relationship between the 
dosage taken and the increased mean serum bromide concentrations (420). 
 
1.10.4 Factors effecting on adherence. 
A wide variability of the adherence rates across hypertensive patients and 
antihypertensive therapies have been shown in several studies. The number of 
participants and duration of follow up were different, which could lead to 
variability of adherence rates. Many studies found moderate to high adherence 
(50–80%) in hypertensive patients (390,421–424). However, low adherence and 
persistence rates (≤ 30% of patients) have been documented by a number of 
studies (425,426).  
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Factors such as sociodemographic, psychosocial or behavioural variables, 
healthcare system, therapeutic regimen and comorbidity factors have been 
studied in an attempt to find associations between these factors and adherence 
rates. The association between these factors and adherence were collected from 
hypertension studies which investigated the relation between antihypertensive 
drug and hypertensive patients.   Factors-related-adherence are described below. 
1.10.4.1 Sociodemographic factors   
Some outcomes for these factors, such as sex, age, race, and status marital were 
inconsistent between different studies. Men were more adherent in some studies 
(426–428) while others found that women were more adherent (424,429), and 
there was no difference in adherence between men and women in other studies 
(430).  Age was treated as a continuous variable (428–430) or categorised into two 
or three groups. The cut-off point at 65 years was used to investigate the effect 
of age on adherence above or below this point (418,422,423). Adherence rates 
increased with age in some studies (428,430). Some studies observed that patients 
aged 65 or more were more likely to adhere to their drugs than those aged less 
than 65 years (422,427), while Krousel-Wood et al., who compared adherence 
among patients aged over 75 with those under 75, found no association between 
age and adherence rates (424). In addition, some studies reported an association 
between younger patients (aged less than 65 years) and good adherence rates 
(426).  
According to Rizzo’s study, Caucasians exhibit better drug adherence (430); 
however, other studies reported no significant association between race and 
antihypertensive drug adherence (422,424). Patients’ education levels and 
knowledge of hypertension were not associated with adherence either (424,431). 
Krousel-Wood et al. found that patients who were married were more likely to 
adhere to their drugs (424). However, no significant difference in adherence was 
observed between patients who were married or living alone in Ren et al.’s study 
(422). 
75 
 
1.10.4.2 Psychosocial / behavioural variable factors  
A negative relationship between depression symptom severity and adherence rates 
was reported in some studies (424,431). Other factors such as health beliefs and 
smoking or drinking habits were not associated with adherence (424,431). Low 
health-related quality of life in a physical way, high Stressful Life Event scores 
and high perceived stress were associated with low adherence rates (424). The 
involvement of patients in treatment decisions enhanced patient adherence (422).  
1.10.4.3 Healthcare systems 
There was a positive relationship between the number of visits to the doctor and 
the adherence measures in several studies (424,425). Patients treated by younger 
doctors were more likely to be adherent (422). Also, patients treated by nurses or 
physicians’ assistants tended to be more adherent to their therapy than patients 
treated by physicians (422). Patients who collected all their antihypertensive 
prescriptions from the same pharmacy were more likely to be compliant (425). 
Moreover, medication adherence increased among patients who entered  
pharmacy care programmes for 12 months, as shown by Lee et al. (390). 
1.10.4.4 Therapeutic regimen and Comorbidity factors  
Various other studies examined aspects of the association between patients and 
the therapeutic regimen factors. Patients who took two drugs in one tablet as a 
combination were more adherence than those who took the drugs separately 
(426,432,433). Also, patients who took multiple doses per day were less likely to 
be adherent (423). 
Adherence and a large number of other medications other than antihypertensive 
drugs were analysed in some studies. A large number of other medications was 
defined as patients who took more than eight other medications in some studies, 
or more than three other medications in other studies (424,425). Patients who 
took more than eight other medications were found to have a negative effect on 
adherence (425), while three other medications was found to have a positive 
effect on adherence (425). High adherence was also found among patients with 
high ‘other medication’ numbers (patients who took five or more medications) 
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(426). The number of other medications was treated as a continuous variable, and 
higher numbers were associated with better adherence (422). 
The effect of initiating a specific antihypertensive class on adherence has been 
tested in a several studies. Most studies concluded that the adherence rate with 
diuretics was the lowest. High adherences was associated with ACEIs, and 
angiotensin-II antagonists in most adherence studies (425,428,430,434). 
Concerning comorbidity factors, patients who had evidence of two or more 
comorbidities (e.g. diabetes, heart disease, dyslipidaemia or obesity) were found 
to exhibit better adherence (426,428,430).   
1.11 Persistence 
1.11.1 Definition and its issues 
Terms such as continuation, discontinuation and switching are widely used in 
persistence studies.  Different persistence methods and definitions have been 
used to define continuers, discontinuers and switchers in these studies.  
Persistence was used to determine if the patient is still taking medication after a 
period of time. The terms persistent and continuation are typically used to 
describe the outcome. Patients who refilled their initial antihypertensive drug on 
or within three months after the one-year anniversary of the beginning date were 
described as persistent users in some studies (435,436). Degli Esposti et al. 
observed patients over one year and considered them as persistent if they 
continued with their initially prescribed drug at enrolment for a duration of > 273 
days (437). Other studies defined a patient as persistent if the last prescription 
covered the study period until the last day of the observation (438,439). Patients 
were also defined as persistent if they did not miss any three of their scheduled 
refills during the year (440). 
A gap in treatment is defined as discontinuation. The duration of the period 
without medication varies in different studies and ranged from 30 to 180 days 
(434,437,440–443). Switchers are patients who change the initial monotherapy to 
another antihypertensive drug. Switchers of a regimen were considered as 
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continuation of therapy in some studies (431,437–439). However, some studies 
considered this as discontinuation (435,442–444). The additional drugs were 
ignored in most studies that focused on studying the initial therapy continuation 
(435,436,442,443). On the other hand, some studies classified the additional drugs 
as modifications of therapy (445,446). Rate of switching varied across studies and 
ranged between 4-15% (443,447). 
Although there are a number of effective antihypertensive agents that have 
proven ability to protect against CV risk and mortality, most of these studies 
included large number of patients who discontinued or switched their drugs. 
persistence rates varied between studies and ranged between 5% to 75% (448). A 
cohort study that examined 5,225 individuals from 48 Swedish primary healthcare 
centres showed that 1% of patients who received antihypertensive prescriptions 
from general practitioners never purchased their drugs, and 14% of patients 
discontinued their drugs after one antihypertensive prescription (449). 
Discontinuation and drug switching may reflect the drugs’ tolerability; in simpler 
terms, patients discontinue or switch medications due to the side effects of the 
drugs (450–452).  
Non-persistence may lead to poor BP control (450,453,454). Moreover, it leads to 
an increase in the cost of medication. It has been estimated that 76.5 million 
pound sterling is spent to treat hypertension per year, and around 26.9 million 
pound sterling of this total cost is attributed to switching or discontinuation 
therapy (455). Corrao et al. reported that 37% of CV outcomes were reduced 
among patients with high persistence compared with those who had very low 
continuation (429). 
Many studies have focused on the use of the initial therapy to measure persistence 
(435,437–439,442). However, others did not (422). Initial therapy was defined  by 
the class of antihypertensive drug in some studies (435,437–439,442,443),whilst 
others specified a specific antihypertensive drug from an antihypertensive drug 
class and compared this with another other specific antihypertensive drug from 
another specific antihypertensive class (432).  
The purpose of studying new patients is to compare relevant variables at baseline 
and  avoid biases that occur with increased duration of therapy that leads to an 
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increase risk of discontinuation (456). New patients are usually identified either 
from the date of diagnosis (446) or by prescription data. For prescription data, 
new antihypertensive drug users are identified if they did not have any 
prescription records during a certain period prior to the inception date. This 
period varied in these studies and ranged between 3 to 12 months 
(434,435,439,443,447,457). 
1.11.2 Factors effecting persistence 
1.11.2.1 Demographic and social factors  
Older (>65 years) female patients exhibit better drug persistence than do young 
men (aged <65) (435,437,439,447,449). Qvarnström et al found that patients with 
high blood pressure tend to have high persistence (449). In contrast, patients with 
severe BP value were shown to be more likely to be non-persistent in Mazzaglia et 
al study (447). High income was associated with good persistence, and there was 
no significant correlation between education levels and persistence in Qvarnström 
et al study (449).  
1.11.2.2 Healthcare systems 
Several studies showed good direct correlation between number of visits to the 
doctor and the persistence rates (438,443). Patients treated by younger doctors 
were more likely to be adherent(437). Large Canadian and Italian studies found 
high persistence rates in patients who had previously been admitted to a hospital 
(437,438). Although, Degli Esposti et all found no association between previous 
hospitalization and persistence using the same Italian population, but with a 
smaller sample (437). Hospital admission was found to be non-significantly 
associated with persistence in Caro et al. study (439). 
1.11.2.3 Comorbidity factors 
Qvarnström reported that patients with diabetes were more likely to continue 
with their drugs. Other CV comorbidities were not significant in this study (449). 
Patients who had evidence of two or more comorbidities, such as diabetes and 
heart disease, were found to be more persistent with their drugs, as shown in 
Degli Esposti et al. study (437). However, Mazzaglia et al. found that comorbidities 
79 
 
were associated with a higher risk of discontinuation among patients with chronic 
disease scores of at least three (447).  
1.11.2.4 Therapeutic regimen factors  
Various other studies examined aspects of the association with therapeutic 
regimen factors. Patients who took two drugs in one tablet as a combination were 
more persistent than those who took the drugs separately (432,440). Also, patients 
who took multiple doses per day were less likely to be persistent (435). Patients 
who took large number of non-hypertensive medications were found to be more 
persistent (439). 
The variation of persistence rates between antihypertensive classes has been 
examined in several studies. Although Benson et al. suggested there were no 
differences in persistence rates between drug classes (442), most studies 
concluded that the persistence rate with diuretics was the lowest. Low 
persistence, in no particular order, were found with β-blockers, CCBs, ACEIs, and 
angiotensin-II antagonists (435–437,447). 
1.11.2.5 Factors affecting switching and additional therapy 
Wong et al. reported that old age, high baseline SBP, increased comorbidity levels 
and patients living in less urbanised regions were associated with medication 
switching. However, this study observed no significant relationship between 
antihypertensive drug switching; they concluded that all drugs have similar 
switching rates (441). Mazzaglia et al.’s study found high treatment switching 
rates, in no particular order, for alpha-blockers, diuretics and CCBs. No significant 
association was found between other factors and switching in this study (447).  
With regards to additional therapy, Patel et al. noted ACEI and diuretics as the 
drugs most needed in addition to other antihypertensive drugs (434). Mazzaglia et 
al. suggested that ARBs, CCBs and ACE were the most required drugs in 
antihypertensive additional therapy. According to this study, the risk of patients 
requiring additional drugs increases with elevated baseline BP and familial history 
of CVD, but decreases with higher chronic disease scores (447).  
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Chapter 2 Methodology 
2.1 Study population  
More than 16000 hypertensive patients attending the Glasgow Blood Pressure 
clinic (GBPC), participated in this series of studies. The GBPC provided the clinical 
information for these subjects. The Information Services Division (ISD) data of 
11568 patients, which included all their antihypertensive prescription 
information, were available through data linkage from the NHS Scotland (ISD). 
Further, information for 613 patients was recorded from the patients’ case notes, 
including their antihypertensive treatment, blood pressure, and clinical 
information. The total number of patients who had GBPC and ISD data was 10,040. 
The number of hypertensive patients who participated in the initiation of 
antihypertensive drug chapter after inclusion and exclusion criteria was 4232. A 
total of 4232 and 3149 participants were included in the persistence study to 
examine persistence at one year and five years, respectively. The study of 
adherence and additional therapy was restricted to those patients who were 
persistent with the medications (3085 for one year and 1979 for five years). The 
concordance study included 443 patients who had GBPC, ISD, and case note data. 
The resistance study included 864 patients who initiated and persisted with their 
treatment for five years and had BP readings. The inclusion and exclusion criteria 
varied between chapters and will be discussed in detail for each chapter. The 
number of patients who were included in each chapter is displayed in flow chart 
2-1. 
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Figure 2-1: Flowchart of number of patients who were included in each chapter.   
GBPC: Glasgow Blood Pressure Clinic, ISD: Information Services Division 
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2.2 The Glasgow Blood Pressure Clinic (GBPC) 
The GBPC provides secondary- and tertiary-level services to hypertensive 
individuals from the West of Scotland. Information from patients attending the 
clinic from 1968 are stored in a computerised database (458,459).  
Demographic and clinical information for more than 16,000 subjects have been 
recorded until 2011. All patients referred to the GBPC were diagnosed with 
hypertension in primary care clinics, using the definitions of hypertension based 
on contemporary guidelines, and if appropriate, treatment was commenced in 
primary care. All patients were treated at the GBPC until their blood pressure (BP) 
control was stabilized by continuing with follow-up at the clinic or in primary care.  
A structured format was used to enter clinical details such as age, weight, height, 
family history of hypertension and heart rate. A structured format was also used 
to assess the presence of existing cardiovascular disease (such as airways diseases, 
angina, cerebrovascular disease, heart failure, ischaemic heart disease, 
myocardial infarction, and stroke), left ventricular hypertrophy, tobacco (any 
versus none) and alcohol use (any versus none).  
24 hours ambulatory blood pressure monitoring, echocardiogram (ECG), exercise 
tolerance testing, plasma renin and aldosterone, chest X-ray, and magnetic 
resonance imaging are available for a subset of patients who need these 
investigation. A structured format transfer to the electronic database afterward. 
2.3 Physician communication and the number of visits 
Blood samples collected at the first visit and during follow-up at the clinic were 
analysed using the hospital laboratory’s auto-analyser. One month after their first 
visit, patients attended the clinic to review all laboratory and clinical results. 
At the clinic, BP measurements were taken manually three times using 
standardized sphygmomanometers at each visit by specialist hypertension nurses; 
the mean of the last two measurements was recorded at each visit. Patients 
attending the clinic were advised to take their regular medications as usual. 
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The frequency of visits to the GBPC mainly depended on the BP levels of the 
individual patients and the presence of other co-morbidities. Usually, more 
frequent clinical visits occurred during the first year for new patients until their 
blood pressure (BP) were control. 
During each visit, the doctor asked the patient about his/her prescribed 
antihypertensive drugs.  If the patient was unsure, the doctor requested that the 
patient bring the drug(s) to the next visit. 
2.4 Laboratory and clinical measurements 
2.4.1 Blood pressure measurement  
The patient was placed in either a supine or sitting position for five minutes prior 
to BP measurement. 
Maintained, and calibrated mercury sphygmomanometers (Accoson Dekamet MK3, 
UK) were used for reading blood pressure. The tight clothing was removed, and 
arm was supported at heart level position. The appropriate cuff size was taken.  
The cuff was inflated above the brachial artery until the pulse disappeared. When 
the pulse appeared again by deflating the cuff, the systolic blood pressure (SBP) 
was recorded as an estimation. The cuff was then re-inflated to 30 mm Hg over 
the SBP estimation, a stethoscope was placed and the cuff was deflated at the 
rate of 2 mm Hg per second. The SBP was recorded when the rhythmic sound 
appeared, and diastolic blood pressure (DBP) was recorded when the sound 
disappeared by continuing the deflation. 
BP measurements were obtained manually two times. Third measurement was 
taken if the second reading was significantly lower. The mean of the last two 
measurements was recorded.  
The difference between the SBP and DBP was defined as pulse pressure. SBP < 140 
mm Hg and DBP < 90 mm Hg were the therapeutic target of blood pressure. 
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2.4.2 Obesity 
The World Health Organisation (WHO) has classified the weight of adults into the 
categories of obesity, underweight and overweight (460). A BMI equal to or more 
than 30 kg/m2 was defined as obesity. Overweight or pre-obesity was defined as 
a BMI between 25 and 29.99 kg/m2. A BMI between 18.5 and 24.99 kg/m2 was 
defined as an optimal weight. 
Calibrated weighing machines were used to measure body weight (Seca 955 chair 
scale). A height stick was used to measure height. 
2.4.3 Renal function 
Estimated glomerular filtration rate (eGFR) was used to evaluate renal function. 
eGFR was calculated from the baseline serum creatinine values. Modification of 
Diet in Renal Disease Study Group (MDRD) equation was used to calculate eGFR. 
The three variable modification were included with serum creatinine values in this 
equation. These variable are age, race, and sex as shown in equation below (461).  
eGFR= 32788 × serum creatinine (in μmol/L) -1.154 × age -0.203 *(1.212 if black) × 
(0.742 if female) 
According to the National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative (NKFKDOQI) and based on eGFR, kidney function was classified into 
normal or 3, 4, and 5 stages (Levey et al., 2003). While a normal kidney was 
considered as having an eGFR ≥ 60 mL/min/1.73 m2, CKD stage 3 was determined 
if the eGFR was between 30 and 59 mL/min/1.73 m2. The eGFRs between 15–29 
mL/min/1.73 m2 and < 15 mL/min/1.73 m2 were considered as CKD stages 4 and 
5, respectively. 
2.5 Smoking status and alcohol status 
Specialist nurses or physicians interviewed patients during their first visit to obtain 
smoking status, alcohol status and family history of hypertension information. A 
copy of this information was kept in the case notes as well as transferred to the 
GBPC electronic database. 
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2.6 The GBPC database  
Clinical characteristics were recorded in the electronic database for all patients 
who had visited the GBPC since its establishment. The database stores the 
information of more than 16,000 patients; it is available for audit and research 
purposes. 
Information from the first visit was recorded in the first row for each patient, 
including the date, SBP and DBP reading, and heart rate. These information during 
subsequent visits to the GBPC were also coded. 
The demographic characteristics were also stored. The stored information 
contains age, gender, BMI, alcohol intake and smoking status. 
In addition, electronic database contains biochemistry results such as eGFR, total 
cholesterol, bilirubin, albumin, ALT, and gamma GT. Other information such as 
the presence of existing cardiovascular disease, LVH, and family history of 
hypertension were also entered.  
The ambulatory blood pressure (AMPB) and the date of blood measurements for 
more than 2000 patients were also saved as database.  
2.7 The Information Services Division (ISD) database 
Pharmacy refill data were obtained from the Prescribing Information System (PIS), 
an electronic database of all National Health Service (NHS) prescriptions dispensed 
to individuals across Scotland, which is maintained by NHS National Services 
Scotland (NSS) (462) and linked to the hospitalisation using the unique patient 
Community Health Index (CHI) number. The PIS is created from information 
supplied by the Practitioner Services Division of the NSS, which is responsible for 
the processing and pricing of all NHS prescriptions dispensed in Scotland (463). 
Data on private (non-NHS) prescriptions are not routinely collected and were 
therefore unavailable for analysis; however, as prescription charges were 
abolished in Scotland in 2011 and the NHS is free at the point of use for the entire 
population, the relative contribution of these prescriptions is expected to be low. 
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The PIS contains fields for a variety of metrics, including prescriber and dispenser 
information (e.g. location and organizational structure) and prescription details 
(e.g. the name, strength, formulation and cost of the medicine). 
Data fields included date of dispensation, the class and name of the medicine, 
and the number of items. Medicines were categorized by both British National 
Formulary (BNF) subsection and approved name. Antihypertensive drugs were 
classified as alpha blockers, angiotensin converting enzyme inhibitor (ACEI) 
Angiotensin II receptor antagonist (ARB), beta blocker (BB), calcium channel 
blockers (CCBs), centrally acting antihypertensive, non-thiazide diuretic, 
potassium sparing diuretics, thiazide diuretic, and vasodilators antihypertensive 
drugs. The number of items referred to those items processed and paid for under 
NHS Scotland, excluding those from GP10A (Stock Order) forms and hospital-based 
prescription forms. 
Prescription data and outcome data was obtained from the Information Services 
Division (ISD) Scotland which provided data for all patients attending the Glasgow 
Blood Pressure Clinic during the period of 31/12/2003 to 31/03/2013.  The CHI 
number had been used to connect the ISD prescription data and the GBPC data 
including the patient’s BP, demographic characteristics and biochemistry results.  
 
2.8 Coding of antihypertensive drugs from patients case 
note. 
Drug treatment and patient characteristics were reviewed and recorded using two 
MS Excel sheets. The history of antihypertensive drug use for each patient was 
coded in the first sheet.  
The antihypertensive drug usage of each patient was recorded from the time they 
were referred to the GBPC from primary care until the last visit. Information from 
the first visit was recorded in the first row for each patient, including the date 
and BP reading, all antihypertensive drugs being taken, discontinuation of any 
antihypertensive drugs. 
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Changes in the patient’s medications during subsequent visits to the GBPC were 
also coded. These changes included the addition of new drugs, substituting a drug 
with another drug, discontinuing a drug, and changes in the dose of the drug. 
Alterations in clinical BP readings due to these changes were coded. The clinical 
BP was recorded before and after the alterations in drug consumption. The 
information recorded in the first sheet included age, sex, and family history of 
hypertension, as well as other CVD episodes. 
Patient characteristics were coded in the first sheet and include the following 
information: all concurrent diagnoses in addition to hypertension, ECHO results, 
ECG results, and ABPM results. 
2.9 Repeatability and reproducibility 
2.9.1 Introduction 
Repeatability is defined as the variation in measurements made on one item 
measured repeatedly by one observer under identical circumstances. 
Reproducibility is defined as the variation in measurements made on the same 
item when one or more factors are varied. This means that measurements are 
made by a different observer, in a different environment or with different 
measurement methods(464). 
The purpose of studying both repeatability and reproducibility was to test 
agreement between two results obtained from the same data, which was recorded 
twice by the same or a different person, to test its precision and/or reliability. 
2.9.2 Methods  
Drug treatment and BP were reviewed and recorded using MS Excel sheet. 
Patient’s information was recorded from the time they were referred to the GBPC 
from primary care until the last visit. These information such as the date of visit, 
BP reading, all their antihypertensive drugs being were coded. 
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The clinical BP was recorded before and after the alterations in drug consumption. 
These information were taken from patient's record which was written by his/her 
physician after patient’s visit. 
For repeatability purposes, these data were recorded twice at two different 
times. For example, the information was first recorded when a patient’s case 
notes were collected during his/her clinical visit and before being seen by his/her 
doctor. The information was recorded a second time when the patient’s case notes 
were collected during his/her subsequent visit and before being seen by his/her 
doctor.  
For reproducibility, Dr Safa Alsanosi, a PhD student, was involved in this study so 
the data would be recorded by another investigator. Dr Alsanosi recorded the 
information that I had independently recorded. Safa and I had the same Excel 
sheet, and we agreed to follow the same protocol when recording information. 
Therefore, these data were recorded by two people at the same time when case 
notes were collected during clinical visits and prior to patients being seen by a 
doctor. 
The effect of changes in BP therapy were calculated by take the difference 
between the BP before and after drug change or addition. Intraclass correlation 
coefficient (ICC) was used to estimate the agreement between two BP value 
alterations, which were repeatedly recorded for the same individuals, same drugs 
and on the same visit date (BP alteration by me versus BP alteration by me for 
repeatability and BP alteration by me versus BP alteration by Safa for 
reproducibility). 
2.9.3 Results 
I recorded 113 patients in duplicate twice at different times. Dr Alsanosi and I 
recorded a total of 265 patients independently.  Regarding repeatability, a high 
degree of reliability was found between alteration of SBP and DBP in both sets of 
my data. The single measure of ICC was 0.976 with a 95% confidence interval from 
0.969 - 0.982, and 0.988 with a 95% confidence interval from 0.984 - 0.991 for 
SBP, and DBP, respectively.  
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SBP, and DBP for reproducibility were 0.985 with a 95% confidence interval from 
0.983 - 0.987, and 0.965 with a 95% confidence interval from 0.960 - 0.969, 
respectively. A high degree of reliability was found between alteration of SBP and 
DBP in my data and Safa data. 
2.10 Ethical approval 
The West of Scotland research ethics service (WoSRES) of the National Health 
Service approved the study of the GBPC database (11/WS/0083). 
2.11 Statistical Analyses 
2.11.1 Statistical packages used 
A statistical analysis was performed using Statistical Package for the Social 
sciences (SPSS) software for Microsoft Windows Version 22.0 (IBM Corporation, 
Armonk, New York, US). 
2.11.2 Summary statistics 
The mean ± standard deviation (SD) for the data normally distributed was used to 
summarise the quantitative variable. A natural logarithm and back-transformed 
were used to transform some of the data that were not normally distributed. The 
percentage of the cohort was used to summarise the categorical data. P-values 
were considered significant when the difference between the groups was less than 
0.05. The Bonferroni method was used to correct the various significance tests 
that resulted from multi comparisons on the same dataset. 
2.11.3 Comparison of two means  
Two sample t test was used to compare the differences between two groups for 
normally distributed continuous data. A natural logarithm was used to transform 
some of the data that were not normally distributed to obtain normal distribution. 
Chi-square or Fisher’s exact tests (for small sizes) were used to compare the 
categorical data. A P-value less than 0.05 between the two groups was considered 
significant. Multiple testing correction was applied to all statistical tests using the 
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Bonferroni method. The Bonferroni was calculated by dividing the number of 
variables that were compared by 0.05. 
2.11.4 Comparison of more than two means  
For normally distributed, the difference between more than two groups of 
continuous data were compared using one way analysis of variance (ANOVA). A 
natural logarithm was used to transform some of the data that were not normally 
distributed to obtain normal distribution. 
Chi-square or Fisher exact tests (for small sizes) were used to compare the 
categorical data. Chi-square test for trend was used to examine the linear 
association in categorical data. P value at 0.05 and Bonferroni value after 
calculation were considered as significant results. 
2.11.5 Logistic regression  
The association of a binary result with possible predictors was investigated by 
using binary logistic regression. Multinomial logistic regression was used to test 
the association of more than two categories with possible predictors. 
The impacts of age, BMI, SBP, DBP, sex, smoking status, alcohol intake, eGFR, 
albumin on persistence, adherence, additional therapy, resistance HT, and blood 
pressure response were tested. These factors were determined based on the 
possibility of an association between the predictors and the outcome, which has 
been shown in previous studies, and on the availability of data. 
The P-value was considered significant when the compression between 2 groups 
was less than 0.05. The Bonferroni method was used to correct the multiple 
significant results. 
2.11.6 Linear regression 
The antihypertensive responses were treated as continuous variables, and the 
association between each class and the patient’s characteristics were examined 
by performing linear correlations. 
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The effects of age, BMI, SBP, DBP, sex, smoking status, alcohol intake, eGFR, and 
albumin on blood pressure response were examined. The selection of predictors 
was based on the possible interaction between the result and these predictors. 
Such an interaction has been shown in previous studies and is dependent on the 
availability of the data. The significance level was considered as a P-value less 
than 0.05.  
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Chapter 3 Characteristics of new patients and 
initiation of first antihypertensive drugs  
3.1 Introduction  
The initiation antihypertensive therapy with BB and diuretics was widely 
recommended in most hypertension guidelines for over three decades. These 
recommendations were based on available evidence of their ability to lower BP 
and reduce mortality and CV outcomes. However, more recently, guidelines have 
changed with BB, and diuretics no-longer recommended as first-line 
antihypertensive  drugs (200,219,220). The recent NICE guidelines recommend  
using them as third- or fourth-line agents (43). 
The superiority of one antihypertensive versus others for certain outcomes has 
been suggested by some meta-analyses (235,465,466). However, these have not 
been validated in larger meta-analyses. The ESH and ESC guidelines state that 
diuretics, BBs, CCBs, ACEIs and ARBs are suitable when starting antihypertensive 
treatment. ESH and ESC guidelines have defined compelling indications for the use 
of specific antihypertensive classes versus as shown in the table 3-1 (41). 
Regarding this table, the ESH and ESC guidelines recommend the use of ACEI or 
ARB with patients who have ESRD or proteinuria. This recommendation is based 
on prior studies. The first study supporting this recommendation was a review 
showing that ACEI and ARB were associated with a reduction in the risk of ESRD 
and a reduction in the level of proteinuria in patients with and without diabetes 
who had advanced renal failure (466). The second study was drawn from a meta-
analysis that concluded that ARBs and ACEI are more effective in reducing 
proteinuria than placebos or calcium-channel blockers in patients with or without 
diabetes and with microalbuminuria or proteinuria (467). However, none of these 
studies recommend the use of AECI or ARBs in patients with ESRD. 
Additionally, recent JNC guidelines have recommended starting with any of the 
main antihypertensive classes (diuretics, BBs, CCBs, ACEIs and ARBs) in non-black 
hypertensive patients. However, JNC guidelines recommend starting with Diuretic 
or CCB in black population and ACEI or ARB with patients who have CKD (40). 
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The recent NICE guidelines recommend starting with ACEI or ARB for patients aged 
below 55 years and CCB for those over 55 years and for people of African or 
Caribbean origin. They suggest using BB and thiazide diuretic as an alternative 
therapy for patients who do not tolerate ACEIs, and CCBs. The NICE committee 
also recommended using a thiazide-like diuretic such as chlorthalidone or 
indapamide instead of using conventional thiazide diuretic such as 
bendroflumethiazide or hydrochlorothiazide. Recent NICE guidelines are 
explained in detail in chapter one, section (1.4.5)(43). 
The purpose of this analysis was to review the treatment regimens of patients who 
attend the GBPC, to identify the characteristics of hypertensive patient who 
started his/her antihypertensive drug in the GBPC, to identify the most prescribed 
antihypertensive drug classes, to evaluate the change of anti-hypertensive drug 
usage during the study period, and to assess the adherence of physicians to 
hypertension guidelines. 
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Table 3-1: Antihypertensive classes recommended for specific indications  
Condition Drug 
Asymptomatic organ damage 
LVH ACE inhibitor, calcium antagonist, ARB 
Asymptomatic atherosclerosis Calcium antagonist, ACE inhibitor 
Microalbuminuria ACE inhibitor, ARB 
Renal dysfunction ACE inhibitor, ARB 
Clinical CV event 
Previous stroke Any agent effectively lowering BP 
Previous myocardial infarction BB, ACE inhibitor, ARB 
Angina pectoris BB, calcium antagonist 
Heart failure 
Diuretic, BB, ACE inhibitor, ARB, mineralocorticoid receptor 
antagonists 
Aortic aneurysm BB 
Atrial fibrillation, prevention 
Consider ARB, ACE inhibitor, BB or mineralocorticoid 
receptor antagonist 
Atrial fibrillation, ventricular rate 
control 
BB, non-dihydropyridine calcium antagonist 
ESRD/proteinuria ACE inhibitor, ARB 
Peripheral artery disease ACE inhibitor, calcium antagonist 
Other 
ISH (elderly) Diuretic, calcium antagonist 
Metabolic syndrome ACE inhibitor, ARB, calcium antagonist 
Diabetes mellitus ACE inhibitor, ARB 
Pregnancy Methyldopa, BB, calcium antagonist 
Blacks Diuretic, calcium antagonist 
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, beta-blocker; BP, 
blood pressure; CV, cardiovascular; ESRD, end-stage renal disease; ISH, isolated systolic 
hypertension; LVH, left ventricular hypertrophy. Table is reproduced from (41) 
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3.2 Method 
The GBPC database was linked to the ISD database to identify initial 
antihypertensive drug usage. This study analysed 4232 hypertensive patients with 
a new antihypertensive prescription who had filled their prescriptions for a period 
of more than one year.   
The definition of a new antihypertensive drug prescription was based on the 
patient showing no receipt of the drug class for at least a continuous four-month 
period prior to 30/04/2004; these patients were on no other antihypertensive 
medications at the time of the initial prescription. The selection of a four-month 
period was based on the fact that the maximum refill prescription in Scotland is 
three months for chronic therapy.  Patients who did not have a prescription for a 
period of four months or more simply initiated treatment. All patients with a new 
prescription of an antihypertensive medication, used as monotherapy, were 
included in the analysis. The mortality records obtained from the ISD were 
reviewed to ensure that all the patients were alive during the study period. 
Demographic and clinical characteristics were compared between 
antihypertensive classes. Variables such as age, gender, SBP, DBP, BMI, smoking 
status, and alcohol intake were studied. Age was determined at the date of 
prescription initiation. The baseline SBP and DBP were recorded one year prior to 
the initiation of treatment. 
One-way ANOVA were used to compare age, SBP, DBP, and BMI. Gender, smoking 
status, and alcohol intake differences were assessed using chi-square test. The 
Bonferroni method was used to correct the significance tests which resulted from 
multiple comparisons on the same dataset. 
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3.3 Results 
3.3.1 Study population 
The initial population of 10,040 represented the total number of patients who had 
GBPC and ISD data. As the inclusion criteria required patients to be selected based 
on data of no drug receipt for at least a continuous four-month period prior to the 
start date, 2077 patients were excluded because they had commenced their drug 
before 30/04/2004.  
Patients with total duration of any prescription data (between the first 
prescription and the last prescription of CV and non-CV drugs) of less than one 
year were excluded (520). This was to study persistence at I year and further 
details are provided in chapter (3). 
Patients with a new prescription of an antihypertensive medication, used as 
monotherapy, were included in the analysis.  Thus, 3211 patients were excluded 
because they were on combination antihypertensive drug classes.  
After these exclusions, 4232 patients who received a prescription for an 
antihypertensive drug during the study period were eligible. The inclusion and 
exclusion details are depicted in the flow chart in figure 3-1. 
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Figure 3-1: Flowchart of inclusion and exclusion criteria of patients first newly prescribed 
antihypertensive drugs.   
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3.3.2 Patient characteristics 
The mean age was 56 ± 14.8 years in this study population. The proportion of 
females was greater than males (57% were females). The mean SBP was 144.5 ± 
20.2 mm Hg and DBP 86.9 ± 11.4 mm Hg. The average BMI was 28 ± 6 kg/m2, with 
38% of total study population overweight (BMI between 25 and 29.99 kg/m2.) and 
33% of the individuals obese (BMI ≥ 30 kg/ m2).  
The proportion of patients who were smokers was 40%. Approximately 56.4% of 
patients took at least 6 units of alcohol per week. The full demographic profile of 
the study population is presented in table 3-2. 
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Table 3-2: Demographics of patients who were prescribed first new antihypertensive drugs. 
Characteristic N Total ALPHA ACEI ARB BB CCB 
CENT_A
CT 
NON_THI
A 
SPIRO THIA VASO 
Male, N (%) 4231 
1824 
(43.1) 
51 
(49.5) 
559 
(52.2) 
203 
(47.) 
409 
(39.8) 
312 
(46.1) 
0 
(0) 
55 
(27.6) 
16 
(38.1) 
217 
(32.9) 
2 
(66.7) 
Age (years) 4231 
56.17 
± 14.86 
64.67 
± 13.13 
53.03 
± 14.18 
54.3 
± 13.28 
53.81 
± 15.07 
59.24 
± 14.63 
56.53 
± 18.18 
67.58 
± 13.81 
60.48 
± 15.04 
57.91 
± 14.28) 
74 
± 8.54 
BMI (kg/m2) 3904 
28.07 
± 6.09 
28.99 
± 6.49) 
28.38 
± 6.09) 
28.14 
± 6.09 
27.4 
± 6.08 
28.07 
± 5.84 
28.59 
± 7.18 
29.5 
± 6.13 
26.88 
± 5.34 
28.03 
± 6.17 
33 
± 8.54 
SBP 
(mm Hg) 
1193 
144.52 
± 20.27 
148.9 
± 23.94 
144.05 
± 19.42 
148.64 
± 21.75 
139.74 ± 
19.39 
145.01 ± 
20.34 
145.8 ± 
11.12 
148.11 
± 24.21 
137.9 ± 
21.89 
144.98 
±18.40 
N.A. 
DBP  
(mm Hg) 
1193 
88.82 
± 11.46 
89.32 
± 14.56 
90.8 
± 11.62 
91.02 
± 11.64 
86.73 
± 11.17 
87.95 
± 12.09 
92.4 
± 11.69 
82.25 
± 11.07 
85.85 
± 10.42 
87.98 
± 9.11 
N.A. 
Smoking (0)* 
(%) 
3591 
2164 
(60.3) 
59 
(59.6) 
536 
(63.1) 
238 
(62.5) 
531 
(59.2) 
317 
(55.6) 
6 
(42.9) 
101 
(60.5) 
20 
(60.6) 
355 
(61.5) 
1 
(33.3) 
Alcohol (1) † 
(%) 
3462 
1511 
(43.6) 
52 
(53.6) 
322 
(39.1) 
165 
(44.5) 
362 
(41.9) 
238 
(43.4) 
6 
(46.2) 
76 
(47.5) 
17 
(53.1) 
272 
(49.5) 
1 
(33.3) 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium 
channel blocker; CENT_ACT, centrally acting antihypertensive drug; NON_THIA, non-thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic; 
VASO, vasodilator antihypertensive drug. SBP, systolic blood pressure; DBP, diastolic blood pressure. N.A., bassline of SBP and DBP not available for these 
classes. Results are summarised as mean ± standard deviation; number (percentage). (0)* is non-smoking; (1) † the consumption is 6<=units per week. 
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3.3.3 Initial antihypertensive monotherapy drugs  
During the study period, 4232 patients received a prescription for an 
antihypertensive drug. The most frequently prescribed antihypertensive drug 
classes were ACE inhibitors (25.3%) and beta-blockers (24.3%), followed by CCBs 
(16%), thiazides (15.6) and ARBs (10.2). 
The number of patients with new prescriptions during the study period was 1071 
(ACEI), 1028 (BBs), 677 (CCBs), 660 (Thiazides), 432 (ARBs), 199 (Non thiazide), 
103 (alpha-blockers), 43 (potassium sparing diuretics), 17 (centrally acting), and 
3 (vasodilators). The full prescription data for all classes is shown in table 3-3. 
Patterns of anti-hypertensive drug usage changed during the study period with an 
increase in prescriptions for ACE inhibitors and ARBs and a decline in prescriptions 
of beta-blockers and diuretics; Table 3-4 shows this pattern of anti-hypertensive 
drug usage by year during the study period with further illustration in figure 3-2. 
Table 3-3: Summary of the number of patients first newly prescribed antihypertensive drugs. 
Drug Class New Prescriptions (%) 
Total N 4232 
ALPHA 103 (2.4) 
ACEI 1070 (25.3) 
ARB 432 (10.2) 
BB 1028 (24.3) 
CCB 677 (16) 
CENT_ACT 17 (0.4) 
NON_THIA 199 (4.7) 
SPIRO 43 (1) 
THIA 660 (15.6) 
VASO 3 (0.1) 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; CENT_ACT, 
centrally acting antihypertensive drug; NON_THIA, non-thiazide diuretic; SPIRO, potassium 
sparing diuretics; THIA, thiazide diuretic; VASO, vasodilator antihypertensive drug. Results are 
summarised as number (percentage). 
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Table 3-4: Percentage of first antihypertensive prescription by year of prescription. 
Class 
2004 
% 
2005 
% 
2006 
% 
2007 
% 
2008 
% 
2009 
% 
2010 
% 
2011 
% 
2012 
% 
ALPHA 4 2 0 0 1 0 0 1 0 
ACEI 19 21 25 40 39 45 52 50 54 
ARB 10 8 12 12 10 11 15 7 23 
BB 26 29 23 14 21 18 11 14 15 
CCB 16 14 15 19 17 16 13 23 8 
CENT 1 0 0 0 0 0 1 0 0 
NON-THIA 6 4 4 2 2 1 2 1 0 
SPIRO 1 1 1 2 1 1 0 0 0 
THIAZ 17 20 20 11 9 7 7 4 0 
VASO 0 0 0 0 0 0 0 0 0 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; 
CENT_ACT, centrally acting antihypertensive drug; NON_THIA, non-thiazide diuretic; 
SPIRO, potassium sparing diuretics; THIA, thiazide diuretic; VASO, vasodilator 
antihypertensive drug. Results are summarised as percentage. 
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Figure 3-2: Percentage of first antihypertensive prescription by year of prescription. 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; 
CENT_ACT, centrally acting antihypertensive drug; NON_THIA, non-thiazide diuretic; 
SPIRO, potassium sparing diuretics; THIA, thiazide diuretic; VASO, vasodilator 
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3.3.4 Demographics of patients grouped according to initial 
antihypertensive monotherapy 
The baseline demographic variables in each monotherapy group are summarised 
and compared with each other in Tables 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, and 3-11. 
Comparisons were made using chi-square tests and ANOVA as appropriate. Given 
the number of tests performed, a Bonferroni correction was applied to the p-
values for multiple testing and p<0.0017 was considered statistically significant. 
CCB, Diuretics (thiazide or non- thiazide) and alpha-blocker groups were older 
than ACEI, ARB and BB groups. The proportion of males were significantly lower in 
the diuretics group compared to Alpha-blocker, ARB, ACEI or CCB groups, while 
the proportion of males prescribed beta-blockers was lower than those taking 
ACEI. 
Baseline systolic blood pressure was higher in the ARB group compared to BB while 
non-thiazide diuretic and BB group had a lower baseline diastolic blood pressure 
compared to ACEI or ARB.   
Patients prescribed BB had a lower BMI than those prescribed non-thiazide 
diuretic. 
Table 3-5: Comparison gender between different first-line antihypertensive classes 
Class Variable P value 
 Male Female ALPHA ACEI ARB BB CCB 
NON_ 
THIA 
SPIR
O 
ALPHA 51(49.5) 52(50.5)        
ACEI 559(52.2) 511(47.8) 0.61       
ARB 203(47) 229(53) 0.66 0.07      
BB 409(39.8) 619(60.2) 0.06 1E-08 0.01     
CCB 312(46.1) 365(53.9) 0.53 0.01 0.8 0.01    
NON_THIA 55(27.6) 144(72.4) 0.0002 1E-10 4E-06 0.0013 3E-06   
SPIRO 16(38.1) 26(61.9) 0.27 0.08 0.33 0.87 0.34 0.19  
THIA 217(32.9) 443(67.1) 0.0012 3E-15 3E-06 0.005 8E-07 0.19 0.5 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-thiazide diuretic; SPIRO, 
potassium sparing diuretics; THIA, thiazide diuretic. The Bonferroni corrected p-value is < 0.0017. Results are 
summarised as number (percentage) 
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Table 3-6: Comparison smoking between different first-line antihypertensive classes 
Class Variable P value 
 
Non-
smoking 
Smoking ALPHA ACEI ARB BB CCB 
NON_ 
THIA 
SPIRO 
ALPHA 59(59.6) 40(40.4)        
ACEI 536(63.1) 314(36.9) 0.51       
ARB 238(62.5) 143(37.5) 0.64 0.85      
BB 531(59.2) 366(40.8) 1 0.11 0.29     
CCB 317(55.6) 253(44.4) 0.51 0.006 0.04 0.19    
NON_THIA 101(60.5) 66(39.5) 0.9 0.54 0.7 0.8 0.29   
SPIRO 20(60.6) 13(39.4) 1 0.85 0.85 1 0.59 1  
THIA 355(61.5) 222(38.5) 0.74 0.58 0.79 0.38 0.05 0.86 1 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-thiazide diuretic; SPIRO, 
potassium sparing diuretics; THIA, thiazide diuretic. The Bonferroni corrected p-value is < 0.0017. Results are 
summarised as number (percentage) 
 
 
 
Table 3-7: Comparison alcohol between different first-line antihypertensive classes 
Class Variable P value 
 
Alcohol(1)
* 
Alcohol(2)
* 
ALPHA ACEI ARB BB CCB 
NON_ 
THIA 
SPIRO 
ALPHA 52(53.6) 45(46.4)        
ACEI 322(39.1) 501(60.9) 0.008       
ARB 165(44.5) 206(55.5) 0.11 0.09      
BB 362(41.9) 502(58.1) 0.03 0.25 0.41     
CCB 238(43.4) 311(56.6) 0.08 0.13 0.79 0.62    
NON_THIA 76(47.5) 84(52.5) 0.37 0.05 0.57 0.19 0.37   
SPIRO 17(53.1) 15(46.9) 1 0.14 0.36 0.27 0.36 0.57  
THIA 272(49.5) 278(50.5) 0.51 0.0002 0.14 0.006 0.05 0.72 0.72 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-thiazide diuretic; SPIRO, 
potassium sparing diuretics; THIA, thiazide diuretic. The Bonferroni corrected p-value is < 0.0017. Results are 
summarised as number (percentage). ). (1)* , the consumption is  <= 6 units per week; (2)*,  the consumption 
is >units per week 
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Table 3-8: Comparison age between different first-line antihypertensive classes 
Class Variable P value 
 Age ALPHA ACEI ARB BB CCB 
NON_ 
THIA 
SPIRO 
ALPHA 64.67±13.14        
ACEI 53.03±14.19 
7E-13       
ARB 54.3±13.28 
1E-09 0.78      
BB 53.81±15.07 
9E-12 0.92 1.00     
CCB 59.24±14.64 
0.01 6.1E-13 7E-07 1.3E-12    
NON_TH
IA 
67.58±13.82 
0.71 5.8E-13 6E-13 5.8E-13 2.1E-11   
SPIRO 60.48±15.04 
0.75 0.02 0.14 0.06 1.00 0.16  
THIA 57.91±14.28 
2E-04 2E-10 0.0013 3.1E-07 0.69 6.0E-15 0.95 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-thiazide diuretic; SPIRO, 
potassium sparing diuretics; THIA, thiazide diuretic. The Bonferroni corrected p-value is < 0.0017. Results are 
summarised as mean ± standard deviation 
 
 
Table 3-9: Comparison BMI between different first-line antihypertensive classes 
Class Variable P value 
 BMI ALPHA ACEI ARB BB CCB 
NON_T
HIA 
SPIRO 
ALPHA 28.99±6.49        
ACEI 28.38±6.1 0.99       
ARB 28.14±6.09 0.93 0.9973      
BB 27.4±6.08 0.17 0.0014 0.26     
CCB 28.07±5.84 0.87 0.9581 1.00 0.21    
NON_THI
A 
29.5± 6.13 0.99 0.2153 0.13 8.1E-05 0.05   
SPIRO 26.88± 5.35 0.53 0.7059 0.87 1.00 0.90 0.13  
THIA 28.03± 6.17 0.85 0.9309 1.00 0.29 1.00 0.04 0.91 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-thiazide diuretic; SPIRO, 
potassium sparing diuretics; THIA, thiazide diuretic. The Bonferroni corrected p-value is < 0.0017. Results are 
summarised as geometric mean (95% confidence interval for the mean) 
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Table 3-10: Comparison systolic blood pressure between different first-line antihypertensive classes 
Class Variable P value 
 SBP ALPHA ACEI ARB BB CCB 
NON_ 
THIA 
SPIRO 
ALPHA 
148.9±23.95        
ACEI 
144.05±19.42 0.94       
ARB 
148.64±21.75 1.00 0.23      
BB 
139.74±19.4 0.28 0.19 1.6E-04     
CCB 
145.01±20.35 0.98 1.00 0.66 0.12    
NON_THIA 
148.11± 24.21 1.00 0.98 1.00 0.34 1.00   
SPIRO 
137.9± 21.89 0.50 0.82 0.24 1.00 0.72 0.58  
THIA 
144.98± 18.41 0.99 1.00 0.73 0.09 1.00 1.00 0.69 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-thiazide diuretic; SPIRO, 
potassium sparing diuretics; THIA, thiazide diuretic. The Bonferroni corrected p-value is < 0.0017. Results are 
summarised as geometric mean (95% confidence interval for the mean) 
 
 
 
Table 3-11: Comparison diastolic blood pressure between different first-line antihypertensive classes 
Class Variable P value 
 DBP ALPHA ACEI ARB BB CCB 
NON_ 
THIA 
SPIRO 
ALPHA 89.32 ± 14.57        
ACEI 90.8 ± 11.63 
1.00       
ARB 91.02 ± 11.64 
0.99 1.00      
BB 86.73 ± 11.18 
0.93 0.002 2.8E-03     
CCB 87.95 ± 12.09 
1.00 0.12 0.12 0.96    
NON_THIA 82.25 ± 11.07 
0.17 5.3E-04 5.1E-04 0.35 0.10   
SPIRO 85.85 ± 10.42 
0.96 0.56 0.51 1.00 0.99 0.95  
THIA 87.98 ± 9.11 
1.00 0.13 0.13 0.95 1.00 0.10 0.99 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-thiazide diuretic; SPIRO, 
potassium sparing diuretics; THIA, thiazide diuretic. The Bonferroni corrected p-value is < 0.0017. Results are 
summarised as mean ± standard deviation 
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3.4 Discussion 
In this chapter I have summarised the selection process and the baseline 
characteristics of the patients selected for studies of persistence and adherence. 
The unique nature of the Glasgow BP Clinic Database which integrates both clinical 
data and prescription refill data offers the ideal resource to study 
antihypertensive drug adherence and persistence. From just over 10,000 patients 
with complete data available, I was able to select 4242 patients who were 
commenced on a new antihypertensive drug as monotherapy and who had follow-
up data of more than 1 year. Patient visits to the GBPC usually continues until BP 
is controlled and then the patients are discharged back to their GPs for follow-up. 
Thus clinic visits are not appropriate to determine follow-up status. All patients 
need to pick their prescription from the pharmacy and all pharmacy-refills are 
obtained by ISD as long as the pharmacy is located in Scotland. If a patient leaves 
Scotland, then pharmacy records will not be available even if the patient was 
refilling their prescription elsewhere. Thus, a sudden cessation of prescription 
pick-up may indicate that the patient has either discontinued their drugs or has 
left Scotland or has died. To ensure that all eligible patients were selected, I had 
to use multiple sources of data to corroborate their status. I used mortality records 
obtained from ISD to ensure that patients were alive during the study period, then 
collected all the prescription refill data for each patient and ensured that each 
patient had obtained a refill prescription of any drug for at least 1 year. By this 
method I was able to include accurately those who discontinued specific 
antihypertensive drug by reviewing collateral data on pharmacy refill of other 
drugs. It is likely that a minority of patients on true monotherapy with one 
antihypertensive drug which they discontinued within one year would have been 
missed by this process. Furthermore, to ensure that the patients were truly on 
monotherapy and the start date of the drug was accurate, I pre-specified that the 
patient should not show any drug receipt for a continuous 4-month period prior to 
the drug start date. As the database has pharmacy refill data from December 2003, 
I only included those patients who had commenced their drug after 30/04/2004 
and showed no record of refill prescription for any antihypertensive drug before 
that date. 
The distribution of antihypertensive monotherapy between 2004 and 2012 show 
that ACEI were most commonly prescribed antihypertensive drug first (25.3%) 
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closely followed by BB (24.3%), then CCB (16%), Thiazides (15.6%), ARB (10.2%). 
The other antihypertensive drugs were less than 5%.  
ACEI or ARBs were the most common monotherapy drugs for hypertension in the 
Health Survey of England 2003 and 2006 (293), which aligns well with the data 
from this study showing around 35% of patients on ACEI/ARB as monotherapy. 
Though BB are the second most commonly prescribed drug as monotherapy in this 
study, reviewing the temporal trends in BB prescription indicates the impact of 
recent guidelines on practice and the lag between publication of guidelines and 
clinical implementation(200). Prior to 2006, NICE Guideline 18 recommended that 
patients under the age of 55 years be commenced on either an ACEI or BB whilst 
those over 55 years or of Afro-Carribean origin be commenced on a CCB or 
thiazide-like diuretic (103). The 2006 NICE Guideline 34 saw the removal of BB as 
a first line agent in hypertension management.  
In the GBPC data, BB monotherapy was the highest in 2004 and 2005 (~25%) then 
it progressively declined to around 14% in 2012. Indeed there was an abrupt 
decline in 2007 to 14% reflecting the publicity around beta-blockers on outcomes 
in hypertensive patients. In comparison, the use of BB monotherapy in HSE 
declined from 29% in 2003 to 21% in 2006 (293). This decline in BB prescription in 
the GBPC is compensated by an increase in ACEI and ARB prescriptions. ACEI 
prescriptions increased from 19% in 2004 to 54% in 2012. 
Current and earlier BHS/NICE guidelines recommend CCBs for those of African 
origin and for those>55 years of age(43). In the GBPC study, almost all patients 
were Caucasian. The GBPC study cohort demonstrates that this guideline 
recommendation is adhered to - the mean age of CCB and diuretic groups are 59 
and 60 years respectively while the mean age of ACEI and ARB group was 53 and 
54 years respectively. The age differences between ACE/ARB and CCB/Diuretic 
groups were statistically significant. 
The sex distribution was similar in the ACEI and ARB monotherapy groups. In 
contrast, there was a preponderance of females (>60%) in BB and thiazide groups. 
The reason for this is unclear and may reflect awareness of sexual dysfunction in 
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males being a common side effect of BB and thiazides(467–470). The high 
representation of women in this cohort is a strength of the study. 
The mean SBP/DBP was 144.5/86.9 for patients who did not initiate treatment. 
These numbers are relatively low, and this could be explained by the gap between 
the date of blood pressure measurement and the initiation date. The BP 
measurements were taken more than one year prior to the initiation date. They 
should be low at the date of measurement, increasing until the date of initiation. 
 Although CCBs are typically prescribed for patients who have isolated systolic HT, 
ARBs were prescribed for patients with high SBP. However, the data represent 
patients who had essential hypertension, and those who had high SBP did not 
necessarily have isolated systolic HT. 
Thus the demographic profile of the GBPC monotherapy cohort reflects a cohort 
of hypertensive patients whose management conforms to contemporary 
guidelines. There are some limitations to this design – the cohort was selected 
from patients referred to a tertiary care hypertension clinic and may not be 
representative of the general hypertensive population. There is no data on 
whether the patient actually took the drug after picking them up from pharmacy. 
The drug therapy is not randomised, so between groups comparisons will be prone 
to confounding which cannot be overcome by simple adjustment for covariates. 
So any results need to be considered in light of this and further confirmatory 
studies will be required before change in clinical practice can happen.   
 
  
110 
 
Chapter 4 Persistence 
4.1 Introduction 
As discussed in the Introduction, randomised clinical trials have clearly shown the 
benefit of BP reduction using antihypertensive medications. However, the full 
benefit of antihypertensive therapy in real life practice can only be obtained if 
patients keep taking their medicines regularly(392,471,472). Persistence with 
treatment is a crucial element in determining the success of any long-term 
therapy. Persistence is the continuous use of medications for the specified 
treatment time period, which, for hypertension, should be maintained life-
long(473). Studies from Europe and North America have estimated that around 
50% of all patients using antihypertensive drugs had discontinued within 6 months 
to 4 years(392,472) implying that poor persistence is a likely explanation for the 
discrepancy observed between the efficacy of drug treatment established through 
clinical trials and the results observed in clinical practice (474). Corrao et al. 
reported that 37% of CV outcomes were reduced among patients with high 
persistence compared with those who had very low persistence (429). Thus an 
important modifiable reason for lack of BP control is failure by patients to take 
their medications as prescribed. Furthermore, high persistence can decrease the 
cost of medications Longer persistence with beta-blockers for the treatment of 
hypertension has been shown to reduce the overall medical costs(388). On the 
other hand, non-persistence leads to an increase in the cost of the treatment. It 
has been estimated that 76.5 million pound sterling is spent to treat hypertension 
per year, and around 26.9 million pound sterling of this total cost is attributed to 
switching or discontinuation therapy. A Department of Health report suggested 
that the expected annual treatment savings in England would be more than £390 
from moving hypertensive patients from non-adherence to adherence (385). 
Discontinuation rates varied between studies and ranged between 5% to 75% (448). 
For instance, a retrospective cohort study by Boris et al demonstrated 10 year 
persistence with antihypertensive medications of 39% (427). Wogen et al showed 
persistence rates of 54% at one year (428). Tremblay et al showed a 1 and 2 year 
persistence of 69.1% and 69.2% respectively in treated hypertensive patients 
(475).  
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A wide variability in the persistence of initial antihypertensive therapy classes 
have been shown in several studies. Most studies showed the highest rates of 
persistence with ARBs and ACE inhibitors, and the lowest with diuretics (435–437). 
Several factors influence persistence. Factors such as sociodemographic, 
psychosocial or behavioural variables, healthcare system, therapeutic regimen 
and comorbidity were associated persistence rates. 
The purpose of this study was to investigate the patterns of long and short-term 
persistence and patterns the variation of persistence rates between 
antihypertensive classes, in a population of treated hypertensive patients 
attending the Glasgow Blood Pressure Clinic. Also, I sought to determine the 
association of persistence with different clinical characteristics such as age, sex, 
BMI, BP value, smoking status, and alcohol intake. 
4.2 Methods 
This study analysed hypertensive patients who filled their first prescription with 
an alpha blocker, ACEI, ARB, CCB, BB, potassium sparing diuretics, centrally acting 
antihypertensive drug, vasodilator antihypertensive drug, non-thiazide diuretic, 
or thiazide diuretic. The details of the patient selection and description of the 
study cohort are presented in Chapter 3. 
While all patients were initially started on monotherapy, during follow-up many 
patients had additional antihypertensive therapies added to the first 
antihypertensive class they had been prescribed. In this study, persistence was 
calculated only for the initial antihypertensive class. Terms such as persistence, 
switching (switching before 120 days, and switching after 120 days), and 
discontinuation are defined in Table 4-1. 
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Table 4-1: Definitions of persistence, switching, discontinuation. 
Terms  Definitions 
Short-term study 
Study of drug persistence over the first year since starting the 
first drug 
Long-term study 
Study of drug persistence over the first five years since starting 
the first drug 
Persistent  
Patients who continued with the initial antihypertensive drug 
class without switching or discontinuing during the first year in 
the short-term study and five years in the long-term study. 
Switcher after 120 
days 
Patients who stopped their first antihypertensive drug and 
changed to a different antihypertensive drug class after an 
interval of more than 120 days from the date of discontinuation. 
Switcher before 120 
days 
Patients who stopped their first antihypertensive drug and 
changed to a different antihypertensive drug class after an 
interval of less than 120 days from the date of discontinuation 
Discontinuer 
Patients who stopped their first antihypertensive drug and did 
not switch to any antihypertensive drug class all through to the 
last day of the study period.  
 
Using the above definitions, the analyses were conducted across two main groups 
– persistent and non-persistent (switcher after 120 days, switcher before 120 days, 
discontinuer). The demographic variables were compared across the groups and 
by different drug classes, using chi-square test, t-test and one-way ANOVA as 
appropriate. The tests were conducted for 1-year persistence and 5-year 
persistence separately. 
Centrally acting antihypertensive drugs and vasodilator antihypertensive drugs 
were excluded from comparison due to the small number of patients using them. 
Multiple testing correction was applied to all statistical tests using the Bonferroni 
method. 
The impact of several independent variables on persistence was examined using 
multivariable logistic regression. Age, BMI, SBP, DBP, sex, smoking status and 
alcohol intake were considered as independent variables. 
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4.3 Results 
4.3.1 Persistence and non-persistence outcome 
The short-term study (one year) of antihypertensive persistence included 4232 
patients. The long-term study (five years) included 3,149 patients who had follow-
up data for 5 years. Overall, short-term and long-term persistence with 
antihypertensive therapy was 72.9% and 62.8% for all drug classes at 1 and 5 years 
respectively. 
The 1-year and 5-year persistence for each drug class are presented in Figure 4-1 
and Table 4-2).  
 
Figure 4-1: 1-5 year persistence for the first-line antihypertensive class. 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; 
NON_THIA, non-thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide 
diuretic. 
 
Long term persistence was significantly lower than short-term persistence for BB, 
CCB, thiazides and non-thiazides. ACEI, ARB, alpha-blockers and potassium sparing 
diuretics showed nominally lower persistence at 5-years compared to 1-year 
however these were not statistically significant (using a Bonferroni corrected p-
value<0.00625). (Table 4-2). 
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Table 4-2: Persistence of different antihypertensive drug classes in 1 and 5 years.  
Drug Class N (1 year) 
Persistence (1 
year) N (%) 
N (5 years) 
Persistence (5 
years) N (%) 
P-value 
ALPHA 103 61(59.2) 88 42(47.7) 0.14 
ACEI 1070 788(73.6) 686 464(67.6) 0.0069 
ARB 432 349(80.8) 325 240(73.8) 0.0270 
BB 1028 759(73.8) 821 508(61.9) 0.0001 
CCB 677 486(71.8) 495 311(62.8) 0.0012 
CENT 17  9(52.9) 12 6(50) N.R. 
NON_THIA 199 133(66.8) 124 62(50) 0.0034 
SPIRO 43 28(65.1) 34 19(55.9) 0.4833 
THIA 660 471(71.4) 563 326(57.9) 0.0001 
VASO 3  1(33.3) 1 1(100) N.R 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; CENT_ACT, 
centrally acting antihypertensive drug; NON_THIA, non-thiazide diuretic; SPIRO, potassium 
sparing diuretics; THIA, thiazide diuretic; VASO, vasodilator antihypertensive drug. The 
Bonferroni corrected p-value is < 0.00625. Results are summarised as number (percentage). 
N.R, not reported due to small sample size in this class. 
Comparing the persistence at 1-year between different drug classes (Table 4-3), 
ARB showed the highest persistence rate among all drug classes. ARB persistence 
at 1-year was also significantly higher than alpha-blocker, CCB, thiazide and non-
thiazide diuretic. For the other drug classes including ACEI, though ARB 
persistence was nominally higher it was not significantly different.  
For 5-year persistence (Table 4-4), ARB showed statistically significant higher 
persistence compared to all drug classes (except spironolactone) including ACEI. 
Also, ACEI showed significantly higher 5-year persistence compared to thiazide 
and non-thiazide diuretics. 
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Table 4-3: The rate of persistence at 1 year between different drugs. 
  Persisters P values 
Class Yes No 
ALPH
A 
ACEI ARB BB CCB 
NON_ 
THIA 
SPIR
O 
ALPHA 61(59.2) 42(40.8)        
ACEI 788(73.6) 282(26.4) 0.003       
ARB 349(80.8) 83(19.2) 1E-05 0.003      
BB 759(73.8) 269(26.2) 0.002 0.96 0.005     
CCB 486(71.8) 191(28.2) 0.01 0.41 8E-04 0.37    
NON_TH
IA 
133(66.8) 66(33.2) 0.21 0.06 2E-04 0.05 0.18   
SPIRO 28(65.1) 15(34.9) 0.58 0.22 0.03 0.22 0.38 0.86  
THIA 471(71.4) 189(28.6) 0.02 0.32 4E-04 0.29 0.9 0.25 0.39 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-
thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic. Results are 
summarised as member (percentage). The Bonferroni corrected p-value is < 0.0017. 
 
Table 4-4: The rate of Persistence at 5 year between different drugs. 
  Persisters P values 
Class Yes No 
ALPH
A 
ACEI ARB BB CCB 
NON_ 
THIA 
SPIRO 
ALPHA 42(47.7) 46(52.3)        
ACEI 464(67.6) 222(32.4) 0.0003       
ARB 240(73.8) 85(26.2) 8E-06 0.05      
BB 508(61.9) 313(38.1) 0.01 0.02 0.0001     
CCB 311(62.8) 184(37.2) 0.009 0.09 0.001 0.77    
NON_T
HIA 
62(50) 62(50) 0.78 0.0002 3E-06 0.01 0.01   
SPIRO 19(55.9) 15(44.1) 0.55 0.19 0.04 0.48 0.47 0.57  
THIA 326(57.9) 237(42.1) 0.08 0.0004 2E-06 0.15 0.12 0.11 0.86 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-
thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic. Results are 
summarised as number (percentage).The Bonferroni corrected p-value is < 0.0017. 
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4.3.2 Characteristics and predictors of persisters and non-
persistors at 1-year 
At 1 year, overall, 72.9% (n = 3085) were persisters and 27.1 %( n=1147) non-
persisters. Non-persisters comprised three sub-groups - switchers (switched before 
120 days and switched after 120 days) and discontinuers. The frequencies of these 
sub-groups for all drug classes are presented in table 4-5. There were 
approximately equal proportion of those who switched before and after 120 days, 
11.4% (n=481) and 11.5% (n= 487) respectively. 4.2% (n=179) discontinued their 
drug by 1 year.  
Among those who switched their primary drug within one year, relatively more 
patients on ACEI switched before 120 days (12.1%) in contrast to after 120 days 
(9.5%). This was slightly higher than ARB (7.4% and 9% respectively). For BB, a high 
proportion switched after 120 days (13%) than earlier (9%). Discontinuation rate 
was higher for alpha-blockers (10.7%). For the other drug, it varied between 2.7% 
and 5%. 
 
Table4-5: Patterns of non-persistence categories during 1 year follow-up. 
Drug Class 
Total N 
 (1 year) 
Non-persisters 
at 1 year N (%) 
Drug switch Discontinuation 
after add-on 
drug (%) 
After 120 days 
N (%) 
Before 120 
days N (%) 
ALPHA 103  42(40.8) 14(13.6) 17(16.5) 11(10.7) 
ACEI 1070  282(26.4) 102(9.5) 129(12.1) 51(4.8) 
ARB 432 83(19.2) 32(7.4) 39(9) 12(2.8) 
BB 1028  269(26.2) 133(12.9) 92(8.9) 44(4.3) 
CCB 677  191(28.2) 81(12) 92(13.6) 18(2.7) 
CENT 17  8(47.1) 6(35.3) 1(5.9) 1(5.9) 
NON-THIA 199  66(33.2) 33(16.6) 23(11.6) 10(5) 
SPIRO 43  15(34.9) 6(14) 7(16.3) 2(4.7) 
THIAZ 660  189(28.6) 73(11.1) 86(13.) 30(4.5) 
VASO 3  2(66.7) 1(33.3) 1(33.3) 0(0) 
Total 4232 1147(27.1) 481(11.4) 487(11.5) 179(4.2) 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, 
non-thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic. The Bonferroni 
corrected p-value is < 0.0017. Results are summarised as number (percentage). 
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Table 4-6 summarises the demographic characteristics of the different groups and 
table 4-7 shows the comparison between persistors and non-persistors. There are 
no substantial differences in the demographic variables between any of the 
groups. Whilst some p-values were nominally significant, these do not remain 
significant when the number of statistical tests are considered. The mean of SBP 
was around 143.78 ± 20.13 mmHg lower among persistors compared to non-
persistors which was 146.88 ± 20.02. 
Patient characteristics were compared between the three non-persistence 
categories (switched after 120 days, switched before 120 days and discontinued). 
The mean age of individuals who switched their drug after 120 days was 
significantly lower than those who switched their drug before 120 days: 53.73 ± 
15.2 years versus 58.13 ± 14.3 years, respectively (P= 0.00001). There were no 
differences between these groups in terms of sex, BMI, SBP, DBP, smoking status 
and alcohol intake, as seen in table 4-6. Age, smoking and alcohol intake were 
found to be nominally different between those who switched before 120 days and 
those who switched after 120 days in the results of the multinomial logistic 
regression model’s table regression (table 4-8). 
Patient characteristics of persistence were compared with non-persistence 
categories (switched after 120 days, switched before 120 days and discontinued). 
Persistent patients were significantly older than those who switched after 120 
days; the mean age of the continuers and those who switched after 120 days were 
56.3 ±14.8 years and 53.7 ± 15.2 years, respectively, and the p-value was 0.002. 
BMI was significantly different between those who persisted and those who 
switched before 120 days. BMI was higher in patients who switched their drug 
before 120 days with mean of 28.75 ± 6.19 kg/m2 compared with those who 
persisted with their drug with mean of 27.95 ± 6.11 kg/m2 (P= 0.042), as seen in 
table 4-6. 
The significant different result was only found with smoking factors between 
continuers and switchers after 120 days in the multinomial logistic regression 
models table (table 4-9). 
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Finally, patient characteristics of persistence and no persistence were compared. 
SBP and BMI were significantly different -Non-persistence subjects had mean SBP 
higher than persistence (146.8± 20.02 versus 143.78 ± 20.13 mm Hg) (P<0.02). 
BMI was high in non-persistence 28.4 ± 6.02 kg/m2, when compared with 
persistence 27.95 ± 6.11 kg/m2 (P<0.026), (table 4-7). However, there is only SBP 
of short-term persistence was identified as significant in binary logistic regression 
model table (table 4-10). 
 
Table 4-6: Comparison of demographics between persisters and non-persisters categories at 
1 year follow-up.  
Characteristic 
Persisters at 
 1 year N (%) 
Non-
persisters at 
 1 year N (%) 
Drug switch 
Discontinuatio
n N (%) After 120 days 
N (%) 
Before 120 days 
N (%) 
N 3085 1147 481 487 179 
Male, N (%) 1347(43.7) 
477(41.6) 
 
205(42.6) 196(40.2) 76(42.5) 
Age (years )*† 56.3 ± 14.84 55.84 ± 14.9 53.73 ± 15.21 58.13 ± 14.28 55.31 ± 15.01 
BMI (kg/m2)‡ 27.95 ± 6.11 28.4 ± 6.01 28 ± 5.80 28.75 ± 6.19 28.45 ± 6.03 
SBP (mm Hg) 143.7 ± 20.1 146.8 ±20 146.9 ± 19.8 147.4 ± 20.54 145.1 ± 19.06 
DBP (mm Hg) 88.61± 11.34 89.51 ± 11.8 90.95 ± 11.72 88.47 ± 11.47 88.83 ± 12.95 
Smoking (0) 
(%) 
1594(60.5) 570(59.6) 245(60.3) 243(59.9) 82(56.9) 
Alcohol (1) 
(%) 
1110(43.6) 
 
401(43.8) 
 
173(44.9) 166(42.5) 62(44.6) 
The quantitative variables are expressed as mean ± SD; and geometric mean (95% confidence 
interval for the mean); number (percentage) for categorical data. Significant at P-value<0.05. *, † and 
‡, variables are significant. *switcher after 120 days vs switchers before 120 days. †persistent vs 
switcher after 120 days. ‡persistent vs switchers before 120 days. Smoking (0) is non-smoker; 
alcohol (1) is <=6 units per week. 
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Table 4-7: Comparison of demographics between persisters and non-persisters at 1 year follow-up. 
Characteristic N Persisters Non-Persiters P_value 
Male, N (%) 4231 1347(43.7) 477(41.6) 0.24 
Age (years ) 4231 56.3 ± 14.84 55.84 ± 14.92 0.38 
BMI (kg/m2) 3904 27.95 ± 6.11 28.4 ± 6.02 0.026 
SBP (mm Hg) 1193 143.78 ± 20.13 146.88(20.02) 0.02 
DBP (mm Hg) 1193 88.61 ± 11.34 89.51(11.81) 0.26 
Smoking (0) (%) 3591 1594(60.5) 570(59.6) 0.64 
Alcohol (1) (%) 3462 1110(43.6) 401(43.8) 0.91 
The quantitative variables are expressed as mean ± SD; and geometric mean  
(95% confidence interval for the mean); number (percentage) for categorical data.  
Significant at P-value<0.05. Smoking (0) is non-smoker; alcohol (1) is <= 6 units per week. 
 
 
Table 4-8: Comparison of predictors between non-persistence categories using Multinomial 
Logistic Regression at 1 year follow-up. 
Reference  
Other non-
persistence  
Population 
characteristics 
O.R 95% CI p value 
Drug switch after 120 
days 
Drug switch 
before120 days 
BMI (kg/m2) 1.013 0.952-1.077 0.69 
DBP (mm Hg) 1.026 0.99-1.063 0.16 
SBP (mm Hg) 0.997 0.978-1.015 0.716 
Age (years ) 0.973 0.948-0.999 0.043 
Male, N (%) 1.206 0.654-2.225 0.549 
Alcohol (1) (%) 2.067 1.086-3.934 0.027 
Smoking (1) (%) 0.545 0.299-0.993 0.047 
Discontinuation 
BMI (kg/m2) 1.060 0.982-1.144 0.136 
DBP (mm Hg) 1.000 0.953-1.049 0.99 
SBP (mm Hg) 1.002 0.977-1.028 0.881 
Age (years ) 0.968 0.935-1.004 0.078 
Male, N (%) 1.114 0.479-2.589 0.802 
Alcohol (1) (%) 1.197 0.49-2.925 0.693 
Smoking (1) (%) 0.582 0.257-1.319 0.195 
Drug switch before120 
days 
Discontinuation  
BMI (kg/m2) 1.047 
0.972-
1.127 
0.229 
DBP (mm Hg) 0.974 0.927-1.024 0.307 
SBP (mm Hg) 1.005 0.98-1.032 0.684 
Age (years ) 0.995 0.96-1.031 0.785 
Male, N (%) 0.924 0.397-2.153 0.855 
Alcohol (1) (%) 1.197 0.237-1.412 0.579 
Smoking (1) (%) 0.582 0.47-2.424 0.876 
O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <=6 units per week. The Bonferroni 
corrected p-value is < 0.017. 
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Table 4-9: Comparison of predictors between persistence and non-persistence categories using 
Multinomial Logistic Regression at 1 year follow-up.  
Reference is  
persistence category 
Population 
characteristics 
O.R 95% CI p value 
 Drug switch before120 
days 
BMI (kg/m2) .999 0.963-1.037 0.967 
Age (years ) 1.015 0.998-1.033 0.081 
SBP (mm Hg) 1.010 0.997-1.022 0.121 
DBP (mm Hg) .991 0.967-1.014 0.432 
Male, N (%) .954 0.613-1.485 0.836 
Alcohol (1) (%) .715 0.454-1.128 0.149 
Smoking (1) 
(%) 
1.077 0.706-1.645 0.73 
 Drug switch after 120 days 
BMI (kg/m2) 1.006 0.969-1.045 0.753 
Age (years ) .991 0.974-1.008 0.299 
SBP (mm Hg) 1.005 0.992-1.019 0.433 
DBP (mm Hg) 1.020 0.993-1.047 0.144 
Male, N (%) 1.156 0.728-1.833 0.539 
Alcohol (1) (%) 1.431 0.895-2.29 0.135 
Smoking (1) 
(%) 
.619 0.398-0.965 0.034 
Discontinuation 
BMI (kg/m2) 1.033 0.987-1.082 0.161 
Age (years ) .989 0.961-1.017 0.431 
SBP (mm Hg) 1.010 0.989-1.032 0.365 
DBP (mm Hg) .998 0.958-1.04 0.932 
Male, N (%) 1.022 0.486-2.15 0.954 
Alcohol (1) (%) .917 0.431-1.953 0.823 
Smoking (1) 
(%) 
.634 0.311-1.291 0.209 
Significant at P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <=6 units 
per week 
 
Table 4-10: Comparison of predictors between persistence and non-persistence using Binary 
Logistic Regression at 1 year follow-up 
Population characteristics O.R 95% CI p value 
Age (years ) 1.001 0.989-1.013 0.842 
BMI (kg/m2) 1.008 0.983-1.033 0.554 
SBP (mm Hg) 1.008 0.999-1.018 0.07 
DBP (mm Hg) 1.003 0.985-1.02 0.775 
Male, N (%) .955 0.695-1.312 0.775 
Alcohol (1) (%) 1.014 0.734-1.4 0.933 
Smoking (1) (%) 1.244 0.919-1.684 0.158 
Significant at P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <= 6 units 
per week. 
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4.3.3 Characteristics and predictors of persisters and non-
persisters at 5-year 
Characteristics and predictors of persisters and non-persisters at 5-years overall, 
62% (n = 1979) were persisters and 37.2 %( n=1170) non-persisters. The frequencies 
of the sub-groups of non-persisters for all drug classes are presented in table 4-
11. There were approximately equal proportion of those who switched before and 
after 120 days, 11.4% (n=360) and 12.4% (n= 390) respectively. 13.3% (n=420) 
discontinued their drug by 5 years. Discontinuation rate was highest for alpha-
blockers (22.7%). For the other drugs, it varied between 9.5% and 16.9%. 
Compared to persistence at 1-year, the 5-year data show that the rate of non-
persistence increased from 27.1% to 37.2%. There was no substantial difference in 
the switcher categories, so the greatest contribution to non-persistence at 5-years 
was from the discontinuers. Whilst the discontinuation rate at 1 year varied 
between 2 2.7% and 10.7%, the rate at 5-years range from 9.5% to 22.75. Despite 
an almost 3 fold increase in the discontinuation rate from 1 year to 5 years for 
ACEI and ARB, these two drug classes still remained the classes with the lowest 
discontinuation rate. 
Table 4-11: Patterns of non-persistence categories during 5 year follow-up. 
Drug Class 
Total N 
(5 year) 
Non-persisters 
at 5 year N (%) 
Drug switch 
Discontinuation 
N (%) After 120 days 
N (%) 
Before 120 
days N (%) 
ALPHA 88 46(52.3) 13(14.8) 13(14.8) 20(22.7) 
ACEI 686 222(32.4) 81(11.8) 76(11.1) 65(9.5) 
ARB 325 85(26.2) 25(7.7) 29(8.9) 31(9.5) 
BB 821 313(38.1) 106(12.9) 75(9.1) 132(16.1) 
CCB 495 184(37.2) 64(12.9) 69(13.9) 51(10.3) 
CENT 12 6(50) 3(25) 1(8.3) 2(16.7) 
NON-THIA 124 62(50) 24(19.4) 17(13.7) 21(16.9) 
SPIRO 34 15(44.1) 6(17.6) 5(14.7) 4(11.8) 
THIA 563 237(42.1) 68(12.1) 75(13.3) 94(16.7) 
VASO 1 0(0) 0, (0) 0(0) 0(0) 
Total 3149 1170(37.2) 390(12.4) 360(11.4) 420(13.3) 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-
thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic. The Bonferroni 
corrected p-value is < 0.0017. Results are summarised as number (percentage). 
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Table 4-12 summarises the demographic characteristics of the different groups 
and table 4-13 shows the comparison between persisters and non-persisters. 
There are no substantial differences in the demographic variables between any 
of the groups. Whilst some p-values were nominally significant, these do not 
remain significant when the number of statistical tests are considered. The 
mean of SBP was 140.48 ± 19.18 lower among persistors compared to non-
persistors 145.92 ± 20.62 (p value =0.0001). 
The mean age was significantly different between non-persistence categories. 
Patients who switched their drug after 120 days tend to be younger than switchers 
before 120 days (59 ± 13.043 vs 54.2 ± 14.5) (p=0.00001), and discontinuers (59 ± 
13.043 vs 55.87±15.06) (p=007). Other variables were non-significant between 
these groups table 4-12.  
Age results were also confirmed in logistic regression models. Alcohol intake was 
significantly different between those who switched after 120 days and those who 
switched before 120 days table 4-14. 
The mean SBP of patients who switched their drugs after 120 days and who 
switched their drugs before 120 days were higher than those who persisted with 
their drugs: 146.8 ± 21.2 mm Hg and 146.4 ± 21.1 mm Hg versus 140.4 ± 19.1 mm 
Hg (p= 0,009, and 0,035), respectively. Patients who persisted with their drug 
tended to be older than those who switched their drug after 120 days (56.6±13.6 
vs 54.1 ± 14.5 years) (p=0.09). On the other hand, those who switched before 120 
days were significantly older than those who persisted, 59 ±13.04 years versus 
56.6 ± 13.6 years, respectively (P=0.015). 
DBP was significantly higher in switchers after 120 days patients (90.7 ± 11.2 mm 
Hg) compared with persistent patients (87.3 ± 10.4 mm Hg) (p= 0.03), table 4-12. 
Multinomial logistic regression found that SBP was also significantly different 
between persistors and discontinuers groups, table 4-15.   
Non persistence group had (higher mean SBP 145.92 ± 20.62 mm Hg, and higher 
mean DBP 89.23 ± 11.04 mm Hg, respectively), than persistence group (140.48 ± 
19.18 mm Hg, and 87.38 ± 10.44 mm Hg, respectively) (P=0.0001, and 0.02, 
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respectively), table 4-14. In a multi-variable model, each 1 mmHg increase in SBP 
was associated with a slightly higher risk of non-persistence, Table 4-17. 
 
Table 4-12: comparison of demographics between persisters and non-persisters 
categories at 5 year follow-up.  
 
Population 
characteristics 
Persisters at 
 5 year N (%) 
Non 
Persisters at 
 5 year N (%) 
Drug switch 
Discontinuatio
n N (%) After 120 
days N (%) 
Before 120 
days N (%) 
N 1979 1170 390 360 420 
Male, N (%) 839(42.4) 488(41.7) 167(42.8) 144(40) 177(42.1) 
Age (years )*† 56.6 ± 13.67 56.2 ± 14.42 54.1 ± 14.57 59 ± 13.04 55.87 ± 15.06 
BMI (kg/m2) 28.01 ± 6.28 28.31 ± 5.83 28.76 ± 5.99 28.23 ± 6.01 27.99 ± 5.52 
SBP (mmHg)‡ 140.4 ± 19.1 145.9 ± 20.6 146.8 ± 21.2 146.4 ± 21.1 144.41± 19.59 
DBP 
(mmHg)∏ 
87.38 ± 10.4 89.23 ± 11 90.73 ± 11.21 89.22 ± 10.9 88.05 ± 10.27 
Smoking (0) 
(%) 
1081(60.6) 618(60.1) 147(45.5) 129(41.2) 160(45.7) 
Alcohol (1) (%) 772(44.5) 436(44.2) 210(61.6) 186(57.4) 222(61.2) 
The quantitative variables are expressed as mean ± SD; and geometric mean (95% confidence 
interval for the mean); number (percentage) for categorical data. Significant at P-value<0.05. *, 
†, ‡, and ∏, variables are significant. *switcher after 120 days vs switchers before 120 days and 
switcher after 120 days vs discontinuer. †persistent vs switchers before and after 120 days 
†persistent vs switcher after 120 days. ‡persistent vs switchers before and after 120 days.∏ 
persistent vs switchers before 120 days. Smoking (0) is non-smoker; alcohol (1) is <= 6units per 
week. 
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Table 4-13: comparison of demographics between persisters and non-persistors at 5 year follow-
up. 
Population 
characteristics 
N Persisters Non-Persisters P value 
Male, N (%) 3148 839(42.4) 488(41.7) 0.71 
Age (years ) 3148 56.62 ± 13.67 56.27 ± 14.42 0.51 
BMI (kg/m2) 2895 28.01 ± 6.28 28.31 ± 5.83 0.112 
SBP (mm Hg) 880 140.48 ± 19.18 145.92 ± 20.62 0.0001 
DBP (mm Hg) 880 87.38 ± 10.44 89.23 ± 11.04 0.02 
Smoking (0) (%) 
2812 
 
1081(60.6) 618(60.1) 0.81 
Alcohol (1) (%) 
2720 
 
772(44.5) 436(44.2) 0.90 
The quantitative variables are expressed as mean ± SD; and geometric mean (95% confidence 
interval for the mean); number (percentage) for categorical data. Significant at P-value<0.05. 
Smoking (0) is non-smoker; alcohol (1) is <= 6units per week. 
 
Table 4-14: Comparison of predictors between non-persistence categories using Multinomial 
Logistic Regression at 5 year follow-up. Significant at P-value<0.05. 
Reference 
Other non-
persistence 
Population 
characteristics 
O.R 95% CI p value 
Drug switch after 
120 days 
Drug switch 
before120 days 
BMI (kg/m2) 1.003 0.943-1.067 0.92 
DBP (mm Hg) 1.026 0.986-1.067 0.21 
SBP (mm Hg) 1.001 0.982-1.02 0.94 
Age (years ) 0.966 0.939-0.993 0.02 
Male, N (%) 1.259 0.645-2.456 0.50 
Alcohol (1) (%) 2.080 1.041-4.158 0.04 
Smoking (1) (%) 0.583 0.305-1.112 0.10 
Discontinuation 
BMI (kg/m2) 0.971 0.911-1.034 0.36 
DBP (mm Hg) 0.993 0.957-1.031 0.72 
SBP (mm Hg) 1.005 0.987-1.024 0.58 
Age (years ) 0.966 0.94-0.992 0.01 
Male, N (%) 1.179 0.621-2.239 0.61 
Alcohol (1) (%) 1.544 0.795-3.001 0.20 
Smoking (1) (%) 0.677 0.365-1.256 0.22 
Drug switch 
before120 days 
Discontinuation 
BMI (kg/m2) 0.911 0.911-1.028 0.286 
DBP (mm Hg) 0.933 0.933-1.006 0.098 
SBP (mm Hg) 0.986 0.986-1.023 0.646 
Age (years ) 0.974 0.974-1.026 0.986 
Male, N (%) 0.498 0.498-1.763 0.84 
Alcohol (1) (%) 0.388 0.388-1.421 0.368 
Smoking (1) (%) 0.628 0.628-2.153 0.632 
Significant at P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <= 6 
units per week. 
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Table 4-15: Comparison of predictors between persistence and non-persistence categories 
using Multinomial Logistic Regression at 5 year follow-up. 
Reference is persistence 
category  
Population 
characteristics 
B 95% CI p value 
Drug switch before120 days 
BMI (kg/m2) 1.005 0.966-1.046 0.801 
Age (years ) 0.999 0.996-1.038 0.108 
SBP (mm Hg) 1.012 0.997-1.026 0.118 
DBP (mm Hg) 1.017 0.971-1.027 0.929 
Male, N (%) 0.913 0.551-1.512 0.723 
Alcohol (1) (%) 0.646 0.385-1.083 0.098 
Smoking (1) (%) 1.130 0.699-1.827 0.617 
Drug switch after 120 days 
BMI (kg/m2) 1.007 0.968-1.047 0.734 
Age (years ) 1.022 0.964-1.002 0.08 
SBP (mm Hg) 1.012 0.997-1.027 0.131 
DBP (mm Hg) 0.983 0.993-1.052 0.133 
Male, N (%) 1.226 0.742-2.026 0.426 
Alcohol (1) (%) 1.392 0.833-2.325 0.206 
Smoking (1) (%) 0.708 0.438-1.145 0.16 
Discontinuation 
BMI (kg/m2) 0.982 0.942-1.024 0.394 
Age (years ) 0.993 0.966-1.003 0.092 
SBP (mm Hg) 1.017 1.003-1.031 0.018 
DBP (mm Hg) 0.984 0.967-1.019 0.592 
Male, N (%) 1.127 0.698-1.818 0.626 
Alcohol (1) (%) 1.019 0.625-1.662 0.939 
Smoking (1) (%) 0.792 0.502-1.248 0.314 
Significant at P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <= 6 
units per week. 
 
Table 4-16: Comparison of predictors between persistence and non-persistence using Binary 
Logistic Regression at 5 year follow-up.  
Population characteristics B 95% CI p value 
Age (years ) 0.994 0.981-1.006 0.329 
BMI (kg/m2) 0.997 0.971-1.024 0.831 
SBP (mm Hg) 1.014 1.004-1.024 0.006 
DBP (mm Hg) 1.004 0.985-1.022 0.705 
Male, N (%) 0.923 0.666-1.279 0.630 
Alcohol (1) (%) 1.026 0.737-1.428 0.880 
Smoking (1) (%) 1.158 0.85-1.579 0.353 
Significant at P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <= 6 
units per week. 
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4.4 Discussion 
Persistence is an important and modifiable element in the success of chronic 
hypertension therapy in real clinical practice. Understanding patterns of 
persistence in different populations and to different drugs will provide valuable 
insights into the applicability of results from randomised clinical trials in real-life 
clinical practice. The experience from clinical trials is that for antihypertensive 
therapy to be effective in controlling BP and then lowering cardiovascular 
morbidity and mortality, antihypertensive drugs must be administered in adequate 
doses continuously for a long period of time. There are many factors that influence 
persistence to antihypertensive medications including tolerability, complexity of 
treatment regimen, cost of therapy, physician factors, perceived or real change 
in quality of life(453). 
In this retrospective analysis of patients started on antihypertensive monotherapy 
at a tertiary care hypertension clinic using data obtained from record linkage 
provided by NHS Scotland Information Services Division, my primary objective was 
to study patterns of persistence over the short-term and long-term to different 
classes of antihypertensive drugs.  
The most important results of my study are the high levels of overall persistence 
to the initial antihypertensive drug in patients attending the Glasgow BP Clinic 
between 2004 and 2012. Specifically, in the first year of therapy overall 
persistence was 73% and at five years it was 63%. In general, 5-year persistence 
was lower than 1-year persistence for all drug classes. These results are slightly 
different from studies in other countries and reflect differences in healthcare 
systems and nature of the study population and the study period. A 3-year study 
from Australia between 2004 and 2006 of 10% random sample of all Australian 
long-term health concession card holders who had been commenced on an 
angiotensin II receptor antagonist (A2RA), an angiotensin-converting enzyme 
inhibitor (ACEI) and/or a calcium channel blocker (CCB) showed the 3 year 
persistence overall of 44%(476). In a German study of health insurance records of 
9513 patients followed-up for 4 years, 66% were persistent at 1 year and 44% at 4 
years (477). A retrospective analysis the drugs database of the Local Health Unit 
of Ravenna (Italy) in 7312 subjects receiving a first prescription for diuretics, beta-
blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) 
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inhibitors or angiotensin II antagonists showed the overall 3 year persistence was 
57.9%(437).  An analysis of new users of antihypertensive drugs in the Italian region 
of Lombardy (n=493623), 42% were persistent on monotherapy at 1 year(478). 
Finally, one year persistence among newly treated uncomplicated Korean 
hypertensive patients (n=45787) was 62.1%(479). Whilst all the above studies were 
observational studies of large cohorts using administrative data, Veronesi et 
al(480). Conducted a controlled study of 2-year persistence of 347 patients 
randomly allocated to ACEI, CCB, ARB, BB and diuretics. They found the overall 2 
year persistence of antihypertensive drugs to be 46%. Thus, in general, the GBPC 
hypertensive population showed greater short-term and long-term persistence 
compared to other cohorts. This difference may reflect true population 
differences in terms of drug persistence and adherence. For example, the 
population of Lombardy is known to have low adherence to antihypertensive 
treatment and this has been shown to be associated with a greater risk of 
hospitalisation for cardiovascular events(481). So while the Lombardy population 
showed very 1-year persistence compared to GBPC, the German and Korean 
populations showed comparable though lower 1-year persistence with GBPC. 
Though there were no studies that studied 5-year persistence, it is clear that long-
term persistence is lower than short-term persistence. It is also likely that the 
GBPC population demonstrates higher persistence in contrast to other studies 
because these patients were a selected cohort as they were referred to a tertiary 
clinic, reviewed by specialist nurses and physicians and attended follow-up at the 
clinic until their BP was controlled. Thus, it is likely that physician and hospital 
factors may have had a role in the high levels of persistence demonstrated. 
Another factor that would have an impact on the estimates of persistence is the 
method of assessment of prescription data used. This is illustrated well in the 
German study (477) where persistence was assessed using two criteria. They used 
two different intervals within which a repeat prescription had to be issued: 180 
days and 360 days. A normal prescription in Germany typically comprises a 
package of up to 100 units (e.g. tablets) representing on average about 100 days 
of treatment. Chronically ill patients usually meet their GP once every 3 months 
for a new prescription. Patients who received repeat prescriptions after 180 days 
were considered as non-persistent in regard to the 180 day criterion. However, 
patients receiving prescriptions after 180 days and before 360 days were 
considered as persistent when using the 360 day criterion. The 180 day criterion 
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is stricter than the 360 day criterion, and it is also more precise since those 
patients who do not take their treatment regularly are less likely to be included 
in 180 day criterion as they will be considered to be non-persistent. Thus, applying 
the 180 day criterion, 66% of the patients were persistent at one year. Applying 
the 360 day criteria, the one year rate was 90%. Similarly, the four-year 
persistence rates using the 180 day and 360 criteria were 44% and 79%, 
respectively. As expected, the rates of persistence were higher when a repeat 
prescription interval of 360 days was applied as the criterion for persistence.  
For the GBPC analysis, I did not define a specific interval for prescription refill in 
the analysis. In Scotland, prescription refills for chronic therapy are usually 
provided for 30 days or 90 days. Thus, our results are more aligned with the 180 
day criterion in the German study. 
The choice of the antihypertensive class initially prescribed appear to be 
associated with persistence rates. Analysing different drug classes separately, BB, 
CCB and diuretics showed significantly lower 5-year persistence compared to 1-
year persistence. While ACEI and ARB did not show any significant difference 
between short-term and long-term persistence. 
Across all drug classes, ARB showed the highest persistence both at 1-year and at 
5 years. ACEI showed significantly higher persistence long-term persistence 
compared to non-ARB classes. Thus this study confirms results from multiple 
studies that showed high persistence of ARBs in contrast to other antihypertensive 
drug classes. In the GBPC, ARB persistence was 81% at one year and 74% at 5 years. 
This is comparable to the results from the German primary care cohort(477) which 
showed ARB persistence of 88% and 69% at 1 year and 4 years using the 360 day 
criteria, however, using the 180 day criterion showed a persistence of 64% and 
30%. The 1-year persistence of ARB was 33% and 44% in the Lombardy and Korean 
cohorts respectively(478,479).  
Several studies have linked discontinuation and side effects that resulted from 
antihypertensive classes (450,482). ARBs have been shown in a number of studies 
to have the best tolerability, and may explain the high persistence of patients 
using ARBs in this study and others (483,484). The side effects of ARBs are 
comparable with those of ACEI; however, ACEI caused cough greater than that 
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caused by ARBs (485). The percentage of patients who suffered from cough 
occurred in 10% of patients who treated with ACEI compared with 2–3% of patients 
who treated with ARBs (486). It is surprising that the both short-term and long-
term persistence rates are comparable between ACEI and ARB. Also the low rates 
of discontinuation of ACEI in the first year, though higher than ARBs not 
substantially higher. This would indicate that the rates of discontinuation of ACEI 
due to its well known side-effect, cough, is not a major issue in its use. 
Studies have shown  a relationship between the persistence and cardiovascular 
outcomes (429,487). So, it may be beneficial in the longer term to initiate 
treatment with an ARB first line in preference to other classes of antihypertensive 
drug to improve treatment persistence which may improve cardiovascular 
outcomes that the low persistence lead to increase the cardiovascular events. 
I divided those who switched into two groups: switching after 120 days and 
switching before 120 days. Patients who switched after 120 days had stopped all 
antihypertensive medication for more than 120 days and restarted another 
antihypertensive class. For those switching before 120 days, the period between 
the discontinuation date of the initial antihypertensive class and the switching 
date to another antihypertensive class was less than 120 days; hence, patients 
switched from the initial class to another class yet did not completely stop all 
antihypertensive medication.  
The group that switched after 120 days was younger than other groups 
(persistence, switching before 120 days and discontinuation). Because patients 
completely stopped their drug before restarting other classes in the switching 
after 120 days group, the reason for switching may not have been related to side 
effects or drug efficacy and may be related to the patient’s behaviour such as 
non-compliance with the drug. Younger patients were non-compliant with their 
drug in some studies that support this theory (422,427,428,430). Other reasons 
may be related to medical advice from doctors to try non-pharmacological therapy 
such as changing lifestyle to control BP without antihypertensive drugs, especially 
in younger patients. In those who switched before 120 days, the reasons were 
adverse effects or poor efficacy. 
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Patients with higher BP at baseline appear to be more likely to be non-persistent. 
This result confirm what found in some study such Mazzaglia et al study (450) 
Strengths and Limitations: 
A major strength of this study is the large cohort of specialist referrals linked to 
prescription refill data over a long period of time. Though the data was 
anonymised, because all the patients were initiated treatment at the Glasgow BP 
clinic, it is unlikely that the study drugs were prescribed to treat other 
concomitant conditions and not hypertension. Refill prescription data are an 
efficient way of determining prescription uptake and avoids errors and biases 
associated with other methods of treatment adherence assessment such as self-
report data and pill-count. However, we can’t reasonably assume that if patients 
continue to pick up repeat prescriptions on a regular basis, they must be taking 
them. Refill prescription data are not affected by recall bias, social desirability of 
response or single point estimation(488). In this study as I reviewed the records of 
all the patients attending the GBPC, this avoided selection bias that is normally 
encountered in questionnaire based studies – this is because in questionnaire 
based studies, there is a greater likelihood that discontinuers may not respond.  A 
major limitation is the lack of standardised criteria for estimation of drug 
persistence. This makes it difficult to directly compare results across multiple 
studies. Another limitation is that this study focusses on monotherapy and not 
combination therapy. There is data to suggest that persistence is better and lower 
rates of discontinuation with combination therapy and this needs to be addressed 
in future studies. 
My persistence analysis was based on all patients who were started on an 
antihypertensive drug and there was no requirement for patients to fulfil a 
minimum number of prescriptions to be included in the study. Thus my estimates 
of persistence are not over-optimistic as even patients who did not pick-up a 
second prescription were included in the analyses. Thus drug discontinuation and 
not picking up a second prescription are all examples of poor persistence. 
In this analysis, the main focus was on persistence to antihypertensive therapy. 
The next question is whether patients who persist with therapy actually adhere to 
the treatment regimen and this is the subject of the next chapter. 
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Chapter 5 Antihypertensive Drug Adherence In 
Relation To Persistence 
5.1 Introduction 
Medication adherence is defined as the extent to which a patient takes 
medications as prescribed by their healthcare providers (489). Adherence rates 
are typically higher among patients with acute conditions, as compared with those 
with chronic conditions (392). Suboptimal adherence is known to reduce the 
effectiveness of essential medications (490). Medication nonadherence is 
recognised as a global public health problem by the WHO (491) mainly because 
this is considered a diagnosable and treatable medical condition (492). For 
instance, almost half of patients become non adherent to their antihypertensive 
medication within 1 year of initiating therapy(427). A recent meta-analysis of 
observational studies involving 376,162 patients assessing drug adherence using 
prescription refill frequency for 7 drug classes (aspirin, statins, and 5 
antihypertensive drug classes) prescribed for primary and secondary prevention of 
cardiovascular diseases showed the mean adherence over all studies was only 57% 
after a median of 2 years (493). Furthermore, mean drug adherence was 
substantively and significantly lower in primary than in secondary prevention 
(493). Kronish et al systematically reviewed and pooled results from observational 
studies of adherence to antihypertena sive medications (n=935920 patients) and 
found adherence to be highest among those prescribed ARBs and lowest among 
diuretic users (494). Several outcome studies found that nonadherence to 
antihypertensive agents significantly increased cardiac and cerebrovascular risk 
(426,429,495). In a study of over 2 million participants, Chowduury et al (489) 
found the absolute risk difference associated with poor medication adherence to 
CVD medication was 13 per 100 000 CVD deaths per year, and ~9% of all CVD cases 
in the EU could be attributable to poor adherence. It has been shown that 
increasing adherence in patients who enrolled in pharmacy care programmes lead 
to improvement in their BP (390). Moreover, non-adherence leads to increased 
treatment costs. An estimated $317.4 billion was spent in 2011 due to non-
adherence (384). Sokol et al. showed that overall healthcare costs and 
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hospitalisation  rates were significantly higher in hypertensive patients who were 
non-adherent to their medications (383). 
Several methods were used to determine the adherence rate. The medication 
possession ratio (MPR) is considered one of the most appropriate methods to 
calculate adherence from pharmacy refill data (407–409). MPRs are becoming 
more widely used because they are objective, good for large populations and long 
treatment times, can be used to calculate average adherence and gaps in 
medication, and capture the frequency of medications obtained by the patient 
(410). Patients were considered to be adherent to their antihypertensive drugs if 
the MPR was 80% or more for their received prescription. This range has been 
determined  based on a study showing that patients who received  at least 80% of 
their antihypertensive drug tended to achieve their blood pressure goal (496). 
Adherence rates varied between studies. Based on MPR calculations, adherence 
ranged between 50–80% in some studies and ≤ 30% in other studies 
(390,421,423,426,427).  Several studies have tested whether adherence was 
affected by initiating with a specific antihypertensive drug class.  The highest 
adherence rates were shown with ACEIs and angiotensin-II antagonists, and the 
lowest adherence rate was shown with diuretics in most studies (425,428,434). 
Adherence has been shown to be affected by several factors such as 
sociodemographic, psychosocial or behavioural variables, the healthcare system, 
therapeutic regimen, and comorbidity which have been discussed in introduction 
chapter.  
Appropriate use of medications need to be considered in the context of both 
adherence (taking medications at the prescribed intervals and dosing regimen) 
and persistence (continuous use of medications for the specified treatment time 
period), which, for hypertension, should be maintained life-long. In the previous 
chapter, I conducted a detailed analysis of persistence to antihypertensive 
therapy and now in this chapter I focus on studying patterns of adherence to 
antihypertensive drugs. I specifically focus on those patients who show persistence 
either short-term or long-term to study adherence patterns. The aim of the study 
is to accurately map out persistence patterns in patients who are persistent as 
patients who discontinue their drugs are both non-adherent and non-persistent 
133 
 
and including them in the study will not inform accurately the real adherence 
level of those who continue to take their drugs long term.  
5.2 Methodology 
 Assessment of adherence using refill prescription data only: 
This study analysed persistence patients in chapter 4. 3085 hypertensive patients 
at one-year and 1979 at five- year study who filled their first prescription alpha 
blocker, ACEI, ARB, CCB, BB, spironolactone, centrally acting antihypertensive 
drug, vasodilator antihypertensive drug, non-thiazide diuretic, or thiazide 
diuretic, and persisted with them. The details of the patient and antihypertensive 
selection of the study cohort are presented in Chapter 4, section 4.3.1. 
Adherence is defined as the percentage of patients who persist with their 
treatment and having an MPR >80%. MPR was calculated for initial 
antihypertensive drug which was persisted at one year and at 5 year to estimate 
adherence. MPR defined as the percentage the quantity of medication actually 
consumed by individuals who persisted with therapies during the study period 
(476). MPR was calculated in the previous studies as the total number of days' 
supply was summed for any antihypertensive medication dispensed (the supply 
days of last dispense were excluded), divided by the sum of the elapsed intervals 
between the last date of prescription and the first date of prescription during the 
specific period and the result multiplied by 100 (422,434). The formulae for 
measuring MPR have been given below.  
 
𝐌𝐏𝐑 =
𝑺𝒖𝒎 𝒐𝒇 𝒕𝒉𝒆 𝒅𝒂𝒚𝒔 𝒔𝒖𝒑𝒑𝒍𝒚 𝒇𝒐𝒓 𝒂𝒍𝒍 𝒇𝒊𝒍𝒍𝒔 𝒐𝒇 𝒕𝒉𝒆 𝒅𝒓𝒖𝒈 𝒊𝒏 𝒕𝒉𝒆 𝒔𝒕𝒖𝒅𝒚 𝒑𝒆𝒓𝒊𝒐𝒅
𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒅𝒂𝒚𝒔 𝒊𝒏 𝒕𝒉𝒆 𝒔𝒕𝒖𝒅𝒚 𝒑𝒆𝒓𝒊𝒐𝒅
× 𝟏𝟎𝟎  
 
So, the quantity of antihypertensive class which was persisted for one year, was 
summed (except the last quantity) and divided by the sum of the elapsed intervals 
between the last date of prescription and the first date of prescription to calculate 
the adherence in one-year. And the quantity of antihypertensive class which was 
persisted for five year, was summed (except the last quantity) and divided by the 
sum of the elapsed intervals between the last date of prescription and the first 
date of prescription to calculate the adherence in five-year. The pharmacy refill 
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prescription data included the date a patient collected their antihypertensive 
drugs and the drug's name, strength of dose, and quantity. The pharmacy refill 
prescription data didn’t show the frequency of doses. I took the first 
antihypertensive drugs that were dispensed in the first prescription date and 
checked with the British National Formulary (BNF) and I found most of these drugs 
should be taken once daily. So, I have made an assumption that all 
antihypertensive agents were taken once daily. 
Some of the antihypertensive drugs were taken with 2 different strengths on the 
same date of collection, and both strengths had same quantity and then dispensed 
in the subsequent prescriptions. In this case, I didn't sum the quantity for both 
strengths, instead; I took only one quantity. For example, if a patient collected 
30 tablets from 5 mg amlodipine and 30 tablets for 10 mg from the same drug at 
the same date, I considered that the patient obtained only 30 tablets at that date.  
MPR was calculated for one-year and five-year from drug initiation. Patients who 
had an MPR ≥80% were considered adherent or highly adherent. Patients who had 
an MPR <80% were described as non-adherent. Non-adherent patients were sub-
divided into moderatel and low adherence. Moderate adherence was defined as 
having an MPR between <80 and ≥60%, and low adherence was defined as having 
an MPR <60%. The terms initial antihypertensive drug, persistence, and 
monotherapy have been defined in the previous chapters (Chapter 4 section 4-2). 
 Assessment of concordance using both clinical notes and refill prescription 
data: 
Concordance is defined as the agreement between the prescriptions that were 
written during the clinical visits and the antihypertensive drugs that were 
collected from the pharmacy. Linking the patient’s clinical records with refill 
prescription data allows a detailed analysis of concordance by including data on 
when the medication was prescribed, the interval between prescription and 
pharmacy pick-up, the concordance between prescription and pharmacy pick-up, 
frequency of clinic visits. The clinical summary obtained from the outpatient notes 
included patient-doctor conversations, all patient clinical results, and current 
antihypertensive drugs for each clinic visit. The doctor’s report included 
instructions such as if the patient needed additional clinical tests whether a new 
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antihypertensive drug was prescribed. All of a new antihypertensive prescription's 
detail were noted including the name of the drug and the amount and frequency 
of the dosage. The date of visit and all the report information were then coded 
for each patient into an Excel spreadsheet.  
The prescription visit is defined as the date of the clinical visit when the new 
antihypertensive drug was prescribed by the doctor, and the subsequent visit is 
defined as the date of the clinical visit following the prescription visit. Patient’s 
were expected to take the new antihypertensive drug before the subsequent visit 
for the doctor to evaluate the effectiveness of the new drug on the subsequent 
visit.  
A drug was considered "taken" if the patient collected the new antihypertensive 
drug prescribed at the prescription visit and before the date of the subsequent 
visit. A drug was considered "not taken" if the patient did not collect the new 
antihypertensive drug prescribed at the prescription visit before the date of 
subsequent visit. The name of the drug collected from the pharmacy was cross-
checked with the name of the drug prescribed by the doctor. The duration 
between the date of the prescription visit and the date of the drug collection from 
the pharmacy was calculated. In summary, three measures were evaluated: 
whether the new drug was taken between the prescription visit and subsequent 
visit or not, whether the patient took the same drug which was prescribed, and 
the duration between prescription visit and drug collection. Using this 
information, patients were classified into three groups. High concordance - 
patients who took their new prescriptions within 30 days from date of prescription 
visits; Partial concordance - patients who took their new prescriptions late (after 
30 days from date of prescription visit); non- concordance – patients who did not 
take their new prescriptions from pharmacy.  
Chi-square test, t-test as appropriate were used to compare the demographic 
variables across the groups and by different drug classes. The tests were 
conducted for 1-year and 5-year separately. 
Centrally acting antihypertensive drugs and vasodilator antihypertensive drugs 
were excluded from comparison due to the small number of patients using them. 
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Multiple testing correction was applied to all statistical tests using the Bonferroni 
method. The impact of several independent variables on persistence was 
examined using multivariable logistic regression. Age, BMI, SBP, DBP, sex, smoking 
status and alcohol intake were considered as independent variables. 
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5.3 Results 
The adherence for patients who persisted with their initial antihypertensive 
classes in chapter 4 was estimated in this chapter. Table 4-2 in chapter 4 included 
number of patients who were persistence and their initial antihypertensive drug. 
Also, the demographic of patients who persistence in one year and the five year 
were represented in table 4-7 and 4-13, respectively.  
3085 of persistent patients who received an initial antihypertensive drug were 
involved in a one-year follow-up study to evaluate their adherence. 1979 were 
involved in a study to evaluate their adherence during a five-year follow-up study.  
Assessment of adherence using data from refill prescriptions and MPR Using MPR, 
adherence was defined if MPR was >80%. Non-adherence (MPR<80%) was sub-
classified into moderate (MPR 60-80%) and low adherence (MPR<60%) using refill 
prescription data in persistent patients. Only 922(29.9%) out of 3085 patients were 
adherent to their drugs in the one-year study. The number of adherent patients 
in the five-year study 464(23.4%) (Table 5-1). 
Adherence by drug class for the 1-year and 5-year study are presented in Table 5-
1 and Figure 5-1. Thiazide diuretics had the lowest adherence among the drugs 
for the one- and five- year follow-up studies and it showed the greatest decline in 
adherence between 1-year and 5-years (from 20.4% to 9.4%) The highest 
adherence rate for one and five years was ACEIs. Though the numbers were small, 
alpha blockers, potassium sparing diuretics and non-thiazide diuretics showed an 
increased in adherence between 1 and 5 years, whilst all other drug classes 
showed a decline in adherence at 5 years. 
Despite overall low rates of adherence, relatively, the adherence rates for ACEI 
were significantly higher ARB, BB, CCB and thiazides at 1 year (table 5-2). CCB 
showed significantly higher adherence compared to thiazides at 1 year. At 5 years, 
ACEI showed significantly higher adherence compared to BB and thiazides; 
potassium sparing diuretics showed significantly higher adherence compared to 
ARB, BB and CCB; and thiazides showed significantly lower adherence compared 
to all other drug classes (table 5-3).  
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Table 5-1: Patterns of adherence of different antihypertensive drug classes for persistent 
patients during one year and five follow-up studies 
Class N (1 year) 
Adherence (1 
year) N (%) 
N (5 years) 
Adherence (5 
years) N (%) 
ALPHA 61 18(29.5) 42 17(40.5) 
ACEI 788 312(39.6) 464 148(31.9) 
ARB 349 99(28.4) 240 50(20.8) 
BB 759 195(25.7) 508 105(20.7) 
CCB 486 147(30.2) 311 77(24.8) 
CENT 9 5(55.6) 6 4(66.7%) 
NON-THIA 133 39(29.3) 62 20(32.3) 
SPIRO 28 11(39.3) 19 12(63.2) 
THIA 471 96(20.4) 326 31(9.5) 
VASO 1 0(0) 1 0(0) 
Total 3085 922(29.9%) 1979 464(23.4%) 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; CENT_ACT, 
centrally acting antihypertensive drug; NON_THIA, non-thiazide diuretic; SPIRO, potassium 
sparing diuretics; THIA, thiazide diuretic; VASO, vasodilator antihypertensive drug. Results are 
summarised as number (percentage). 
 
 
 
Figure 5-1: Percentage of adherence for all antihypertensive classes during one and five 
years.  
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; 
CENT_ACT, centrally acting antihypertensive drug; NON_THIA, non-thiazide diuretic; 
SPIRO, potassium sparing diuretics; THIA, thiazide diuretic; VASO, vasodilator 
antihypertensive drug. 
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Table 5-2: The rate of adherence at 1 year between the initial and persist antihypertensive 
monotherapy. 
Class 
No-
adherence 
Adherence 
P values 
ALPH
A 
ACEI ARB BB CCB 
NON_
THIA 
SPIR
O 
ALPHA 43(70.5) 18(29.5)        
ACEI 476(60.4) 312(39.6) 0.13       
ARB 250(71.6) 99(28.4) 0.88 3E-04      
BB 564(74.3) 195(25.7) 0.54 6E-09 0.38     
CCB 339(69.8) 147(30.2) 1 8E-04 0.59 0.09    
NON_T
HIA 
94(70.7) 39(29.3) 1 0.03 0.82 0.39 0.92   
SPIRO 17(60.7) 11(39.3) 0.47 1 0.28 0.13 0.3 0.37  
THIA 375(79.6) 96(20.4) 0.13 1E-12 0.01 0.04 5E-04 0.03 0.03 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, 
non-thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic. Results are 
summarised as number (percentage).The Bonferroni corrected p-value is < 0.0017. 
 
 
Table 5-3: The rate of adherence at 5 year between the initial and persist antihypertensive 
monotherapy. 
Class 
No-
adherence 
Adherence 
P values 
ALPH
A 
ACEI ARB BB CCB 
NON_
THIA 
SPIR
O 
ALPHA 25(59.5) 17(40.5)        
ACEI 316(68.1) 148(31.9) 0.3       
ARB 190(79.2) 50(20.8) 0.01 0.002      
BB 403(79.3) 105(20.7) 0.006 8.E-05 1     
CCB 234(75.2) 77(24.8) 0.04 0.04 0.31 0.19    
NON_T
HIA 
42(67.7) 20(32.3) 0.41 1 0.06 0.05 0.27   
SPIRO 7(36.8) 12(63.2) 0.17 0.01 2E-04 1E-04 7E-04 0.03  
THIA 295(90.5) 31(9.5) 1E-06 2E-14 2E-04 1E-05 3E-07 1E-05 8E-08 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-
thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic. Results are 
summarised as number (percentage).The Bonferroni corrected p-value is < 0.0017. 
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More detailed analyses of the non-adherence groups (MPR<80%) sub-classified into 
moderate (MPR 60-80%) and low adherence (MPR<60%) was done next. The 
distribution of these three categories of adherence at 1 and 5 years are presented 
in Table 5-4. The rates of low-adherence, were higher across all drug classes at 1 
year compared to 5 years, whilst rates of moderate adherence were consistently 
lower across all drug classes at year 1compared to year 5.  
 
Table 5-4: Patterns of adherence categories of different antihypertensive drug classes for persistent 
patients during one year and five year follow-up studies 
Class 
Adherence categories for one years Adherence categories for  5years 
Total N 
(1 year) 
High 
adherence 
Moderate  
adherence 
Low 
adherence 
Total N 
(5 year) 
High 
adherence 
Moderate  
adherence 
Low 
adherence 
ALPHA 61 18(29.5) 12(19.7) 31(50.8) 42 17(40.5) 20(47.6) 5(11.9) 
ACEI 788 312(39.6) 137(17.4) 339(43) 464 148(31.9) 205(44.2) 111(23.9) 
ARB 349 99(28.4) 67(19.2) 183(52.4) 240 50(20.8) 136(56.7) 54(22.5) 
BB 759 195(25.7) 148(19.5) 416(54.8)  508 105(20.7) 257(50.6) 146(28.7) 
CCB 486 147(30.2) 100(20.6) 239(49.2) 311 77(24.8) 167(53.7) 67(21.5) 
CENT 9 4(55.6) 2(22.2) 2(22.2) 6 4(66.7%) 2(33.3) 0(0.0) 
NON_TH
IA 
133 39(29.3) 24(18) 70(52.6) 62 20(32.3) 23(37.1) 19(30.6) 
SPIRO 28 11(39.3) 6(21.4) 11(39.3) 19 12(63.2) 6(31.6) 1(5.3) 
THIAZ 471 96(20.4) 78(16.6) 297(63)  326 31(9.5) 169(51.8) 126(38.7) 
VASO 1 0(0) 0(0) 0(100) 1 0(0) 1(100) 0(0.0) 
Total 3085 922(29.9) 575(23.4) 1588(51.5) 1979 464(23.4) 986(49.8) 529(26.7) 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; CENT_ACT, centrally acting antihypertensive 
drug; NON_THIA, non-thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic; VASO, 
vasodilator antihypertensive drug. Results are summarised as number (percentage). 
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5.3.1 Patient’s characteristics for adherence at one year 
The different clinical characteristics of hypertension patients stratified by 
adherence and non-adherence were compared in Table 5-5.  
In univariate analyses of baseline characteristics and adherence, male patients 
were more likely to be adherent than non-adherent patients (47% versus 42%). 
Adherent patients has a slightly higher BMI than non-adherent patients. A higher 
baseline SBP or DBP was significantly associated with greater adherence. 
In the multivariable model, only age and BMI showed a significant direct 
association with adherence (Table 5-6). 
Table 5-5: Demographics and characteristics of persistent patients classified according to 
pattern of adherence at one year follow up. 
Characteristics N 
1-year adherence 
P value 
Non adherence Adherence 
Male, N (%) 3084 911(42.2) 436(47.2) 0.01 
Age (years ) 3084 55.97±14.99 57.06± 14.49 0.06 
BMI (kg/m2) 2854 27.8±5.98 28.29± 6.4 0.047 
SBP (mm Hg) 908 141.466±19.87 148.525± 20.43 7.75E-07 
DBP (mm Hg) 908 87.704±10.97 90.461± 11.9 0.01 
Smoking (0) (%) 2635 1153± (60.4) 441(60.7) 0.93 
Alcohol (1) (%) 2547 796± (43.1) 314(44.7) 0.47 
The quantitative variables are expressed as mean ± SD; and geometric mean (95% confidence 
interval for the mean); number (percentage) for categorical data. Significant at P-value<0.05. 
Smoking (0) is non-smoker; alcohol (1) is <= 6 units per week. 
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Table 5-6: Binary logistic regression of association between predictors and adherence at 
one year follow up. 
 OR 95% CI p value 
Age (years ) 1.012 0.998-1.025 9E-02 
BMI (kg/m2) 1.040 1.012-1.068 0.004 
SBP (mm Hg) 1.008 0.998-1.018 0.13 
DBP (mm Hg) 1.004 0.985-1.024 0.67 
Male, N (%) 0.896 0.631-1.274 0.54 
Alcohol (1) (%) 1.112 0.778-1.588 0.56 
Smoking (0) (%) 1.139 0.815-1.592 0.45 
Significant at P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <= 6 units 
per week. 
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5.3.2 Patient’s characteristics for adherence at five year 
The table 5-7 shows the results of the univariate analysis of baseline 
characteristics and adherence. Only sex was statistically significant among these 
variables, while male patients showing higher adherence.  
The multivariable analysis presented in Table 5-8 showed that only age was 
significantly associated with adherence. Older age was associated with increased 
adherence. 
Table 5-7: Demographics and characteristics of persistent patients classified according to 
pattern of adherence at five year follow up 
Characteristic N 
5-year adherence 
P value 
Non adherence Adherence 
Male, N (%) 3084 618(40.8) 221(47.7) 0.01 
Age (years ) 3084 57.4±13.55 56.38±13.71 0.16 
BMI (kg/m2) 2854 28.43±6.81 27.88± 6.11 0.11 
SBP (mm Hg) 908 141.3±18.01 140.25±19.52 0.58 
DBP (mm Hg) 908 87.95±11 87.21± 10.28) 0.47 
Smoking (0) (%) 2635 827(60.4) 254(61.2 0.82 
Alcohol (1) (%) 2547 597(45) 175(43) 0.49 
The quantitative variables are expressed as mean ± SD; and geometric mean (95% confidence 
interval for the mean); number (percentage) for categorical data. Significant at P-value<0.05. 
Smoking (0) is non-smoker; alcohol (1) is <= 6 units per week. 
 
Table 5-8: Binary logistic regression of association between predictors and adherence at 
five year follow up. 
 B 95% CI p value 
Age (years ) 1.022 1.003-1.04 0.02 
BMI (kg/m2) 1.025 0.991-1.059 0.15 
SBP (mm Hg) 0.995 0.981-1.01 0.53 
DBP (mm Hg) 1.016 0.99-1.043 0.23 
Male, N (%) 0.784 0.5-1.231 0.29 
Alcohol (1) (%) 1.226 0.774-1.943 0.39 
Smoking (0) (%) 1.210 0.79-1.852 0.38 
Significant at P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <= 6 
units per week. 
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5.3.3 Assessment of concordance using data from both case 
notes and refill prescriptions 
This study included 443 patients whose prescriptions were reviewed using case 
notes and pharmacy refill date. Case note review of these 443 patients identified 
989 new antihypertensive prescriptions from the hospital physician during the 
study period. Of these 989 new prescriptions from the hospital physician, 773 
(78.2%) of them were identical to the drugs dispensed from the pharmacy. Only 4 
(0.4%) of the antihypertensive drug prescriptions dispensed from the pharmacy 
were for different from those ordered in the prescriptions (either different within 
a class or different class). Perindopril, atenolol, lisinopril, and amlodipine were 
prescribed, however, ramipril, bisoprolol, enalapril, and lercanidipine 
respectively were dispensed instead of the prescribed drugs. 212 (21.4%) out of 
989 new antihypertensive prescriptions given by GBPC physicians were not 
obtained from the pharmacy. Figure 5-2. 
777 of the antihypertensive prescriptions were picked-up from pharmacy. 
472(61%) of them were picked up within 30 days after the prescribing visit date 
(early collection). This is the frequency of prescriptions being picked-up and each 
patient have been prescribed more than one drug at different times during their 
follow-up period. 305(39%) of these antihypertensive prescriptions were picked 
more than 30 days after the prescribing visit date (late collection). Figure 5-3. 
136 (30%) patients took all their newly prescribed medicines early (less than 30 
days from the prescribing visit date). These patients were described as high 
concordance. 307 (70%) patients did not take any of their drugs or picked-up their 
drugs late (more than 30 days from the prescribing visit date). These patients were 
described as low concordance. 
Low-concordance was sub-classified into partial and non-concordance. Partial 
concordance: 149 (34%) patients who picked-up all their prescriptions but picked-
up one or more of them late. Non-concordance: 158 (36%) patients who did not 
pick up any of their prescribed drugs. 
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Figure 5-2: Comparison between drugs prescribed and drug collections. 
Take the same drug: % of patients who collect the same drugs was prescribed. Take 
different drug: % of patients who collect the different drugs than that were prescribed. Not 
take at all: % of patients who not collect their drug prescriptions. 
 
 
 
Figure 5-3: Patient’s behaviours with their antihypertensive prescriptions.  
Take drug later: % of patients who collect their drugs prescribed after 30 days from 
prescription visit. Take drug early: % of patients who collect their drugs prescribed within 
30 days from date of prescription visit. Not take at all: % of patients who not collect their 
drugs prescriptions. 
 
78.2%
0.4%
21.4%
Take the Same drug
Take different drug
Not taken at all
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5.3.4 Patient characteristics of concordance  
Six clinical characteristics of hypertension patients (sex, age, BMI, days between 
visits, smoking status, and alcohol intake) were examined between concordance 
and non-concordance groups. Except days between visits, these variables were 
not significantly different between concordance and non-concordance groups. 
Days between visits were higher in low concordance groups (103.6 days (95% CI: 
95.3, 112.6)) than days between visits in the high concordance group (81.3 days 
(95% CI: 71.8, 92)). Days between visits were also higher in high and partial-
concordance groups with 81.3 days (95% CI: 71.8, 90) and 83 days (95% CI: 74.9, 
93), receptively, than days between visits in the non-concordance group (103.54 
± 81.62 Days). No significant found between high and partial-concordance groups 
(table 5-9, 5-11). 
Only sex, age, were included in a multivariable test model because a small number 
for other variables. This test found that an increase in days between visits was an 
independent factor leads to make patient’s pick-up their prescriptions drug or not 
pick them at all. Table 5-10, and 5-12. 
 
Table 5-9: Demographics and characteristics of patients classified into high 
concordance and low concordance (partial+ non- concordance). 
Characteristic N High-concordance 
Partial + Non 
concordance 
P Value 
Male, N (%) 401 61(52.6) 163(57.2) 0.44 
Smoking (0) (%) 249 35(68.6) 122(62.6) 0.51 
Alcohol (1) (%) 227 19(41.3) 84(46.4) 0.62 
Dyes between visits 
(days) 
443 
98.344±67.50 136.37± 141.59 
0.001 
Age (years ) 401 55.8 ±14.79  54.78± 12.97 0.49 
BMI (kg/m2) 353 28.76±5.47 29.21± 5.71 0.50 
The quantitative variables are expressed as mean ± SD; and geometric mean (95% 
confidence interval for the mean); number (percentage) for categorical data. Significant at P-
value<0.05. Smoking (0) is non-smoker; alcohol (1) is <= 6 units per week. 
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Table 5-10: Binary logistic regression of association between predictors and high 
concordance 
Characteristic O.R 95% CI P value 
Dyes between visits 0.995 0.99-1 0.003 
Age (years ) 1.004 0.99-1.02 0.673 
Male, N (%) 1.240 0.79-1.94 0.346 
Significant at P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <=6 
units per week. 
 
 
 
Table 5-11: Demographics and characteristics of patients grouped into high 
concordance, partial+ non- concordance. 
Characteristic N 
High- 
concordance 
Partial- 
concordance 
Non- concordance 
P 
value 
Male, N (%) 401 61(52.6) 82(60.3) 81(54.4) 0.42 
Smoking (0) (%) 249 35(68.6) 61(60.4) 61(64.9) 0.59 
Alcohol (1) (%) 227 19(41.3) 44(45.8) 40(47.1) 0.81 
Dyes between 
visits (days) 
443 81.3(71.8-90) 83(74.9-93) 130.3(117.7-144.2) 4E-07 
Age (years ) 401 55.88±14.794 54.74± 12.989 54.82±13.002 0.78 
BMI (kg/m2) 353 
28.3(27.3-29.3) 28.6(27.6-29.6) 28.8(27.9-29.7) 
0.30 
The quantitative variables are expressed as mean ± SD; and geometric mean (95% confidence 
interval for the mean); number (percentage) for categorical data. Significant at P-value<0.05. 
Smoking (0) is non-smoker; alcohol (1) is <= 6 units per week. 
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Table 5-12: Multinomial logistic regression of association between predictors and high 
concordance. 
Reference 
Population 
characteristics 
O.R 95% CI p value 
High concordance 
Partial- concordance 
Age (years ) -0.007 0.97-1.01 0.49 
Dyes between visits 
(days) 
0.002 1-1.01 0.43 
Male, N (%) 0.32 0.83-2.3 0.22 
Non- concordance 
Age (years ) -0.0002 0.98-1.02 0.99 
Dyes between visits 
(days) 
0.007 1-1.01 0.0001 
Male, N (%) 0.11 0.67-1.86 0.67 
Partial- 
concordance 
Non- concordance 
Age (years ) 0.007 0.99-1.03 0.48 
Dyes between visits 
(days) 
0.006 1-1.01 0.0003 
Male, N (%) -0.211 0.49-1.32 0.40 
Significant at P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <= 6 units 
per week. 
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5.4 Discussion 
The main findings from the analyses presented in this chapter are low levels of 
adherence over the short term (1-year) and long-term (5-years). the study of 
adherence was restricted to those patients who were persistent with medications 
for the duration of the study. The reason for restricting the study of adherence to 
only those who are persistent is to obtain a more reliable estimate of patient 
adherence those exposed to the drug for specified periods of time. This would 
remove any biases introduced by discontinuers (patients who took the drug 
initially but then discontinued early), as lots of discontinuers would inflate the 
estimates of non-adherence among those who are persistent and make any 
comparison between drugs impossible. Concordance has been also studied in this 
chapter. I reviewed the patients’ case notes and their prescription refill data to 
check whether or not the prescribed medications were picked up from the 
pharmacy during clinical visits. This chapter answered two important questions: 
Have the prescribed medications been collected? Have the medications that were 
collected have been taken regularly? Thus, the results of this chapter complement 
the results of the previous chapter. 
Around 30% of patients were adherent to their antihypertensive drugs at 1 year 
and only 23% at 5-years using an MPR >80% criteria for defining high adherence. 
Thiazide diuretics showed the lowest adherence at 5 year compared to all drug 
classes and the greatest decline in adherence from year 1 (from 20% to 9.5%). 
compared to all drug classes. In contrast ACEI showed the highest adherence 
compared to all major drug classes in year 1 and also showed the highest 
adherence in Year 5 against BB and thiazide diuretics. On undertaking a more 
granular analysis of non-adherence by classifying them into moderate and low 
adherence, the striking finding was the consistency in these rates across all drug 
classes. More importantly the higher rates of low adherence at year 1 declined by 
over half in year 5 and this was related to a corresponding increase in the rates of 
moderate adherence. 
In a large meta-analysis (489) of adherence to cardiovascular drugs in over a 
million participants, the overall prevalence of good adherence to cardiovascular 
medications was 60% and adherence to antihypertensive drugs was 59% (42% to 
77%). This is quite different from the adherence in the GBPC in my study and there 
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are various reasons for this. The Chowdhury et al study was a meta-analysis of 26 
studies which included data from clinical trial registers, insurance databases and 
healthcare registers and thus were based on affluent settings which may spuriously 
report higher levels of adherence than in the general population. The 
measurement of adherence in the Chowdhury et al study also were not uniform 
across studies and the types of adherence assessments were pharmacy refill data 
based on the MPR(14 studies) or PDC (12 studies); by other indirect measures 
including self-reports (6 studies); and 2 by direct measures (e.g. electronic 
monitoring systems or blood tests) (489). In contrast my study was a study of 
hypertensive patients attending a specialist clinic and required to have data on 
persistence over two study time-periods, 1-year and 5-year for inclusion in the 
study. The Chowdhury et al study reported the range of adherence to be very wide 
from 4.9% to 93.3%. 
The novel findings from my study is the estimation of adherence in the same 
population attending a specialist hypertension clinic over the short-term and long-
term. The results indicate that even in patients are persistent, adherence tend to 
decline over the long term. Whilst the rate of low adherence were high by year 1, 
the rates of moderate low adherence were increased by 50% by year 5. The impact 
of this moderate change in adherence over the long term has not been studied 
before and this merits further outcome studies. Most of the published studies on 
adherence have studied adherence only at one time point usually around 1- 2 years 
and the results show consistently poor adherence to cardiovascular medications. 
My study provides rigorous estimates of the problem in a hypertensive population. 
I have also studied concordance and it is surprising that only 30% of patients were 
concordant by picking up their prescriptions within 30 days of clinic visit. Though 
my measure of concordance is not the ideal metric, it provides insight into the 
behaviour of patients in terms of pharmacy pickup of prescriptions. More 
importantly 36% of patients did not pick up any prescriptions after first 
prescription. Thus measures to improve adherence will require interventions to 
improve concordance. 
Analyses of the determinants of adherence in this study showed only age to be a 
significant determinant. The duration between the prescription visit and 
subsequent visit was significant for prescriptions taken, and prescriptions not 
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taken. Patients who had a fewer days between their prescription visit and 
subsequent visit seemed to take their antihypertensive prescription. On the other 
hand, patients who had more days between the prescription visit and subsequent 
visit seemed to not taken at all. The relationship between the number of visits to 
the doctor and adherence has been investigated in numerous studies. It has been 
shown that patients who had more visits to the doctor showed higher adherence 
to the antihypertensive drugs than those who had fewer visits (424,425). Other 
studies have shown variable association between adherence and age, social status, 
health literacy, existence of co-morbid conditions, polypharmacy, no-fill of first 
prescription, irregular refills obtained, uncertainty about the effectiveness, 
prohibitive costs, and serious adverse events (422,428,430,489,497). 
The main limitation of using the MPR method is that it does not provide 
information about dose frequency or whether patients have been advised to split 
pills which is on the known disadvantage of using MPR (410). However, 98% of the 
antihypertensive drugs used in my adherence study are recommended to be used 
once daily based on the British National Formulary. In most cases, old CCBs and 
BBs may be used more than once daily, but they are less likely to be prescribed 
nowadays according to most recent guidelines. The availability of drugs in 
different strengths minimises the chance that patients will split pills. Also, only 
patients with certain co-morbidities (e.g., those with renal or hepatic impairment) 
might need very low doses. 
In summary, whilst adherence to antihypertensive drugs is low, adherence is not 
greatly dependent on the class of drugs prescribed. This means interventions to 
improve adherence can be broadly applied. However, few interventions to 
improve adherence to cardiovascular drugs have been successfully implemented, 
and those that have shown a benefit have tended to be complex, costly, and 
difficult to sustain (498–500). The results of my study reinforce the need to reliably 
measure adherence levels over the short and long term and assess their impact on 
outcomes and test interventions that can improve adherence and consequently 
survival. 
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Chapter 6 Additional therapy  
6.1 Introduction  
The initiation of a specific antihypertensive drug class was varied according to 
hypertensive guidelines. Recent NICE  guidelines recommend initiating with ACEI 
or ARB  for patients under 55 years and with CCB for patients over 55 years or of 
African-Caribbean  descent (43). Recent JNC guidelines recommend starting with 
a diuretic or CCB for black patients and diuretics, BBs, CCBs, ACEIs and ARBs  with 
non-black patients (40). On the other hand, ESH and ESC guidelines suggest 
initiating with diuretics, BBs, CCBs, ACEIs and ARBs are viable (41). Despite the 
proven safety and efficacy of these recommended  antihypertensive drug classes 
(or other antihypertensive classes), poor BP control remains an issue worldwide 
(273,274). Few patients are able to achieve a blood pressure goal (140/90 mm Hg) 
using only one antihypertensive drug as a monotherapy (247,275). 
Initiating a combination therapy of two or more antihypertensive drugs has shown 
greater efficacy in reducing blood pressure and CV events than monotherapy. A 
recent meta-analysis of 11,000 hypertensive patients revealed that greater BP 
reductions were achieved when combining two different antihypertensive drug 
classes than the reductions achieved by doubling the dose of an individual agent 
(276). The ALERT study showed that cardiovascular structure and function 
measurements were more improved when low doses of two antihypertensive drugs 
(angiotensin-converting enzyme inhibitor and calcium channel blocker) were 
combined than with a high dose of either single agent(277).  Despite the greater 
efficacy of using multiple antihypertensive drug classes, initiating with 
antihypertensive drug combinations leads to increased pill burdens, which is 
associated with lower adherence rates(423,433). 
This chapter will analyse the following items: evaluate the number of patients 
who were persistent with an initial antihypertensive drug class without any 
additional therapy and the number of patients who needed additional 
antihypertensive therapy; investigate which antihypertensive drug classes 
required one or more additional antihypertensive drugs than others; study which 
independent variables increased the probability that patients required additional 
antihypertensive therapy. 
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6.2 Methodology 
3,085 and 1,979 hypertensive patients were analysed for one-year and five-year 
studies, respectively. This analysis included patients who initiated a new 
antihypertensive drug class and were persistent with this intonation during the 
one- and five-year follow-up studies. The terms persistence and new 
antihypertensive drugs were defined in chapters two and three. 
The number of antihypertensive drug classes that were added to the initial 
antihypertensive drug class was calculated. All additional antihypertensive drug 
classes were counted until the last day of the study. Additional therapy was 
defined as the number of antihypertensive drug classes that were added to the 
persistence-initiated antihypertensive drug during 365 days for the one-year study 
and 1,825 days for the five-year study. 
The non-additional therapy group was defined as patients who continued with the 
initial antihypertensive drug class without needing additional antihypertensive 
therapy. The additional therapy group was defined as patients who required 
antihypertensive therapy in addition to their initial antihypertensive drug. The 
proportion of non-additional to additional patients was estimated. A chi-square 
test was used to compare the proportions of each initial antihypertensive drug 
class that were persistent without requiring additional therapy and which needed 
additional therapy with the other initial antihypertensive classes. The Bonferroni 
method was used to correct the various significance tests resulting from multiple 
comparisons on the same dataset. 
Chi-square test, t-test were used to compare the demographic variables across 
the groups and by different drug classes. The tests were conducted for 1-year and 
5-year separately. 
The impact of age, BMI, SBP, DBP, sex, smoking status and alcohol intake as the 
independent variables on the additional therapy was tested using multivariate 
logistic regression. 
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6.3 Results 
6.3.1 Additional therapy during persistence period of different 
antihypertensive drug classes  
3,085 and 1,979 patients who were persistent with their initial antihypertensive 
drug were included in the one- and five-year studies respectively. Of these 
subjects, 1363(44.2%) needed additional antihypertensive drugs in the one-year 
study and 1422(71.8%) required additional antihypertensive drug therapy in the 
five-year study.  
The number of patients who required additional antihypertensive drug therapy 
during the one-year study was 47(77%) (Alpha-blockers), 76 (57%) (Non-thiazide 
diuretic), 5 (55%) (Centrally acting), 240 (49.4%) (CCBs), 230 (48.8%) (Thiazide 
diuretic), 156 (44.7%) (ARBs), 326 (41.4%) (ACEIs), 272(35.8%) (BBs), and 10(35.7%) 
(potassium sparing diuretics). The number of patients in the five-year study was 
38 (90.5%) (Alpha-blockers), 50 (80.6%) (Non-thiazide diuretics), 255(78.2%) 
(Thiazide diuretics), 237(76.2%) CCBs, 173(72.1%) (ARBs), 319(68.8%) (ACEIs), 
335(65.9%) (BBs), and 8(42.1%) (potassium sparing diuretics) Table 6-1. 
The percentage of patients who were persistent for one and five years and who 
required additional antihypertensive drug therapy was highest for alpha-blockers 
and lowest for BB. Those on BB monotherapy who were persistent at one year 
were less likely to require additional drug therapy than those on alpha-blockers, 
CCB, non-thiazide diuretic, or thiazide diuretic. Patients on BB were less likely to 
need additional therapy than those on alpha-blockers, and non-thiazide during the 
five-year study. Patients on ACEI is significantly higher than those on alpha-
blockers or on non-thiazide diuretic at one-year study, no significant difference 
occurred between patients on ACEI and those on other antihypertensive classes at 
five-year study.  Table 6-2, and table 6-3. 
All antihypertensive classes at five year appeared to require additional therapy, 
with no significant difference between most antihypertensive classes. 
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Table 6-1: The proportion of additional and non-additional therapy for patients who 
persist with first line- antihypertensive drugs during one and 5 years. 
Class 
Additional therapy - one year Additional therapy - 5 years 
N No additional 
therapy N(%) 
Additional 
therapy N(%) 
N No additional 
therapy N(%) 
Additional 
therapy N(%) 
ALPHA 61 14(23) 47(77) 42 4(9.5) 38(90.5) 
ACEI 788 462(58.6) 326(41.4) 464 145(31.3) 319(68.8) 
ARB 349 193(55.3) 156(44.7) 240 67(27.9) 173(72.1) 
BB 759 487(64.2) 272(35.8) 508 173(34.1) 335(65.9) 
CCB 486 246(50.6) 240(49.4) 311 74(23.8) 237(76.2) 
CENT 9 4(44.4) 5(55.6) 6 0(0) 6(100) 
NONTHIA 133 57(42.9) 76(57.1) 62 12(19.4) 50(80.6) 
SPIRO 28 18(64.3) 10(35.7) 19 11(57.9) 8(42.1) 
THIAZ 471 241(51.2) 230(48.8) 326 71(21.8) 255(78.2) 
VASO 1 0(0) 1(1) 1 0(0) 1(100) 
Total 3085 1722 (55.8%) 1363(44.2) 1979 557(28.2) 1422(71.8) 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; CENT_ACT, 
centrally acting antihypertensive drug; NON_THIA, non-thiazide diuretic; SPIRO, potassium 
sparing diuretics; THIA, thiazide diuretic; VASO, vasodilator antihypertensive drug. Results are 
summarised as number (percentage). 
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Table 6-2: Comparison between the initial and persistence antihypertensive therapies based 
on additional therapy requirements at one year study 
Class 
Additional therapy P values 
No Yes ALPH
A 
ACEI ARB BB CCB NON_ 
THIA 
SPIR
O 
ALPHA 14(23) 47(77)        
ACEI 462(58.6) 326(41.4) 7E-08       
ARB 193(55.3) 156(44.7) 3E-06 0.3      
BB 487(64.2) 272(35.8) 6E-10 0.03 0.005     
CCB 246(50.6) 240(49.4) 4E-05 0.005 0.18 2E-06    
NON_THI
A 
57(42.9) 76(57.1) 0.01 9E-04 0.02 5E-06 0.12   
SPIRO 18(64.3) 10(35.7) 3E-04 0.7 0.43 1 0.18 0.06  
THIA 241(51.2) 230(48.8) 3E-05 0.01 0.26 7E-06 0.9 0.1 0.24 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-
thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic. Results are 
summarised as number (percentage).The Bonferroni corrected p-value is < 0.0017. 
 
 
Table 6-3: Comparison between the initial and persistence antihypertensive therapies based 
on additional therapy requirements at five year study. 
Class 
Additional therapy P values 
No Yes ALPH
A 
ACEI ARB BB CCB NON_ 
THIA 
SPIRO 
ALPHA 4(9.5) 38(90.5)        
ACEI 145(31.3) 319(68.8) 0.002       
ARB 67(27.9) 173(72.1) 0.01 0.39      
BB 173(34.1) 335(65.9) 8E-04 0.37 0.09     
CCB 74(23.8) 237(76.2) 0.05 0.03 0.28 0.002    
NON_THI
A 
12(19.4) 50(80.6) 0.27 0.06 0.2 0.02 0.51   
SPIRO 11(57.9) 8(42.1) 1E-04 0.02 0.009 0.05 0.002 0.74  
THIA 71(21.8) 255(78.2) 0.07 0.003 0.11 1E-04 0.57 1 0.45 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-
thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic. Results are 
summarised as number (percentage).The Bonferroni corrected p-value is < 0.0017.. 
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6.3.2 Percentage patients who required two or three 
antihypertensive drug based on the initial antihypertensive 
drugs 
Additional therapy was classified into three groups one, two, and three groups. 
Group one represented patients who persist with the initial antihypertensive drugs 
without need to any additional therapy.  Group two, patients who persist with 
initial drug and required one more antihypertensive drug. Group three, patents 
who persist first line drug and required to adding two or more antihypertensive 
drug during the study.   
722 (23.4%) persistent patients required one more antihypertensive drug class and 
641 (20.8%) patients needed two or more antihypertensive drugs in addition to the 
initial antihypertensive drug therapy during the one-year study. In the five-year 
study, the number of persistent patients who required one additional drug therapy 
was 501 (25.3%) and those who required two or more additional drug therapies 
was 921 (46.5%). Table 6-4. 
Persistent patients at one year were most likely to require one additional 
antihypertensive drug therapy if they were taking thiazide diuretic and less likely 
if they were on alpha blocker, and non-thiazide diuretic. During the five-year 
study, patients on alpha-blocker, CCB or non-thiazide diuretic were less likely to 
need one additional antihypertensive drug therapy and more likely if they were 
on thiazide diuretics. In general, Patient on thiazide diuretic more likely to need 
one more antihypertensive drug at one and five year studies. 
Persistent patients at one year and five years who were on BB, ACEI, and ARB were 
the less likely to require two or more additional antihypertensive and more likely 
if they were on alpha-blockers, CCB, and non-thiazide diuretic (table 5-6, and 5-
7, figure 6-1, and 6-2).   
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Table 6-4: Number of antihypertensive drugs were required after the initial the drug. 
Class 
Persistors with additional therapy 
1 year 
Persistors with additional therapy 
5 years 
N 0 drug 
(%) 
+1 drug 
(%) 
>2 drugs 
(%) 
N 0 drug 
(%) 
+1 drug 
(%) 
>2 drugs 
(%) 
ALPHA 61 14(23) 12(19.7) 35(57.4) 42 4(9.5) 4(9.5) 34(81) 
ACEI 788 462(58.6) 185(23.5) 141(17.9) 464 145(31.3) 115(24.8) 204(44) 
ARB 349 193(55.3) 80(22.9) 76(21.8) 240 67(27.9) 66(27.5) 107(44.6) 
BB 759 487(64.2) 167(22) 105(13.8) 508 173(34.1) 134(26.4) 201(39.6) 
CCB 486 246(50.6) 114(23.5) 126(25.9) 311 74(23.8) 59(19) 178(57.2) 
CENT 9 4(44.4) 1(11.1) 4(44.4) 6 0(0) 3(50) 3(50) 
nonTHIA 133 57(42.9) 26(19.5) 50(37.6) 62 12(19.4) 11(17.7) 39(62.9) 
SPIRO 28 18(64.3) 2(7.1) 8(28.6) 19 11(57.9) 1(5.3) 7(36.8) 
THIAZ 471 241(51.2) 135(28.7) 95(20.2) 326 71(21.8) 108(33.1) 147(45.1) 
VASO 1 0(0) 0(0) 1(1) 1 0(0) 0(0) 1(100) 
Total 3085 1722(55.8) 722(23.4) 641(20.8) 1979 557(28) 501(25.3) 921(46.5) 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; CENT_ACT, centrally 
acting antihypertensive drug; NON_THIA, non-thiazide diuretic; SPIRO, potassium sparing diuretics; 
THIA, thiazide diuretic; VASO, vasodilator antihypertensive drug. Results are summarised as number 
(percentage). 
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Table 6-5: Comparison patients who required one or two additional therapy based on their 
initial antihypertensive therapy in one year study.  
Class 0 drug +1 drug >2 drugs 
P values 
ALPH
A 
ACEI ARB BB CCB NON_T
HIA 
SPI
RO 
ALPH
A 
14(23) 12(19.7) 35(57.4)        
ACEI 462(58.6) 185(23.5) 141(17.9) 2E-12        
ARB 193(55.3) 80(22.9) 76(21.8) 8E-09 0.154      
BB 487(64.2) 167(22) 105(13.8) 1E-16 0.012 6E-04     
CCB 246(50.6) 114(23.5) 126(25.9) 4E-07 5E-04 0.129 2E-08    
NONT
HIA 
57(42.9) 26(19.5) 50(37.6) 0.004 2E-06 0.001 5E-10 0.02   
SPIRO 18(64.3) 2(7.1) 8(28.6) 7E-04 0.73 0.891 0.3 0.5 0.1  
THIAZ 241(51.2) 135(28.7) 95(20.2) 4E-09 0.032 0.65 1E-05 0.23 0.0013 0.75 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, 
non-thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic. Results are 
summarised as number (percentage).The Bonferroni corrected p-value is < 0.0017. 
 
 
Table 6-6: Comparison patients who required one or two additional therapy based on their initial 
antihypertensive therapy in five year study. 
Class 0 drug +1 drug >2 drugs 
P values 
ALPHA ACEI ARB BB CCB NON
_THI
A 
SPIR
O 
ALPHA 4(9.5) 4(9.5) 34(81)        
ACEI 145(31.3) 115(24.8) 204(44) 2.0E-05       
ARB 67(27.9) 66(27.5) 107(44.6) 8E-05 0.55      
BB 173(34.1) 134(26.4) 201(39.6) 2E-06 0.19 0.094     
CCB 74(23.8) 59(19) 178(57.2) 0.005 9E-04 0.02 6E-06    
NON-
THIA 
12(19.4) 11(17.7) 39(62.9) 0.062 0.007 0.023 9E-04 0.38   
SPIRO 11(57.9) 1(5.3) 7(36.8) 0.0001 0.095 0.063 0.187 
0.006
9 
0.005  
THIAZ 71(21.8) 108(33.1) 147(45.1) 1.8E-04 0.077 0.33 0.002 0.11 0.06 0.019 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, non-
thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic. Results are 
summarised as number (percentage).The Bonferroni corrected p-value is < 0.0017. 
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Figure 6-1: Percentage of patients required one or two additional therapy in five year study. 
0 drug: patient who didn’t need any additional therapy. +1drug: patients who need one 
additional therapy. >2 drug: patients who need two or more additional therapy. 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; 
NON_THIA, non-thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide 
diuretic.  
 
 
 
Figure 6-2: Percentage of patients required one or two additional therapy in one year study. 
0 drug: patient who didn’t need any additional therapy. +1drug: patients who need one 
additional therapy. >2 drug: patients who need two or more additional therapy. 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; 
NON_THIA, non-thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide 
diuretic.  
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6.3.3 Patient characteristics for additional drug therapy at one 
year 
The average age of the additional drug therapy group was 60.02 ± 14.07 years, 
which is higher than the mean age of the non-additional drug therapy group (53.34 
± 14.79 year). The mean of BMI was significantly higher in the additional drug 
therapy group (28.74 ± 6.21 kg/m2) than in the non-additional drug therapy group 
(27.3 ± 5.96 kg/m2). The additional drug therapy group had a mean systolic BP 
that was higher than the non-additional drug therapy group 146.64 ± 22.28 mm Hg 
versus 141.52 ± 18.32 mm Hg. The percentage of patients took <=6 units of alcohol 
per week significantly higher in the additional drug therapy group than in the non-
additional drug therapy group (46% versus 41.6%).  
In a multivariable model, the factors associated with increased risk for needing 
additional drugs were age, BMI and SBP. Increasing age, BMI, and SBP were 
associated with an increased likelihood of additional therapy (table 6-8).  
 
 
Table 6-7: Patient demographics of Additional antihypertensive therapy in persistent 
patients during one year study. 
Characteristic N 
Additional therapy - 1 year 
P-value 
No Yes 
Male, N (%) 3084 749(43.5) 598(43.9) 0.86 
Age (years ) 3084 53.34±14.79 60.02±14.07 0.006 
BMI (kg/m2) 2854 27.3±5.96 28.74± 6.21 5.2E-12 
SBP (mm Hg) 908 141.52±18.32 146.64± 22.28 0.0004 
DBP (mm Hg) 908 89.02± 10.57 88.08±12.26 0.125 
Smoking (0) (%) 2635 911 (61.9) 683(58.7) .092 
Alcohol (1) (%) 2547 591 (41.6) 519(46) 0.03 
The quantitative variables are expressed as mean ± SD; and geometric mean (95% confidence 
interval for the mean); number (percentage) for categorical data. Significant at P-value<0.05. 
Smoking (0) is non-smoker; alcohol (1) is <=6 units per week. 
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Table 6-8: Binary logistic regression of association between variant predictors and 
additional therapy at one year study. 
Characteristic O.R 95% CI p value 
Age (years ) 1.051 1.037-1.065 4E-13 
BMI (kg/m2) 1.042 1.014-1.071 0.003 
SBP (mm Hg) 1.011 1.001-1.021 0.03 
DBP (mm Hg) 1.001 0.982-1.021 0.92 
Male, N (%) 1.192 0.85-1.673 0.31 
Smoking (0) 
(%) 
1.240 0.898-1.712 0.19 
Alcohol (1) 
(%) 
1.059 0.752-1.489 0.74 
Significant at P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <= 6 
units per week. 
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6.3.4 Patient characteristics for additional drug therapy at five 
years 
Older patients tended to require additional therapy (58.45± 13.49 year) 
more often than younger patients (51.93 ±13.03). The additional drug 
therapy group tended to have a higher BMI than the non-additional drug 
therapy group (28.74 ± 6.48 kg/m2 versus 26.12 ± 16.17 kg/m2). The 
additional drug therapy group had a mean SBP (142.36 ± 19.95 mm Hg) that 
was higher than the non-additional drug therapy group (135.74 ± 16.17 mm 
Hg). The proportion of patients took <=6 units of alcohol per week was 
higher in the additional drug therapy group than in the non-additional drug 
therapy group (47% versus 38%). All demographic results between additional 
and non-additional drug therapy groups are presented in table 6-9. 
In a multivariable model of the seven predictor variables, only four were 
statistically significant: age, BMI, SBP, and alcohol intake (as shown in 
Table). Increases in these factors were associated with increases in the 
probability that additional drug therapy would be required. Table 6-10. 
 
Table 6-9: Patient demographics of Additional antihypertensive therapy in persistent 
patients during 5 year study. 
Characteristic N 
Additional therapy -5 year 
P-value 
No Yes 
Male, N (%) 1978 224(40.3) 615(43.2) 0.21 
Age (years ) 1978 51.93±13.03 58.45±13.49 3E-22 
BMI (kg/m2) 1822 26.12±16.17 28.74±6.48 4.6E-19 
SBP (mm Hg) 579 135.74±16.17 142.36±19.95 0.0002 
DBP (mm Hg) 579 87.63±9.9 87.28±10.66 0.65 
Smoking (0) (%) 1784 327(61.7) 754(60.1) 0.80 
Alcohol (1) (%) 1734 198(38.3) 574(47.2) 0.003 
The quantitative variables are expressed as mean ± SD; and geometric mean (95% confidence 
interval for the mean); number (percentage) for categorical data. Significant at P-value<0.05. 
Smoking (0) is non-smoker; alcohol (1) is <=6 units per week. 
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Table 6-10: Binary logistic regression of association between variant predictors and 
additional therapy at five year study. 
Characteristic O.R 95% CI p value 
Age (years ) 1.043 1.025-1.062 3E-06 
BMI (kg/m2) 1.080 1.035-1.127 0.0004 
SBP (mm Hg) 1.017 1.001-1.033 0.04 
DBP (mm Hg) 0.994 0.967-1.021 0.67 
Male, N (%) 0.819 0.519-1.292 0.39 
Smoking (0) (%) 1.259 0.814-1.949 0.3 
Alcohol (1) (%) 0.615 0.388-0.977 0.04 
Significant at P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <= 6 
units per week. 
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6.4 Discussion 
44.2% of patients who were persistent after one year required additional 
antihypertensive drug therapy, while 71.8% of them required additional 
antihypertensive drug therapy at five years. The percentage of patients who 
required three different antihypertensive drug classes or more was 20.8% and 
46.5% in the one-year and five-year studies, respectively.  
BB and AECI are the antihypertensive drug classes most likely to continue as a 
monotherapy without requiring additional antihypertensive drug classes during the 
initial year and five years of follow-up.  
Clinical trials and observational studies showed that white individuals who 
received monotherapy antihypertensive drugs, particularly younger patients, 
responded to BB and ACEI better than CCB and diuretics, while black patients, 
especially older patients, responded better to CCB and diuretics than BB and ACEI 
(501–503). Also, higher plasma renin activity (PRA) was shown to be associated 
with weaker blood pressure responses to thiazide diuretics and greater responses 
to BB in monotherapy drugs(504). Black people 55 years or older tend to have 
lower renin concentrations than individuals who are younger than 55 or are in the 
white population(103). On this basis, NICE Guideline 18 recommends that patients 
under the age of 55 years begin with either an ACEI or BB whilst those over 55 
years or of African-Caribbean origin be commenced on a CCB or thiazide-like 
diuretic. Subsequent  publications of NICE guidelines have seen BB and thiazide 
removed as first-line  agents following publications concluding that BBs are less 
effective and associated with a higher risk of stroke and that thiazide is associated 
with increased risk of developing diabetes (200,505). The most recent NICE 
publication refined the guideline for first-line hypertension management by 
removing thiazide-like diuretics and BBs as first-line agents while retaining ACEI 
and CCB based on age and race considerations (43).  
In this study, BB and ACEI were the antihypertensive drug classes most likely to 
continue as drug monotherapy without requiring additional antihypertensive drug 
classes during the one- and five-year follow-up studies. The higher responses to 
BB and ACEI to additional drug therapy study may relate to the demographic 
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population in Scotland where most people are white and black/African people 
represent less than 0.5% of the Scottish population (506).   
Age, sex, BMI, and alcohol intake were the independent factors most likely to lead 
an increase in the probability of patients to take multiple antihypertensive drugs. 
Several studies showed these factors were associated with uncontrolled blood 
pressure (295,299,304,507). 
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Chapter 7 Antihypertensive Persistence and 
Adherence on Blood pressure response and 
Resistant Hypertension 
7.1 Introduction 
The hypertension control rate in Scotland is low and was estimated at 53% in 2011. 
Many factors that affect BP response have been discussed in the introduction 
chapter. Some of these factors relate to (1) patient characteristics such as age, 
sex, and ethnicity; (2) patient behaviour such as obesity, excessive alcohol intake, 
smoking, and adherence or (3) healthcare systems such as the patient-doctor 
relationship, and the number of visits.  
There are large inter-individual variations in patients' response to the 
antihypertensive drug classes (197). A number of studies have shown that younger 
white individuals responded better to BB and ACEI than CCB and diuretics and that 
older black patients responded better to CCB and diuretics than BB and 
ACEI(248,501–503). These studies have been considered by the NICE guidelines in 
its recommendations for initiation of antihypertensive drugs. NICE guidelines 
classified patients starting antihypertensive drug therapy into two classes based 
on age and race (ACEI or ARB for patients age <55 and CCB for patient ≥ 55)(43). 
Also, JNC guidelines have recommended starting antihypertensive drug classes 
based on ethnicity but did not recommend a specific class based on age (diuretic 
or CCB were recommended for black patients and diuretics, BBs, CCBs, ACEIs, and 
ARBs for non-black patients) (40).   
Resistant HTN is defined as the failure to achieve BP control despite the 
concomitant use of three antihypertensive drug classes. BP is controlled when 
SBP<140 mm Hg and DBP<90 mm Hg. This definition of resistant HTN is somewhat 
arbitrary with regard to the requirements that a diuretic be one of the three 
classes, the blood pressure goal for diabetes mellitus or renal dysfunction be 
<130/80 (SBP/DBP) mm Hg, or the number of medications required to achieve the 
BP control (508). 
Resistant HTN is a global issue. Several studies have found that 20-35% of patients 
could not achieve BP target even though they received more than three 
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antihypertensive drug classes (31,32,509). The prevalence of resistant HTN varied 
among hypertensive patients and ranged from 10-30% in different studies. 
However, this percentage might overestimate or underestimate resistance due to 
the inclusion criteria and the restrictions posed by the study treatment 
protocols(508,510,511). A higher risk of renal and CV events has been associated 
with resistant HTN (512). 
Resistant HTN can be true or false. It has been shown that false resistant HTN is 
frequently caused by poor adherence, white coat hypertension, or inappropriate 
BP measurement methods, such as using small cuffs on large arms. True resistant 
HTN may result from many factors. Factors contributing to true resistant HTN 
include the following: lifestyle factors (weight gain, obesity, excessive alcohol 
intake, dietary salt, etc.); drug-related causes (e.g., non-steroidal anti-
inflammatory agents (NSAIDs)); obstructive sleep apnoea; and secondary 
hypertension (renal artery stenosis, renal parenchymal disease, etc.)(508). 
This aim of this chapter is evaluate the prevalence of resistant HTN. The effect of 
the initiation of different antihypertensive classes on resistant HTN, and to study 
which independent variables that affect BP response. 
7.2 Methodology 
 Assessment of resistance hypertension: 
All primary HTN patients who initiated their antihypertensive drugs and attended 
the outpatient hypertension clinic at Western Infirmary hospital were included in 
this part of this study. Antihypertensive prescriptions for these patients were 
taken from ISD data and linked with GBPC data. The initiation of antihypertensive 
drugs was selected from ISD data as described in chapter two. This study only 
included patients who were persistent with their initial drugs for five years. The 
BP measurements were recorded during the five-year period. All additional 
therapies that were added to the initial drug therapy were calculated until the 
last day of the five-year follow-up study.  
For patients who took one or two different antihypertensive classes during the 
five-year follow-up study, the BP measurements were taken after the last 
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antihypertensive class that was added during the study. For patients who took 
three different antihypertensive classes or more during the study, the BP 
measurements were taken after third antihypertensive class.  
Patients were classified into three groups: controlled, uncontrolled, and resistant 
HTN. Controlled patients took one, two, or three different antihypertensive 
classes of drugs and achieved BP control (<140/90 mm Hg). Uncontrolled patients 
took one or two different antihypertensive classes of drugs and did not achieve BP 
control. Resistant patients took three or more different antihypertensive classes 
of drugs and did not achieve BP control. The BP readings taken more than a week 
after the antihypertensive drugs were prescribed were analysed.  
The rates of resistance and control were compared between the initial 
antihypertensive classes (Alpha, ACEI, ARB, BB, CCB, non-thiazide diuretics, 
spironolactone, and thiazide diuretics). The aim of this comparison was to 
investigate which antihypertensive classes led to BP control or resistance if the 
patients initiated and were persistent with one of them. Multivariable multinomial 
logistic regression was used to assess the factor of the initiation a specific 
antihypertensive class on the resistance HTN. P-values were considered significant 
if the value was less than 0.05. 
Lifestyle factors (BMI, smoking, and alcohol), patient characteristics (age and 
sex). In addition to these factors, eGFR and albumin were tested between these 
groups. These factors were found to affect some of the antihypertensive drug 
classes discussed in this chapter. A chi-square test for categorical and numerical 
data was used to compare these factors between resistant and controlled groups. 
P-values were considered significant if the value was less than 0.05. A t-test was 
used for quantitative variables.  
These factors were also tested as independent factors to evaluate which one of 
them could be associated with resistance. Multivariable binary logistic regression 
was used to assess these factors and their relation to resistance. P-values were 
considered significant if the value was less than 0.05. 
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 Assessment of blood pressure response: 
This part of the study used data collected from patients attending the GBPC who 
had hypertension. BP measurements, antihypertensive drugs data, patient’s 
characteristics, and clinical results for those patients were taken from patient 
case notes, GBPC data, and ISD data. ISD data has been used to detect the initial 
antihypertensive class and any new antihypertensive classes have been taken after 
the initiation. The terms initiation antihypertensive drugs were defined in 
chapters three. A new mono antihypertensive class was collected between two 
clinical visits and only one drug prescribed medication lie between these visits. A 
new antihypertensive classes from case notes were considered. A new 
antihypertensive drugs prescription in the case note, should be collected from 
pharmacy if the pharmacy prescription data available. The blood pressures were 
taken close to when the antihypertensive drug was collected, so the BP was taken 
within the six months before the date of collection antihypertensive therapy from 
pharmacy. The BP measures that were used to assess BP reduction were taken 
between one week to one year following the collection of the antihypertensive 
drug. Although, one year is a long time to determine BP readings, this period is 
based on observation data, and thus the date of measurement could not be 
controlled. This is the only available method with which to include a large number 
of patients. The duration between two clinical visits (date of prescribed drug and 
subsequent visit) for the new antihypertensive classes from the case note which 
were prescribed but they didn’t have the relevant information of prescription 
data, were two weeks and one year. The antihypertensive drug was not changed 
during the period between the two BP measures. SBP must be above 140 at the 
date of the prescribed drug or prior date of drug collection. 
The BP responses were compared for the different antihypertensive drug classes 
that were initially used as monotherapies. To compare the rate of blood pressures 
response between these antihypertensive classes, antihypertensive drugs were 
classified as responders and non-responders. A drug is defined as a responder when 
it leads to a reduction in a BP that is greater than the median fall. Drugs that 
cannot achieve this target are defined as non-responders.  Median reduction fall 
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has been taken for all antihypertensive drugs which were initiated. Factors effect 
on blood pressure response have been adjusted between the various 
antihypertensive classes. The rate of blood pressure response has been compared 
before and after adjustment between these drugs, using multinomial logistic 
regression. Chi-square and analysis of variance (ANOVA) were used test the 
demographic variation between antihypertensive classes.  
Secondly, the new antihypertensive class medications which were prescribed at 
the initiation or after the initiation were considered. Any a new single 
antihypertensive class was prescribed or collected between two clinical visits, was 
selected. The SBP was measured in these two clinical, before and after collections 
drugs. Age, gender, smoking, alcohol, BMI, eGFR, and albumin were considered 
and tested with the blood response for each antihypertensive class. A multiple 
linear regression is used predict the association between these factors and blood 
pressure reduction.  
7.3 Results 
7.3.1 The prevalence of resistant hypertension 
A total of 864 patients who were persistent with their initial antihypertensive drug 
for five years and had their BP data available. Of these patients, 20 patients were 
excluded because the BP reading was taken less than a week after the 
antihypertensive prescription was collected. In addition, 29 patients received 
more than three antihypertensive classes and were excluded they could not be 
classified as controlled, uncontrolled, or resistant HTN by the definitions used for 
this study. The final sample included 815 patients who were persistent with their 
initial antihypertensive drug and either had controlled on blood pressure one to 
three antihypertensive classes or had uncontrolled blood pressure on more than 
one antihypertensive classes. 
The controlled HTN group included 318(39%) patients (took ≤3 antihypertensive 
classes and BP controlled), uncontrolled HTN group included 234 (29%) patients 
(took < 3 antihypertensive classes and BP uncontrolled) and resistant HTN group 
included 263(32%) (took ≥ 3 antihypertensive classes and BP uncontrolled). Figure 
7-1. 
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509 (62%) patients used diuretic drugs alone or with other antihypertensive drug 
classes. Most resistant HTN patients (82%) received diuretics along with other 
antihypertensive classes. On the other hand, 52% of controlled HTN patients 
received diuretics drugs either as a first-line antihypertensive drug or as additional 
therapy.  
 
 
Figure 7-1: Percentage of hypertensive patients who received antihypertensive drug during 
five years dividing based on blood pressure control (<140/90 mm Hg). 
Controlled: patients who received ≤ 3 antihypertensive classes and achieved blood 
pressure control. Uncontrolled: patients who received <3 antihypertensive classes and 
didn’t achieve blood pressure control. Resistance: patients who received ≥ 3 
antihypertensive classes and didn’t achieve blood pressure control. 
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7.3.2 Effect of the choice of initial antihypertensive therapy on 
resistance 
The percentage of patients who were persistent and who had resistant HTN was 
alpha-blockers (80%), non-thiazide diuretic (50%), CCB (36.3%), ARB (32.8 %), ACEI 
(29.5%), Thiazides (28.7%), and spironolactone (15.4%). The percentages of 
patients who resistance HTN, controlled HTN, and uncontrolled HTN have been 
represented in table 7-1 based on the initiation of antihypertensive class. 
The impact of the initiation of different antihypertensive classes on resistant 
hypertension was tested between two clearly defined groups, controlled and 
resistant HTN groups. Patients with uncontrolled hypertension were excluded from 
this comparison because it was unclear what could happen for their blood pressure 
when they receive the third antihypertensive class. 
Patients who initiate with alpha-clocker and non-thiazide diuretic more likely to 
be resistance HTN higher than those who initiate with ACEI. Table 7-2 showed the 
impact of the first line antihypertensive classes on resistance HTN.  
Table 7-1: The percentage of controlled and resistant hypertensive patients 
based on first-line antihypertensive class. 
Class N Resistant Controlled 
Uncontrolled 
hypertension 
ALPHA 15 12(80) 3(20) 0 
ACEI 132 52(29.5) 80(45.5) 44(25) 
ARB 88 42(32.8) 46(35.9) 40(31.3) 
BB 126 54(29.7) 72(39.6) 56(30.8) 
CCB 87 45(36.3) 42(33.9) 37(29.8) 
NON_THIA 20 13(50) 7(26.9) 6(23.1) 
SPIRO 9 2(15.4) 7(53.8) 4(30.8) 
THIA 104 43(28.7) 61(40.7) 46(30.7) 
Total 815 263(32.3) 318(39) 234(28.7) 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, 
non-thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic. Results are 
summarised as number (percentage). 
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Table 7-2: Binary logistic regression of the association between the first-line 
antihypertensive drug and resistance HTN. 
Reference 
Other antihypertensive 
classes 
OR 95% CI p value 
ACEI 
ALPHA 0.163 0.044-0.604 0.007 
ARB 0.712 0.413-1.228 0.222 
BB 0.867 0.528-1.424 0.572 
CCB 0.607 0.351-1.048 0.073 
NON_THIA 0.35 0.131-0.935 0.036 
SPIRO 2.275 0.455-11.379 0.317 
THIA 0.922 0.546-1.557 0.761 
THIA 
ALPHA 0.176 0.047-0.662 0.01 
ACEI 1.084 0.642-1.831 0.761 
ARB 0.772 0.436-1.368 0.375 
BB 0.94 0.555-1.591 0.817 
CCB 0.658 0.371-1.168 0.153 
NON_THIA 0.38 0.14-1.03 0.057 
SPIRO 2.467 0.489-12.457 0.274 
Abbreviations: ALPHA, alpha-blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; NON_THIA, 
non-thiazide diuretic; SPIRO, potassium sparing diuretics; THIA, thiazide diuretic. Significant at 
P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <=units per week. 
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7.3.3 Patient characteristics and predictors of resistant and 
controlled hypertension 
Table 7-3 showed demographic and clinical results for resistant and controlled 
HTN groups. Compared to the controlled HTN group, patients with resistant HTN 
tended to be older (60.1 ± 12.4 years versus 54.1 ± 13.8 years) with higher BMI 
(30.79 ± 6.9 k/m2 versus 28.1 ± 5.2 k/m2). Serum albumin in the controlled group 
(43.9 ± 3.3 g/dL) was higher than in the resistant group (43.2 ± 3.7 g/dL).  
Multivariable binary logistic regression was performed to investigate the effects 
of sex, age, BMI, eGFR, albumin, smoking status, alcohol intake, and adherence 
on the likelihood of resistant. Of the eight predictor variables only two were 
statistically significant: age, and BMI (as shown in Table 7-4). Increased age was 
significantly associated with resistant HTN [0.954(0.94-0.97) p=6.6E-08]. 
Increased BMI [0.921(0.89-0.96) per kg/m2] is significant risk factors of resistance 
HTN. 
 
Table 7-3: Demographic and characteristics of controlled and resistance groups 
Characteristic N resistance controlled  P-value 
Male, N (%) 581 123(46.8) 149(46.9) 1 
Age (years ) 581 60.1 ± 12.4 54.1 ± 13.8 6.6E-08 
BMI (kg/m2) 525 30.79 ± 6.9 28.1 ± 5.2 4.3E-07 
eGFR 476 76.7 ± 69.7 71.8 ± 14.8 0.908 
Albumin 475 43.2 ± 3.7 43.9 ± 3.3 0.047 
Smoking (0) (%) 472 113(59.8) 165(58.3) 0.775 
Alcohol (1) (%) 450 96(53.3) 132(48.9) 0.387 
The quantitative variables are expressed as mean ± SD; and geometric mean (95% confidence 
interval for the mean); number (percentage) for categorical data. Significant at P-value<0.05. 
Smoking (0) is non-smoker; alcohol (1) is <=6 units per week. 
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Table 7-4: Binary logistic regression of association of different predictors with resistance 
HTN 
Predictors (unit) O.R  95% CI P-value 
Age (years ) 0.954  0.94-0.97 3E-05 
Male, N (%) 1.339  0.84-2.13 0.219 
Alcohol (1) (%) 1.203  0.75-1.93 0.444 
Smoking (0) (%) 0.978  0.63-1.52 0.921 
BMI (k/m2) 0.921  0.89-0.96 3E-05 
Albumin (mmol/L) 1.037  0.97-1.11 0.262 
eGFR_0m (mL/min/1.73 m2) 0.99  0.98-1 0.127 
Significant at P-value<0.05; O.R: odds ratio; Smoking (0) is non-smoker; alcohol (1) is <= 6 units 
per week. 
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7.3.4 A compassion blood pressure response between the 
antihypertensive classes 
7.3.4.1 Study population 
The total number of new antihypertensive classes was 9324. A total of 6714 
antihypertensive classes were excluded for the following reasons. First, other 
antihypertensive classes were prescribed with new antihypertensive classes 
before the blood pressure measurement (3091 new drugs were excluded). Second, 
212 new antihypertensive classes were excluded because they were not collected 
from the pharmacy. Third, the new antihypertensive classes were excluded 
because the SBP was less than 140 mm Hg on the date of the clinical visit when 
the drug was prescribed (2265 drugs). Fourth, new drugs were excluded (1080 new 
antihypertensive drugs) when SBP was not measured in the six months before the 
date of antihypertensive class collection, for a period of more than one year after 
the date of antihypertensive class collection, or within one week prior to the date 
of collection. Finally, 66 new drugs were excluded because the duration between 
the two clinical visits was less than two weeks or was more than one year for 
antihypertensive classes that were prescribed based on case notes but without ISD 
data information. 
After these exclusions, 2610 new antihypertensive class were included. Of these 
antihypertensive classes, 494 were defined as the first-line prescriptions. The 
antihypertensive classes that were included were classified as alpha blockers, 
ACEI, ARB, BB, CCB, non-thiazide diuretics, spironolactone, and thiazide diuretics. 
There were 217, 376, 405, 267, 566, 139, 237, and 403 classes, respectively. The 
inclusion and exclusion profiles are illustrated in figure 7-2. 
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Figure 7-2: Flowchart of inclusion and exclusion criteria for the new antihypertensive 
classes. 
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7.3.4.2 Population Characteristics for Patients with initial use of 
Monotherapy of antihypertensive class  
The distribution of antihypertensive drug classes in the 494 patients with first 
prescription were 142, 96, 68, 87, and 77 for ACEI, ARB, BB, CCB, and thiazide 
diuretic, respectively. 24 patients who took alpha blocker, non-thiazide diuretic, 
and spironolactone were excluded from BP response comparison because of small 
sample sizes.  
Only age was significantly different between antihypertensive classes. Patients 
who started their medications with CCBs, or thiazide diuretic were older than 
those who started their drugs with ACE inhibitors, ARBs or beta-blockers.  
 
  
Table 7-5: Demographic of hypertensive patients who started with first-line 
antihypertensive drugs.  
  ACEI ARB BB CCB THIA 
N 142 96 68 87 77 
Male, N (%) 74(58.3) 49(52.7) 27(41.5) 31(43.7) 32(42.7) 
Alcohol (1) (%) 29(36.3) 36(52.2) 23(43.4) 25(45.5) 32(53.3) 
Smoking (0) (%) 58(67.4) 45(64.3) 37(63.8) 34(60.7) 44(65.7) 
eGFR 
(mL/min/1.73 m2) 
77.5±15.6 76.9±23.5 74.2±15.9 76.6±15.8 73.5±14.05 
Albumin (mmol/L) 
44.7±2.9 43.66±2.9 43.35± 3.5 43.98±3.3 43.93± 3.2 
BMI (kg/m2) 28.4±4.8 27.8±4.9 27.5±5.6 27.63±5.2 27.9±4.501 
Age (years )* 48.56±13.9 51.7±12.1 52.1±16 55.06±14.2 56.7±14 
SBP (mm Hg) 
161.8±17.1 164.2±16.2 163.2±19.9 163.4± 15.8 160.1±14.2 
The quantitative variables are expressed as mean ± SD; and geometric mean (95% confidence 
interval for the mean); number (percentage) for categorical data. Significant at P-value<0.05. 
Smoking (0) is non-smoker; alcohol (1) is <=6 units per week.* Significant factors. 
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7.3.4.3 Comparison BP responder between first-line antihypertensive class 
The responder and non-responder rates were determined based on decrease in BP 
before and after adjustment for covariates. The frequency of non-responders and 
responders were 48.7% (n = 228) and 51.3% (n=240) respectively unadjusted and 
after BP adjustment for covariates, they were 43.7% (n = 149) and 56.3% (n=192) 
respectively.  
Table 7-6 presents the differences in classifying responder status if covariates 
were not included in the assessment of BP response. Thus, if raw BP drop was 
considered CCB would be considered the drug with the best response rate. 
However, after adjusting the BP response for age, gender, smoking, alcohol, BMI, 
eGFR, and albumin the top drugs with the best response rates were ARB (67.6%), 
ACEI (64%), BB (53.4%), while CCB (42.9%) had the lowest rate.  The difference 
between drug classes among responders were not statistically significant if 
response was based on univariate analysis (table 7-7), whilst in the adjusted 
model, the rates of responders for ACEI, ARB were significantly higher than the 
rates for CCB or thiazides (table 7-8). 
 
Table 7-6: Percentage of responder and non-responder before and after blood pressure 
adjusted. 
Antihypertensive 
classes 
Before adjustment After adjustment 
Non-responder 
N(%) 
Responder 
N(%) 
Non-responder 
N(%) 
Responder 
N(%) 
Total number 228(48.7) 240(51.3) 149(43.7) 192(56.3) 
ACEI  62(44.3) 78(55.7) 31(36) 55(64) 
ARB  49(51) 47(49) 24(32.4) 50(67.6) 
BB  38(55.9) 30(44.1) 27(46.6) 31(53.4) 
CCB  37(42.5) 50(57.5) 32(57.1) 24(42.9) 
THIA  42(54.5) 35(45.5) 35(52.2) 32(47.8) 
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor 
blocker; BB, beta-blocker; CCB, calcium channel blocker; THIA, thiazide diuretic. Results are 
summarised as number (percentage). Median fall were 13, and 11.5 for adjusted and non-
adjusted population.  Responder: when a reduction in a BP>median. Significant at P-value<0.05.  
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Table 7-7: Multinomial logistic regression of association between the initiation of 
antihypertensive class and BP response for unadjusted population. 
Reference 
Other antihypertensive drugs 
P value Antihypertensive 
classes 
O.R 95%CI 
ACEI 
ARB 1.312 0.779-2.208 0.307 
BB 1.594 0.889-2.856 0.117 
CCB 0.931 0.542-1.598 0.795 
THIA 1.51 0.863-2.64 0.149 
 
ARB 
BB 1.215 0.651-2.267 0.541 
CCB 0.71 0.396-1.273 0.25 
THIA 1.151 0.631-2.1 0.647 
 
BB 
THIA 0.584 0.308-1.108 0.308 
CCB 0.947 0.492-1.826 0.492 
 
CCB THIA 1.622 0.874-3.008 0.125 
Significant at P-value<0.05. O.R: odds ratio 
 
Table 7-8: Multinomial logistic regression of association between the initiation of 
antihypertensive class and BP response for adjusted population. 
Reference 
Other antihypertensive drugs 
P value Antihypertensive 
classes 
O.R 95%CI 
ACEI 
ARB 0.852 0.442-1.642 0.631 
BB 1.545 0.784-3.045 0.209 
CCB 2.366 1.188-4.709 0.014 
THIA 1.941 1.012-3.72 0.046 
 
ARB 
BB 1.815 0.893-3.688 0.1 
CCB 2.778 1.353-5.701 0.005 
THIA 2.279 1.151-4.512 0.018 
 
BB 
CCB 1.531 0.731-3.206 0.259 
THIA 1.256 0.621-2.54 0.526 
 
CCB THIA 0.82 0.402-1.675 0.587 
Significant at P-value<0.05. O.R: odds ratio 
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7.3.4.4 The association between predictors and different antihypertensive 
classes  
A multivariable regression analyses was conducted to determine the best 
predictors of response in each drug class separately and the results of these are 
summarised below.  The relations between some factors were positive between 
predictors and blood pressure response, with an increase of predictors leading to 
an increase in blood pressure response. On the other hand, some of these relations 
were negative, with an increase in the factor leading to a decrease in blood 
pressure response. The relations between different predictors and BP response for 
each class are illustrated in table 7-9.    
 Alpha-blockers 
217 patients who took alpha- blockers. Age was a statistically significant predictor 
of a SBP response to alpha-blockers. Each 1-year increase in age equated to an 
increase in the BP response of 0.31 mm Hg for patients who took alpha-blockers.  
 ACEI 
ACEI antihypertensive class was taken by 376 patients. Age, BMI, and eGFR were 
statistically significant predictors of a BP response to ACEI. Each 1-year increase 
in age equated to a decrease in BP response of 0.31 mm Hg for patients who took 
ACEI. Similarly, for BMI, an increase of 1 kg/m2 in BMI equated to a 0.66 mm Hg 
decrease in BP response for patients who took ACEI. Also, for eGFR, an increase 
of 1 mL/min/1.73 m2 in eGFR equated to a 0. 0.25 mm Hg decrease in BP response 
for patients who took ACEI. 
 ARBs 
405 of ARB antihypertensive class were received by hypertensive patients. Age 
was a statistically significant predictor of a BP response to ARBs. Each 1-year 
increase in age resulted in an increase in the BP response of 0.2 mm Hg for patients 
who took ARBs. 
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 Non-thiazide diuretics 
139 patients were included. For BMI, an increase of 1 kg/m2 in BMI equated to a 
1.2 mm Hg decrease in the BP response for patients who took non-thiazide 
diuretics. 
 Potassium sparing diuretics  
237 patient using spironolactone were included. Each 1-unit decrease in alcohol 
intake equated to a 9.498 mm Hg decrease in the BP response for patients who 
took spironolactone. 
 Thiazide 
403 Patients taking thiazide were included. For BMI, an increase of 1 kg/m2 in BMI 
equated to a 0.61 mm Hg decrease in the BP response for patients who took 
thiazide. Each 1-unit increase in albumin equated to a 0.770 mm Hg decrease in 
the BP response for patients who took thiazide. For eGFR, an increase of 1 
mL/min/1.73 m2 in eGFR equated to a 0.15 mm Hg increase in the BP response for 
patients who took thiazide. 
Patients who took CCB, and BB were 566, and 267, respectively.  No association 
was found between these predictors and BB and CCB. All these results were 
represented in table 7-9.
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Table 7-9: Multiple linear regression of association between predictors and BP pressure response for each antihypertensive class. 
 ALPHA ACEI ARB BB CCB NON-THIA SPIRO THIA 
Characteristics         
N 217 376 405 267 566 139 237 403 
Male N (%) -1.93(3.35) -1.53(2.64) -1.80(2.28) 2.38(3.59) 2.45(2.12) -8.49(5.49) -6.94(4.30) 4.45(2.26) 
Age (years ) 0.35(0.15)* -0.31(0.1)† -0.20(0.09)* 0.01(0.12) -0.04(0.08) -0.04(0.22) -0.24(0.17) -0.09(0.08) 
Alcohol (1) (%) 4.88(3.29) 1.79(2.69) -2.82(2.30) -4.275(3.72) 2.15(2.13) -4.45(5.74) -9.49(4.22)* 3.77(2.31) 
Smoking (0) (%) 0.52(3.02) 1.14(2.53) -2.51(2.14) -2.51(3.28) -0.68(1.95) 0.61(4.87) -1.74(3.86) -2.44(2.17) 
BMI (kg/m2) -0.26(0.18) -0.66(0.25)* -0.12(0.15) 0.13(0.31) 0.15(0.16) -1.20(0.51)* -0.004(0.35) -0.61(0.18)† 
Albumin (mmol/L) -0.48(0.46) -0.27(0.37) -0.48(0.31) 0.02(0.47) -0.12(0.25) 0.74(0.65) -0.90(0.55) -0.79(0.32)* 
eGFR 
(mL/min/1.73 m2) 
0.11(0.07) -0.25(0.08)† -0.07(0.05) -0.11(0.11) 0.05(0.06) 0.10(0.13) -0.12(0.13) 0.15(0.07)* 
B(stander error). * P < 0.05. † P<0.005. Significant at level <0.05. Regression coefficients greater than 0 indicate increase BP with increase in value of 
predictor variable. 
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7.4 Discussion 
The goal of hypertension management is to reduce long-term cardiovascular risk 
and this is achieved through lifestyle modification and lifelong prescription of 
antihypertensive drugs. Success of this approach requires not only physician 
factors but also a patient motivated to take the prescribed medications and 
maintain a healthy lifestyle. Resistant hypertension, commonly defined as the 
failure to reach blood pressure goals in patients adhering to adequate or maximal 
doses of an appropriate 3-drug regimen that includes a diuretic. This definition of 
resistant hypertension implies that patients fully adhere to their therapy and 
hence the reason why the true prevalence resistant hypertension in the population 
is variable in different studies ranging from 5-30% (41). None of the large surveys 
of resistant hypertension considered drug adherence or persistence as a potential 
cause of resistant hypertension. However, recent studies where drug assays have 
been used to measure drug adherence showed about 50% of patients of the 
patients labelled as having resistant hypertension have been reported to be non-
adherent to prescribed medication (513). 
In my study of drug response and resistant hypertension, I proposed to examine 
the prevalence of resistant hypertension in patients attending the Glasgow BP 
Clinic who were persistent to antihypertensive therapy. The reason for this 
analysis is to determine the rates of controlled hypertension and resistant 
hypertension in patients attending a secondary care clinic using a combination of 
case-note review and pharmacy prescription refill data. Thus this study is a very 
detailed analysis of response in hypertensive patients that incorporates both data 
on physician prescription and patient behaviour in terms of prescription pick-up. 
The striking finding from my analysis is that even in the tertiary care clinic and 
despite evidence of persistence to therapy, only 39% of patients had controlled 
hypertension and 32% of patients were classified as resistant hypertension. More 
importantly, almost 82% of patients with resistant hypertension were 
appropriately prescribed diuretics, and 52% of controlled hypertensive patients 
were on diuretic therapy. Thus this cohort of patients with resistant hypertensions 
were rationally prescribed appropriate drugs of proven efficacy. One limitation of 
my study is that I do not have objective evidence of the bioavailability of the 
prescribed drugs through surrogate measures – for instance, urine drug assays 
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(514,515). However, all the patients included in my study did pick up their 
prescriptions and were persistent, so this data reflects the rates of control and 
resistance when long term drug therapy is considered. Most of the studies of 
resistant hypertension that incorporated adherence measures used urine drug 
assays at one time point. Urine drug assays while useful do have some limitations 
- while they unequivocally document the ingestion of a drug, they cannot provide 
information on when the drugs were taken or omitted; drug measurement is 
affected by the white-coat adherence phenomenon whereby patients tend to 
improve their adherence before and after clinic visits. Another limitation of my 
study is that using refill prescription data alone may result in an overestimation 
of adherence, for example patients may not consume the drugs they picked up 
from pharmacy. Despite these limitations, the estimate of resistant hypertension 
in my cohort of patients who are persistent on therapy is within the range reported 
by other studies. It is more important to consider the low rates of controlled 
hypertension. It is likely that this may reflect low adherence to therapy or true 
non-response to drugs.  
To determine responder status in this observational study is challenging as there 
is no way to control for confounding. Nevertheless, it would be useful to assess if 
all drug classes have similar response. In randomised controlled trials of 
antihypertensive therapy, the usual metric used to assess drug response is a drop 
in systolic blood pressure of 10 mmHg or more. Whilst this is a simple and suitable 
measure in RCTs where treatment is controlled and groups are matched for known 
and unknown confounders, this cannot be applied in observational studies. So in 
my study, a metric of BP response that takes in account the overall population 
response to therapy is required. Thus, I decided to define overall response by first 
obtaining the overall median decline in BP in the groups and then define responder 
as those whose BP response was greater than the median drop in BP. Furthermore, 
to address covariates that may affect BP response, I calculated the adjusted BP 
response after correcting for covariates and defined responder status using the 
median of the adjusted response. Using this method, ARB, and ACEI showed 
significantly higher responder rates than thiazides or CCB.   
The ASCOT study included 19,257 hypertensive patients were randomized to 
receive one of two antihypertensive drugs: BBs and thiazide diuretics, or CCBs and 
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ACEIs to achieve BP targets <140/90 mmHg for patients without diabetes and 
<130/80 mmHg for those with diabetes at baseline. Patients who randomized to 
CCBs and ACEIs treatment were the most protective against the risk of developing 
resistant hypertension. In my study, patients who initiated with ACEI achieved BP 
control in greater numbers and had lower rates of resistant hypertension than 
patients who were initiated with other antihypertensive classes. Patients who 
were initiated with alpha-blocker and non-thiazide diuretics were more likely to 
have resistant hypertension.  
Age and BMI were the factors with the greatest influence on resistant HTN. As 
shown in previous studies(302,303,510), hypertensive patients who were older and 
had higher BMIs were more likely to be resistant. 
Hypertensive patients who started their treatment with ACE, ARB, or BB were 
better responders and this is supported by data presented in chapter six, which 
showed that patients who started their treatment with BB, ACEI, and ARB were 
less likely to require additional antihypertensive drug compared with those on 
CCB, or thiazides.  
Age was the factor with the greatest effect on BP response for different 
antihypertensive drug classes. The BP response with ACEI and ARB increased in 
younger patients and decreased in older patients. In contrast, the BP response 
with alpha-blockers increased in older patients and decreased in younger patients.  
BMI was the second factor that frequently affected the BP response. Increased BMI 
lead to decreased BP response in patients taking ACEI, thiazide, and non-thiazide 
districts. Several studies have shown that increased BMI is associated poor BP 
control for patients who received antihypertensive drugs (296,306,307) and there 
is a close relationship between BMI and sympathetic activity and salt sensitivity 
(516–519).  
The effect of eGFR on SBP response was different in ACEI and thiazide diuretics. 
The decease eGFR led to decreased SBP response in patients taking thiazide, while 
an increase in eGFR led to decreased BP response in patients taking ACEI. It has 
been shown in a previous study that the effectiveness of thiazide was decreased 
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when eGFR was decreased to less than 40 mL/min/1.73 m2 (520). 
Antihypertensive. Some studies have found that the relationship between eGFR 
and ACEI can lead to a temporary decrease of eGFR, particularly during the first 
two weeks after initiation with ACEI(521). 
Finally, the increase of albumin led to decreased BP response in patients taking 
thiazide diuretics (522). Free thiazide diuretic concentration can be reduced 
because a high affinity of binding between thiazide diuretic and albumin which 
has been cited in several studies (523,524). 
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Chapter 8 General discussion 
8.1 General overview 
A recent health survey showed that the prevalence of hypertension is Scotland is 
32.5%. Despite 15.5% of hypertensive patients receiving antihypertensive drugs, 
47% of them failed to achieve BP control (288). BP control varies in different 
regional groups. For instance, the HTN control rate is higher in England than in 
Scotland, with rates of 60% and 53%, respectively(288,292).  Adherence and 
persistence are considered the most common reasons for uncontrolled HTN and 
have led to increases in HTN treatment costs. While it is important to study 
persistence and adherence and the factors that lead to their increase, the 
prevalence of adherence and persistence in Scotland remains unknown. Previous 
studies that have estimated the prevalence of adherence and persistent were 
performed mainly in England or overall UK and more importantly in specific 
subgroups of patients requiring renal denervation. Data from Scotland is lacking 
and this is required because though the same healthcare system operates across 
the UK, there are crucial differences – for instance, there are no prescription 
charges in Scotland in contrast to England and this will have a major impact on 
adherence and persistence for chronic disease management. 
Pharmacy refill data is becoming more widely used to estimate adherence and 
persistence because it provides large population information for adherence and 
has been validated by comparing it with the gold standard method, electronic 
monitoring (MEMS)(419). Only two studies by Jones et al (1995) and Hasford et al 
(2002) have estimated persistence based on prescription databases in the UK. 
Jones et al (1995) found that 40–50% of a new prescribed medication showed 
persistence (443).  However, a high proportion of practices in Scotland were not 
included in this study. Data from hypertensive patients from France, Germany and 
the UK in the Hasford et al study (446) showed persistence to be 46.8% at 1-year.  
I demonstrated for the first time the prevalence of both persistence and 
adherence in Scotland based on a large hypertension clinic database of 
prescriptions and patients’ characteristics.  The rate of persistence, adherence, 
patients needing additional therapy and resistance was estimated from 
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hypertensive patients who started their first-line antihypertensive drug and 
showed that National Institute for Health and Clinical Excellence (NICE) guidelines 
were adhered to for HTN management. Patients who were first prescribed ACEI, 
ARB or BB were younger than those prescribed CCB or diuretics (thiazide and non-
thiazide). Sex was also different between the antihypertensive classes, and 
patients who started with thiazide diuretics or BB were less likely to be men 
compared with those prescribed ARB or ACE. ACEI and BB were the most newly 
prescribed antihypertensive classes. However, the patterns of antihypertensive 
drug usage changed during the course of the study. Over the years, while new 
prescriptions of BB and thiazide diuretics declined, prescription of ACEI and ARB 
increased  
This study revealed a high rate of persistence with patients who started their new 
antihypertensive classes. Persistence rates were 72.9% and 62.8% for all 
antihypertensive classes at 1 and 5 years, respectively. The adherence rate for 
those patients who persisted with their initial antihypertensive drug was low with 
only 29.9% and 23.4% of patients adhering to their drugs during the 1- and 5-year 
studies, respectively. The higher persistence and adherence rates were found with 
patients who started their treatments with renin-angiotensin system (RAS) (ACEI 
and ARB) antihypertensive classes. Diuretics (thiazide and non-thiazide) had the 
lowest persistence and adherence rates among the drugs for the 1- and 5-year 
follow-up studies. Age was an important factor affecting persistence and 
adherence. Older patients were more likely to persist and adhere to their 
antihypertensive treatment than younger patients. Baseline BP, BMI and alcohol 
use also had an effect on adherence and persistence. Days between visits was an 
important factor that led to patients either not collecting their prescriptions. 
Patients who had later follow-up appointments for the subsequent visit were more 
likely to not collect their prescriptions. 
The additional therapy rate for patients who persisted with their initial 
antihypertensive drug was high, particularly 5 years after starting their treatment. 
Of the patients who were persistent with the initial antihypertensive treatments, 
44.2% and 71.8% required additional antihypertensive drug therapy in the 1- and 
5-year studies, respectively.  There were 20.8% of patients in 1 year and 46.5% in 
5 years that required two or more antihypertensive drugs be added to the first 
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antihypertensive drug.  Patients on ACEI, ARB and BB were more likely to continue 
with their drug without the need for additional therapy and were less likely to 
need two or more additional therapies in both 1 and 5 years. In contrast, alpha 
blockers, non-thiazide diuretics and CCB were the antihypertensive classes 
requiring the addition of two or more antihypertensive drugs with the first drug. 
When I assessed the BP responses in patients who persisted with the first 
antihypertensive drug for 5 years, 61% did not achieve BP control and 32% had 
resistant HTN. Patients who started with alpha-blockers, non-thiazide diuretics 
and CCB were more likely to have resistant HTN. Patients on ACEI, thiazide 
diuretics and BB tended be less likely to have resistant HTN. The BP responses for 
the initial antihypertensive drugs were better in patients who started with ACEI, 
ARB and BB. These patients had higher rates of BP responses than other groups 
after adjusting for risk factors. However, only ACEI and ARB were significant. 
Increasing age, and BMI levels were the most important factors associated with 
increases in additional therapy rates and persistent HTN. Other factors, such as 
an increase in alcohol use, were associated with an increase in additional therapy 
rates. 
Finally, factors that were shown to have an effect on BP responses were tested 
with the reduction of SBP. BMI increases were associated with attenuated 
decreases in BP with ACEI, non-thiazide diuretics and thiazide diuretics. The 
effect of age on BP reductions varied between antihypertensive drugs.  Younger 
patients were more likely to respond to ACEI and ARB, while older patients were 
more likely to respond to alpha blocker. An increase in eGFR was associated with 
a decrease in SBP reduction with ACEI and a decrease in eGFR was related with a 
decrease of SBP reduction in thiazide diuretics.  Alcohol use was associated with 
the decreased BP reductions of spironolactone. Patients who had high albumin 
levels and were taking thiazide diuretics were more likely to have low BP 
reductions. 
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8.2 Comparing methods 
It is important to identify the initiation of antihypertensive drugs in persistence 
and adherence studies for the following reasons: to compare relevant variables, 
to determine the duration of drug therapy that leads to the increased risk of 
discontinuation (456), and to identify the initial drug and any drugs that were 
switched with or added to the initial drug. For these reasons, initial 
antihypertensive drugs were identified in most studies so as to evaluate the 
persistence and adherence using an antihypertensive drug database. New 
antihypertensive drug users have been identified in several studies by that if 
patients did not have any prescription records during a certain period prior to the 
inception date (434,435,439,447,457). Although, Suarez et al suggested that going 
1 year without antihypertensive medication is an accurate duration to identify a 
new user of an antihypertensive class (525), several studies chose durations of less 
than 1 year to determine new users.  Thirty-two new users were determined from 
the UK General Practice Research Database (UKGPRD) and were compared using 
their questionnaire data in the Suarez et al study. New users in this study were 
defined as those patients who did not have any antihypertensive prescription for 
the same class during a 4-month period prior to 1 June 1994. Patients who 
initiated, added or switched their antihypertensive drug were considered as new 
users (525). In spite of finding a low agreement between the UKGPRD and 
questionnaire in detecting new users during the 4 months before the inspection 
date, there are several limitations to this study. Some of these limitations include: 
the study had a small number of patients and failed to distinguish between 
patients who initiated and those who were ongoing with their therapy; a 
questionnaire is not a standard method to compare the results with the 
prescription data method; some patients appeared confused about the recent 
initiation of an antihypertensive drug; and the data from antihypertensive 
prescriptions were taken from a database of general practices in the UK, but not 
from pharmacy data, which reflects the reality of drug collections from the 
pharmacy. 
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The duration without medication of less than 1 year has been identified in a 
several studies. Other studies have used 3 months (e.g. Benson et al study ) (442), 
4 months (e.g. Jones et al study) (443), 6 months (e.g. Dezii et al; and Patel et al) 
(434,440) and 10 months was used in studies by Caro, Salas et al and Caro, 
Speckman et al(438,439). However, in a number of studies, the new users of an 
antihypertensive class were not determined (422,430,432). 
In this study, new users of antihypertensive drugs were determined if no receipt 
of any antihypertensive class of drugs was identified for at least a continuous 4-
month period prior to the inspection date, which was 30 April 2004. Choosing a 4-
month period was based on the fact that most patients refill their prescription 
monthly, and the maximum refill is for 3 months in some cases.  Patients who did 
not have a prescription for a period of 4 months or more, they just initiated their 
treatment.  Other possibilities included those patients who did not have a 
prescription for a 4-month duration and those that stopped taking their 
medication. In this case, patients who initiated their treatment after 4 months or 
more of discontinuation, restarted their treatment. Age, which has been seen as 
an important factor in choosing a drug, and is also an important factor affecting 
adherence, persistence and BP control, was determined at the date of the 
prescription initiation. The baseline SBP and DBP were recorded 6 months prior to 
the initiation of treatment.    
Compliance or persistence have been used interchangeably in the literature to 
estimate adherence (526). Persistence is the term used to identify if the patient 
is still taking medication after a period of time, and has been used to estimate 
adherence in a number of studies (439,440,442,443). The MPR has typically been 
used to estimate compliance. Patients were considered compliant if they took at 
least 80% of their medication during the study period (MPR ≥ 80). MPR or 
compliance has been used to estimate adherence in several studies (421,430,431). 
Several studies have defined both terminologies in their reports (e.g. Wogen et 
al; Giovanni et al; Boris et al; Bimal et al) (427–429,434). Wogen et al used MPR 
to define compliance and a continuation of therapy without discontinuation for 
persistence (428). Giovanni et al used persistence and MPR to express a patient’s 
compliance and persistence at continuing treatment during their study (429). 
Patients needed to be persistent (i.e. continue their therapy) and compliant (MPR 
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≥ 80) to be considered adherent in the Boris et al and Bimal studies (427,434). A 
gap in treatment is defined as a discontinuation. The duration of the period 
without medication varies between these studies. Discontinuation was a 60 day 
gap in studies by Bimal et al and Jenifer et al, and 90 days in the Giovanni et al 
study. Boris et al used a different definition of discontinuation, whereby a patient 
discontinued their treatment if they failed to collect at least two prescriptions 
during the year. The duration of the period without medication varies in different 
studies and ranges from 30 to 90 days, but in some studies it was 180 days (441).  
In this study, I defined persistence as patients continuing their therapy during the 
study period. I used both MPR and persistence to estimate adherence. Thus, the 
MPR was calculated for patients who persisted with their treatment, and when 
MPR ≥ 80 for these patients was considered to be adherence to their treatment. 
In most studies, the MPR has been calculated for all patients. The MPR was 
calculated for patients who stopped the initial treatment and switched to another 
treatment in the studies by Rizzo and Simons et al, Okano et al and Wang et al 
studies (421,430,431). Furthermore, MPR was calculated for persistence and 
discontinuation in the studies by Wogen et al, Giovanni et al, Boriset al, and Bimal 
et al (427–429,434). The aim of calculate MPR only for patients who persisted with 
their treatment to estimate adherence in my thesis was for the following reasons: 
patients who discontinued their treatment were considered partially non 
adherent, to calculate MPR for patients who persisted with their treatment make 
patients using the drug for the same time period. Using 120 days without 
treatment to define discontinuation to include all patients who could still take the 
medication. The maximum refill in Scotland is 3 months in some conditions, 
choosing 60 or 90 to define discontinuation may lead to consider some of patients 
who still take their medications as discontinuer.  
Terminologies pertaining to switching therapy and additional therapy have been 
used in several studies. Switching usually indicates that a patient has discontinued 
the initial drug and changed to another drug, and the percentage of switching has 
been estimated in several studies (435,445–447,457).  Additional therapy is 
defined as having a drug be added to the initial drug and this has also been 
estimated in various studies (446,447). If the drug is added to the initial drug, 
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patients are still considered persistent while switching is considered in sometime 
considered as continuous  (457), and as discontinue (428,435). 
I used the same terminology (switching and additional therapy) with the same 
definitions, and patients who switched their initial antihypertensive class to 
another class were considered as non-persistent. Patients are considered 
persistent even if the persisted antihypertensive class, which was prescribed at 
enrolment, was combined with another antihypertensive class. However, 
switching has been classified into two groups. The first group involves a new 
antihypertensive medication that has been changed from the original 
antihypertensive drug after 120 days from the date of discontinuance. The second 
group includes a new antihypertensive medication that has been changed from 
the antihypertensive agent before 120 days from the date of discontinuance. 
There is significant differences between these two groups. Patients in group one 
totally stop their drug usage and restart again with a different drug. Patients in 
group two continue with their medication but with a different antihypertensive 
class.  
The selection of patients, drugs and inclusion and exclusion criteria varied 
between studies. Most or all antihypertensive classes were included in most 
adherence and persistence studies. Some studies selected a specific drug instead 
of studying all classes. For instance, amlodipine, atenolol triamterene, nifedipine 
and quinapril were selected in the Benson et al study(442), while valsartan, 
amlodipine and lisinopril were investigated in the Wogen et al study(428). 
Exclusion criteria were also different. Patients taking nitrates, antiarrhythmics, 
digoxin, warfarin, loop diuretics and migraine medicines, or patients with 
cardiovascular disease or hepatic and renal diseases were excluded in several 
studies. The reason for excluding these patients may have been because certain 
drugs may not be used as an antihypertensive drug for HTN alone, but may be used 
for other diseases(435,436,438,445).  
Different ages were used in the studies and included patients who were ≥ 18, > 
20, > 30, > 40 and ≥ 65 years. The reason for selecting specific ages was unknown 
in several studies and may have been related to the patients’ demographic data. 
Some studies gave reasons for selecting a specific age. For instance, Jones et al 
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included patients who were aged > 40 years because, as they claim, the 
prevalence of HTN in patients ≤ 40 years was low (443). However, Boris et al 
included patients aged > 20 years because patients younger than 20 years were 
more likely to have secondary HTN(427). 
I include all adults hypertensive patients aged 18 and more who took any type of 
antihypertensive drugs that patients were initiated treatment at the Glasgow BP 
clinic, it is unlikely that the study drugs were prescribed to treat other 
concomitant conditions and not hypertension. 
8.3 Future plans 
The future directions from my study can be described under three themes – 
validation, clinical implication and clinical application.  
Validation 
This study is observational and thus validation is required to a) confirm the 
adherence levels using a more objective measure like urinary drug assays, 
medication event monitoring system (MEMS) or Proteus Digital Health Inc 
(Redwood City, CA). MEMS provide unique information about patients’ behaviour 
regarding the use of their medications. This information could not be obtained by 
any other method and was used to measure medication adherence. The 
information that was recorded on a computer chip each the time bottle was 
opened included the number of doses taken daily (displayed as a calendar plot), 
the number of hours that elapsed since the last time the bottle was opened, and 
the frequency of days on which a dose was taken at a specific hour. This device 
can collect reliable data that can then be transferred to a computer for analysis. 
Although some consider MEMS as the gold standard for adherence assessment, the 
data could be recorded even when the patients open and shut the cap without 
taking the medication. Urinary drug assays are the only adherence method that 
can confirm that patients have actually taken the drugs. Adherence can be 
monitored by detecting the existence of the drug in the urinary sample. The 
disadvantages of this method are that urine drug levels cannot detect fluctuations 
in adherence between clinic visits, and the assessment of the degree of adherence 
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can be influenced by variations in pharmacokinetics and metabolism between 
individuals. Moreover, adherence can be affected by so-called white coat 
adherence, where patients temporarily improve their drug adherence a few days 
prior to urine analysis. b) assess persistence and adherence level in a more 
representative cohort of patients – for example those treated in primary care as 
this is the centre where the greatest proportion of hypertensive patients are 
managed c) Determine the best and representative metric of adherence and 
persistence – adherence and persistence are dynamic processes and the relevance 
of short-term omissions, duration of therapy, switching of drugs, the uncertainty 
due to long refill intervals, short persistence versus prolonged persistence all need 
to be evaluated in the overall assessment. 
Clinical implications 
The relationship between drug adherence/persistence and BP control is difficult 
to demonstrate. Nevertheless, this is important to obtain an unbiased estimate of 
this effect and it will inform clinical applications. The major challenge here is the 
fact that patient behaviour promptly changes when they realise that drug 
adherence is being assessed. This results in white coat adherence which is 
temporary improvement in adherence and thus dilutes any blood pressure 
differences between treated and control patients. Any studies will also need to 
consider selection bias as patients who participate in adherence studies tend to 
have a higher drug adherence compared to those who decline to participate. Any 
validation study should also show effect on outcomes, so future studies of drug 
adherence and persistence should demonstrate not only improvements in BP 
control but also test if this improvement in BP control leads to improved 
cardiovascular benefit, better quality of life. 
Clinical applications 
There is a large volume of observational data mainly from analyses of 
administrative databases that suggest good drug adherence is associated with 
better clinical prognosis. However, it is not evident whether interventions that 
improve adherence will reduce cardiovascular events. More crucially, there are 
no simple interventions to improve adherence and persistence. Simple 
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interventions like reminders (phone, mobile text, email), pill organisers, 
involvement of family members need to be tested in different subgroups to 
identify who would benefit the most and if these lead to a significant impact in 
outcomes or quality of life. Other methods like a multi-disciplinary approach using 
psychologists, pharmacists, nurses may be effective but not economical for 
universal use. As hypertension therapy inevitably requires poly therapy, any 
method that simplifies therapy, for example using combination pills or poly pills 
enabling single day dosing may have advantages. Another solution is to try and 
avoid pharmacotherapy for hypertension by using device therapy, but 
unfortunately recent experience with device therapy have not be encouraging. 
In summary, adherence and persistence is an important area of future research 
that is essential to develop novel treatment methods to decrease the global 
burden of hypertension. My studies in the Glasgow BP Clinic have shown how the 
utilisation of multiple strands of clinical data can yield useful information which 
can inform future studies. 
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